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Background: Depressed patients who do not respond to second-line antidepressant drugs are
characterised as suffering from treatment-refractory depression (TRD). Chronic psychosocial stress
hypothalamic–pituitary–adrenal (HPA) axis dysfunction is associated with attenuated responses to
antidepressants. Corticosteroid co-administration reduces the increase in forebrain 5-hydroxytryptamine
with selective serotonin reuptake inhibitors, whereas antiglucocorticoids have the opposite effect. A
Cochrane review suggesting that antiglucocorticoid augmentation of antidepressants may be effective in
treating TRD included a pilot study of the cortisol synthesis inhibitor, metyrapone. The Antiglucocorticoid
augmentation of antiDepressants in Depression (ADD Study) was a multicentre randomised
placebo-controlled trial of metyrapone augmentation of serotonergic antidepressants in patients with TRD.
Objective: To determine the efficacy and safety of augmentation of standard serotonergic antidepressants
with metyrapone 500mg twice a day for 3 weeks in patients with TRD.
Methods: A total of 165 patients with moderate to severe TRD aged 18–65 years were randomised to
metyrapone 500mg twice daily or placebo for 3 weeks, in addition to ongoing serotonergic antidepressants.
The primary outcome was improvement in Montgomery–Åsberg Depression Rating Scale (MADRS) score
5 weeks after randomisation estimated using analysis of covariance. Secondary outcomes included the
degree of persistence of treatment effect for up to 6 months, and also safety and tolerability of metyrapone.
ADD included substudies investigating the potential mechanism of action of metyrapone, and utilised a
comparator group of healthy participants.
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Results: The estimated mean difference for each of our study outcomes between randomised groups,
5 weeks post randomisation (allowing for variation between centres and whether or not patients originate
from primary or secondary care) was MADRS –0.51 [95% confidence interval (CI) –3.48 to 2.46]; Beck
Depression Inventory (BDI) –2.65 (95% CI –6.41 to 1.10); Clinical Anxiety Scale 0.46 (95% CI –1.20 to
2.12); State–Trait Anxiety Inventory 1.2 (95% CI –0.6 to 3.0); European Quality of Life-5 Dimensions
0.015 (95% CI –0.069 to 0.099); EuroQol visual analogue scale 5.6 (95% CI –0.7 to 12.0); and Young
Mania Rating Scale –0.04 (95% CI –0.52 to 0.45). The differences were not statistically significant
and were small in relation to the change from baseline in both groups that was observed immediately
after completion of therapy. Endocrinological data required for compliance assessment are not yet
available. HPA function, similar in patients and control subjects, was not associated with differing clinical
responses. Neuropsychological impairments were found, along with changes in brain structure and
function, but no effect of metyrapone was seen on these measures.
Discussion: The inclusion criteria led to the sample being broadly representative of patients with TRD, within
the UK NHS, with high anxiety and BDI scores. Metyrapone augmentation of antidepressants is not efficacious
for outpatients with TRD who are moderately depressed. There was no obvious benefit associated with the
use of metyrapone, either on the primary outcome or over the period of follow-up, and this negative result
extended to other secondary outcomes. Metyrapone was well tolerated. There were no serious adverse events
attributable to it and adverse events were as common with the placebo. HPA axis function was not associated
with differing clinical or neuropsychological outcomes.
Conclusions: The results of the study suggest that although metyrapone augmentation was well tolerated, it
is ineffective in the treatment of refractory depression. This finding is contrary to a previous proof of principle
study in more acutely unwell patients. Future research should consider whether or not antiglucocorticoid
treatments, such as metyrapone, should be targeted at patients with confirmed hypercortisolaemia.
Trial registration: Current Controlled Trials ISRCTN45338259.
Funding details: This study was funded by the National Institute for Health Research Efficacy and
Mechanism Evaluation (EME) programme, a MRC and NIHR partnership.
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Plain English summary
Depression is common and can have a terrible impact on patients and their families. Guidelinesrecommend talking therapies for patients with milder depression and adding antidepressants for
moderate and severe depression. However, antidepressants work in only about 70% of sufferers. Why this
happens is not known. One possibility is that increases in the stress hormone cortisol may reduce the
effectiveness of antidepressants. Cortisol rises when people are stressed and may stay high in depression.
Raised cortisol reduces the effect of antidepressants on the chemicals in the brain, which are thought to
be important in how they work. Small studies have suggested that reducing the level of cortisol produces
better outcomes for depression. We have tested the drug metyrapone, which blocks the production of
cortisol, in a group of 165 people who remained depressed after previous treatment with at least two
antidepressants. Metyrapone was given for 3 weeks. We investigated whether or not it led to benefits over
the next 6 months compared with a group of similar people who received dummy tablets. Both groups of
depressed people improved but there was no difference between them. There was also no difference in
anxiety scores or quality of life with metyrapone treatment. Changes in memory, processing emotions and
brain function were found in the depressed patients but no effects of metyrapone were found. It appears
that this particular drug does not produce benefits for such patients. Further research is needed to find a
treatment that reduces the effects of cortisol and improves the outcome for depression.
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Scientific summary
Background
Many patients (approximately 30–50%) with depression do not respond to first-line antidepressant drugs.
Responses to a second antidepressant are also disappointingly low (approximately 30%). Such non-responding
patients are characterised as suffering from treatment-refractory depression (TRD). Chronic psychosocial stress
and dysfunction of the hypothalamic–pituitary–adrenal (HPA) axis are both common in depression, and are
associated with an attenuated clinical response to antidepressants. In preclinical studies, co-administration of
corticosteroids leads to a reduction in the ability of selective serotonin reuptake inhibitors (SSRIs) to increase
forebrain 5-hydroxytryptamine, whereas co-administration of antiglucocorticoids has the opposite effect.
A Cochrane review suggested efficacy of antiglucocorticoid augmentation of antidepressants in patients with
depression, with the largest effect size seen with metyrapone, a cortisol synthesis inhibitor that crosses the
blood–brain barrier (Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P. Antiglucocorticoid
treatments for mood disorders. Cochrane Database Syst Rev 2008;1:CD005168). A positive double-blind,
placebo-controlled randomised trial of metyrapone was conducted in a centre in Germany, with
63 depressed inpatients.
Objectives
The Antiglucocorticoid augmentation of antiDepressants in Depression (ADD Study) was a multicentre,
patient-randomised, double-blind placebo-controlled trial of metyrapone augmentation of serotonergic
antidepressants in patients with TRD in the UK NHS. The primary objective was to determine whether or
not metyrapone (500mg twice a day) for 21 days is efficacious in augmenting ongoing treatment with
conventional serotonergic antidepressants in TRD. The primary outcome by which this objective was
assessed was the Montgomery–Åsberg Depression Rating Scale (MADRS) scored at baseline and 2 weeks
post treatment (week +5 from randomisation) in a representative sample of depressed patients who had
failed to respond to at least two courses of antidepressants, drawn from primary care and psychiatric
outpatient clinics in the UK. Treatment with metyrapone was compared with treatment with placebo,
using analysis of covariance. Secondary clinical objectives were to (1) determine the clinical effect size at
2 weeks post completion of treatment (5 weeks post randomisation) of a 3-week course of metyrapone
(vs. placebo) augmentation of antidepressants; (2) assess whether or not any observed response was
sustained for up to 21 weeks post cessation of metyrapone; (3) assess whether or not metyrapone
augmentation improves patients’ quality of life (QoL) using the self-completed EuroQol EQ-5D instrument
(European Quality of Life-5 Dimensions); (4) assess the tolerability and safety of metyrapone augmentation
in this study population; and (5) assess the mechanism of action of metyrapone in mechanistic substudies
using neuropsychological, neuroendocrine and neuroimaging outcomes.
Assessment of additional secondary outcome measures of symptomatology [Clinical Anxiety Scale (CAS),
Beck Depression Inventory (BDI), State–Trait Anxiety Inventory (STAI) and Young Mania Rating Scale
(YMRS)] were conducted at the same time points as described for the MADRS.
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Methods
A total of 165 patients with moderate to severe TRD, aged 18–65 years, were randomised to metyrapone
500mg twice daily or placebo for 3 weeks, in addition to ongoing treatment with serotonergic
antidepressants. Treatment occurred between weeks 0 (randomisation) and week +3 relative to randomisation.
Patients were assessed on the above outcomes at –2, 0, +3, +5, +8, +16 and +24 weeks. Inclusion criteria
were that the patient had (1) a major depressive episode assessed using the Structured Clinical Interview for
DSM (SCID) (Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition, DSM-IV); (2) a Hamilton
Depression Rating Scale-17 item (HDRS17) score of ≥ 18 at weeks –2 and 0; (3) a Massachusetts General
Hospital Treatment Resistant Depression (MGH-TRD) staging score of 2–10 at week –2 as a measure of
treatment refractoriness; and (4) current treatment with a single agent or combination antidepressant
treatment [which included a serotonergic drug (a SSRI), a tertiary amine tricyclic, venlafaxine, duloxetine or
mirtazapine]. At the point of randomisation, patients were required to have been on their current
antidepressant medication, at the current dose, for a minimum of 4 weeks, and this medication needed
to be continued unchanged during the trial. Exclusion criteria included any other DSM-IV axis 1 diagnosis other
than an anxiety disorder; a physical comorbidity that would make metyrapone inappropriate; pregnancy or
breastfeeding; use of medication that would interfere with metyrapone; and dependence on alcohol or other
drug(s) in the past 12 months and/or current harmful use of such substances. Metyrapone treatment potentially
engenders hypocortisolaemia, with manifestations including a risk of postural hypotension, hyperkalaemia and
hyponatraemia. Therefore, safety assessments included serum cortisol measures at week +1, as well as
measuring sitting and standing blood pressure and urea and electrolytes at weeks +1 and +5. Serious adverse
events (SAEs) and adverse events (AEs) were routinely enquired for and recorded. Tolerability was further
assessed using the Toronto Side Effects Scale (TSES). Metyrapone administration has previously been shown to
cause an increase in levels of 11-deoxycortisol, and the increase in 11-deoxycortisol between weeks –2 and +1
was to be used, when available, as a measure of adherence to medication, as this has been shown to be highly
sensitive to treatment with metyrapone. The study also investigated a number of mechanistic objectives,
including whether or not the patients had evidence of baseline hypercortisolaemia and, if present, whether or
not this had any impact on clinical and neuropsychological outcomes. A comparator group was also recruited
to support these mechanistic investigations.
Results
Overall, 877 patients were referred to the study team: 237 from primary care, 320 from secondary care
and 310 as self-referrals following media exposure of the study or seeing posters. The origin of 10 patients
was unclear. A total of 284 underwent detailed screening for eligibility. The remainder were either deemed
to be ineligible on the basis of a brief telephone screen or did not follow up contact, and 173 were
deemed to be eligible. Of the 111 who did not meet inclusion criteria, 10 did not meet the criteria for a
major depressive episode using the SCID, 52 had HDRS17 item scores of <18, 17 had axis 1 disorders
other than anxiety, nine were on an inappropriate antidepressant, three had MGH-TRD staging scores
outside the range of 2–10, 18 had physical disorders that excluded them, and five had other miscellaneous
exclusion criteria (three patients were excluded for more than one reason).
Eight patients subsequently dropped out before randomisation (i.e. between weeks –2 and 0) and so
165 patients were randomised (82 to placebo and 83 to metyrapone). Of these, 143 (86.7%) completed
the primary outcome at +5 weeks (74 on placebo and 69 on metyrapone). A further 39 dropped out
between week +5 and week +24, so that 104 (63%) completed the study (58 on placebo and 46 on
metyrapone). The groups were well balanced at randomisation in terms of demographics and key clinical
variables. The mean MADRS score for the groups indicated moderate to severe depression, with MGH
scores well in the range of treatment resistance. The group showed evidence of high Beck Depression
Inventory (BDI) scores. There was evidence of high scores on measures of anxiety, and comorbid anxiety
conditions were frequent.
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The estimated mean difference for each of our study outcomes between randomised groups 5 weeks post
randomisation (adjusting for variation between centres, whether or not patients originate from primary or
secondary care and baseline score) was MADRS (the primary outcome measure) –0.51 (95% CI –3.48 to
2.46); BDI –2.65 (95% CI –6.41 to 1.10); Clinical Anxiety Scale (CAS) 0.46 (95% CI –1.20 to 2.12); STAI
1.2 (95% CI –0.6 to 3.0); European Quality of Life-5 Dimensions 0.015 (95% CI –0.069 to 0.099); EuroQol
visual analogue scale 5.6 (95% CI –0.7 to 12.0); Young Mania Rating Scale –0.04 (95% CI –0.52 to 0.45).
The differences were not statistically significant for any measure and tended to be small in relation to the
change in both groups observed at week +5. Response rates were low and almost identical in both groups
(21.6% in the placebo group and 20.3% in the metyrapone group). Remission rates were similarly low
and almost identical in the two groups at this time point.
Endocrinological data required for compliance assessment are not yet available. HPA axis function, similar
in patients and control subjects, was not associated with differing clinical responses. A wide range of
neuropsychological impairments were found, along with changes in brain structure and function, but no
differential effect of metyrapone was seen on these measures.
Metyrapone was generally well tolerated. There were 14 SAEs reported for 11 of the patients randomised
to study medication (five in the group randomised to metyrapone and six in the group randomised to
placebo) but none was attributed to metyrapone and most occurred well after the period of active drug
treatment. Non-serious AEs were more common and broadly similar in type and frequency between the
two groups, but we cannot exclude the possibility that treating patients with metyrapone may increase the
risk of AEs. Of particular note, however, is that metyrapone did not increase the risk of suicidal ideation or
suicide attempts. Scores on the TSES were broadly similar between the two groups, with no evidence of a
difference in the frequency of postural hypotension or dizziness.
Conclusions
The broad inclusion criteria led to the sample being broadly representative of patients with TRD who are
treated within the NHS. The sample had high anxiety and BDI scores and frequent comorbid anxiety.
No evidence was found that metyrapone augmentation of serotonergic antidepressants is efficacious for
patients with moderate to severe depression – managed in NHS secondary care outpatient clinics or by
general practitioners in primary care – who have failed to respond to at least two antidepressants. There
was no obvious benefit to its use either on the primary outcome or over the period of follow-up, and this
negative result extended to other secondary outcomes, such as the CAS, BDI and quality-of-life measures.
Metyrapone was well tolerated by this group and there were no serious AEs attributable to it. AEs were as
common in patients treated with placebo. Clinical outcomes have not yet been analysed with respect to
the measure of adherence utilised.
A wide range of neuropsychological impairments were found along with changes in brain structure and
function, but no differential effect of metyrapone was seen on these measures. This population with TRD
was characterised by increased exposure to childhood adversity (compared with the control subjects) and
normal HPA axis function. These findings accord with the existing literature in chronic populations; the
former predicts non-response to treatment. However, baseline HPA axis function, change in cortisol
awakening response in response to drug treatment or severity of childhood trauma did not predict clinical
response to metyrapone.
There are very few data specifically on the neuropsychology of treatment-resistant depressed groups.
Those studies that have been conducted suggest that deficits are restricted to tests of processing speed. In
this TRD sample we see broad deficits in verbal and visuospatial working memory and emotion processing
compared with healthy control subjects. Deficits in attention were not general and, instead, were restricted
to the executive control of attention. These findings are indicative of an impairment in effortful processing
in TRD. No differential effects of metyrapone were seen on these measures.
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Trial registration
This study is registered as ISRCTN45338259.
Funding
Funding for this study was provided by the Efficacy and Mechanism Evaluation programme of the National
Institute for Health Research.
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Chapter 1 Background and objectives
Scientific background
Depression is a common disorder, affecting some 10% of the population.1 It is rated by the Disease
Control Priorities Project as one of the leading medical contributors to the global burden of disease.2 It can
become long-lasting and may recur frequently. Depression has a large negative impact on the quality of
life (QoL) of service users and their carers. It is associated with high morbidity (depression has been
identified as one of the leading causes of work days lost and working-age adults receiving disability
payments in the UK)3 and mortality, through suicide and increased deaths from cardiovascular disease.4
Clinical guidelines recommend the use of antidepressant medication for the treatment of a moderate to
severe depressive episode.1,5 Antidepressant drugs have established efficacy compared with placebo in
clinical trials; however, in naturalistic settings many patients have unsatisfactory outcomes. The large
pragmatic STAR*D study conducted in the USA showed that, even with protocol-driven treatment,
first-line therapy with a selective serotonin reuptake inhibitor (SSRI: citalopram) in over 2500 patients was
associated with remission in only 28% and response (defined as a 50% decrease in symptom scores) in
< 50% of patients.6 Further, second-line treatment in the STAR*D study with an alternative antidepressant
was associated with an even lower remission rate of 20–25%.7 Much of the burden of depression is
consequent on this treatment-refractory depression (TRD).
Clinical response to antidepressant treatment may be influenced by a number of factors but an inadequate
neurochemical response is one likely mechanism of non-response. The majority of antidepressants, on
long-term administration, elevate forebrain levels of 5-hydroxytryptamine (serotonin; 5-HT). The clinical
importance of this is supported by the fact that acute depletion of tryptophan (the precursor of 5-HT) can
lead to the rapid return of depressive symptoms in patients treated with antidepressants.8,9 There is a
long-held notion that life events and lack of social support predict worse treatment outcomes in patients
with depression.10 The mechanism of this may relate to the hypothalamic–pituitary–adrenal (HPA) axis. It is
well established from animal and human studies that glucocorticoids influence multiple aspects of 5-HT
neurotransmission (including the sensitivity of 5-HT1A autoreceptors and postsynaptic 5-HT receptor
efficacy,11–14 which are postulated to be central to the antidepressant mechanism of action).15 Furthermore,
dysregulation of the HPA axis can reduce the effects of antidepressants in the frontal cortex. Implantation
of corticosteroid-releasing pellets in rodents to induce an HPA axis dysregulation has been shown to
attenuate the ability of antidepressants to elevate forebrain 5-HT levels.16 Interestingly, there is also
increasing evidence that antiglucocorticoid treatments have the opposite effect by enhancing the
forebrain 5-HT response to antidepressants.17 This suggests that reducing normal physiological levels of
glucocorticoid receptor activation can increase the elevation of 5-HT in response to SSRIs. These data
suggest a potential mechanism by which antiglucocorticoid strategies can enhance the clinical effectiveness
of antidepressants in clinical practice.
Hypothalamic–pituitary–adrenal axis abnormalities are often demonstrated in patients with mood disorders.
HPA axis dysregulation in depression is often characterised – particularly in those with melancholic symptoms –
by a flattened cortisol diurnal rhythm with elevated trough levels of cortisol18 and by attenuated negative
feedback effects of corticosteroids on adrenocorticotrophic hormone (ACTH) and cortisol release.19 There is
increasing evidence that such dysregulation is associated with poor prognosis, including non-response to
antidepressants and future relapse.20–26 Further, a Cochrane review suggested efficacy of antiglucocorticoid
augmentation of antidepressants in patients with depression with the largest effect size seen with
metyrapone,27 a cortisol synthesis inhibitor that crosses the blood–brain barrier. There have been several
open – including randomised – studies of metyrapone augmentation of antidepressants, showing efficacy in
TRD.28–32 In addition, a successful proof-of-concept double-blind, placebo-controlled randomised study has
been conducted by Jahn et al.33 in a centre in Germany, with 63 depressed inpatients. Patients were all
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being treated with a serotonergic antidepressant and were randomised to add-on treatment with metyrapone
(1 g/day for 3 weeks) or placebo. The primary outcome measure was the percentage of responders [defined
by an improvement of ≥ 40% on the Hamilton Depression Rating Scale-17 item (HDRS17)] 5 weeks after
randomisation (i.e. 2 weeks after cessation of metyrapone or placebo augmentation). Patients receiving
metyrapone were significantly more likely to respond than those receiving placebo, with an effect size of
Cohen’s d= 0.63. Kaplan–Meier analysis revealed a faster response with metyrapone, which was well
tolerated and without serious side effects.
Previous research has shown, in patients with depression, hyperactivation of the amygdala and other
limbic structures and hypoactivation in prefrontal neocortical regions, specifically in response to negative
emotional stimuli,34 although such findings have been inconsistent and may, for instance, not be present in
patients with mild to moderate depression.35 They have been shown to be altered by levels of serotonin.36
Neurocognitive deficits and mood-congruent biases have been reported in depression, although there are
inconsistencies which may be related to the population studied. We investigated these and the neural basis
of working and episodic memory, including the encoding and retrieval of emotional memories in patients
with TRD on the basis that this population may be more homogeneous and likely to display neurocognitive
deficits than an undifferentiated depressed group.
Previous electroencephalographic studies have entailed two main elements: (1) prediction of treatment
response and (2) investigation of the neural correlates of emotional processing and memory.
1. Treatment response prediction A number of electroencephalography (EEG) variables recorded prior to the
commencement of antidepressant treatment have been shown to predict response in patients with major
depressive disorder.37 For example, studies of EEG frequency spectrum have generally found that
responders have greater alpha power prior to treatment,38–42 although there have been negative findings.43
In addition to absolute alpha power, there have also been findings suggesting that antidepressant
non-responders show alpha hemispheric asymmetry with lower power in the right hemisphere compared
with the left,42,44,45 with a claim that this asymmetry has a sensitivity of 64% and specificity of 71% in
identifying responders.42 An alternative power spectrum band that has been explored extensively is the
theta band. This work suggests that lower frontal theta power is associated with greater response to
antidepressants,40,41,46 with a sensitivity and specificity of 64% and 62%, respectively.46 In line with
hypotheses that activity/metabolic rate in the rostral (pregenual) anterior cingulate cortex (rACC) predicts
antidepressant response,47–51 there are findings from three independent research groups that EEG rACC
theta activity, which closely correlates with rACC positron emission tomography glucose metabolism,52
predicts response53–55 with an effect size of 1.3.54 Aside from EEG frequency power in various bands, there
has also been considerable research into the ability of the loudness dependency of auditory evoked
potentials (LDAEPs) to predict response. LDAEPs have been argued to reflect serotonergic function in
humans,56 although the greatest promise for this measure is as a potential biomarker of antidepressant
response.57 The LDAEP’s ability to predict antidepressant response has been replicated by more groups than
for any other EEG method described above, and includes more patients than any other technique.37,58–65
Critically, the LDAEP is also reported to be able to predict response to serotonergic and noradrenergic
antidepressants differentially.57,66 In the light of these findings, an obvious question is whether or not the
ability to predict antidepressant response is improved by combining different EEG parameters. Bruder et al.42
combined global alpha power (sensitivity 73% and specificity 58%) and alpha asymmetry (sensitivity 64%
and specificity 71%) and found an overall sensitivity of 83% and specificity of 68%. An additional study66
combined theta activity localised to rACC and the LDAEP technique, showing that this had the ability to
discriminate between responders and non-responders with an effect size of 1.4.
BACKGROUND AND OBJECTIVES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
2. Neural correlates of emotional processing and memory An aim of the EEG mechanistic studies is to
examine the effects of metyrapone treatment on emotional context on memory retrieval. In studying
emotional memory retrieval, presentation of emotional items in the recognition test phase of a memory
task is a potential confounder. This may lead to the activation of brain regions engaged in the
emotional perception and arousal that occur during the presentation of emotional stimuli, rather than
relating the effects of emotion on memory retrieval. A paradigm through which retrieval of a neutral,
emotionally non-arousing, object is tested, following encoding of the objects in an emotionally
manipulated context, can potentially eliminate this difficulty. The ADD Study utilised such a paradigm,
based on the event-related potential (ERP) work of Smith et al.:67 an emotional source memory task
(ESMT). In this paradigm, recognition of a neutral, emotionally non-arousing, visual object is tested,
following encoding of the objects in an emotional context [the object is presented superimposed on
emotional pictures from the International Affective Picture Set (IAPS) or emotional faces]. This technique
provides temporal information regarding neural activity, which would not be possible with functional
magnetic resonance imaging (fMRI). It demonstrates that retrieval of emotional items, compared with
neutral ones, shows increased activity of lateral temporal areas, bilaterally, early in the retrieval process
and a later component over left temporofrontal regions.67,68
In addition, a putative ERP equivalent of long-term potentiation (LTP)69 was also investigated. This involves
presenting a high-frequency visual stimulus (a black and white chequerboard) to subjects, which has been
shown to increase the amplitude of early visual ERPs69 for 30–60 minutes. This task is of interest given
that animal studies have demonstrated that LTP is highly sensitive to corticosteroids.70 As a result, we
hypothesised that changes in the cortisol awakening response (CAR) in patients following metyrapone
treatment would correlate with the magnitude and duration of the ERP marker of LTP.
Objectives
The primary aim of the ADD Study was to examine the efficacy and safety of metyrapone augmentation
of serotonergic antidepressants in a patient randomised placebo-controlled trial in patients with major
depression who had not responded to at least two courses of antidepressants in their current episode. The
study extends research in this area by exploring the translatability of the proof-of-concept study described by
Jahn et al.33 to an outpatient, primary and secondary care, UK NHS population. To date, all published studies of
the use of antiglucocorticoids in patients with TRD have used short treatment periods of 1–3 weeks,27 which
can appear counterintuitive in such a potentially chronic condition. However, evidence suggests that the
clinical effects of antiglucocorticoids on HPA axis function persist after their administration has ceased.71,72
The persistence of effects on depressive symptoms and QoL was, therefore, examined in the ADD Study for
21 weeks after stopping metyrapone treatment compared with the 2-week follow-up period of Jahn et al.33
The exact mechanism by which metyrapone may enhance antidepressant efficacy is unknown. A secondary
aim of the ADD Study was to explore the impact of metyrapone on HPA axis function, and the hypothesis
that metyrapone leads to altered neural responsiveness to glucocorticoids with an increase in the
frontocortical 5-HT response to antidepressants. In addition, a number of studies in subsamples, drawn
from the main randomised controlled trial (RCT) population, were also undertaken using EEG and fMRI
techniques, assessment of neuropsychological function, and genetic variability to address this mechanistic
aim. The substudies are detailed in a paper73 describing the protocol in detail, which also outlines
the hypotheses tested and the rationale for the tests utilised. The protocol below is consistent with the
SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 recommendations
(see www.spirit-statement.org/spirit-statement/).
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Primary clinical objective
The primary objective is to determine whether or not metyrapone (500mg twice a day) for 21 days is
efficacious in augmenting conventional serotonergic antidepressants in TRD in a NHS primary and
secondary care setting. The primary outcome by which this objective is assessed is the Montgomery–Åsberg
Depression Rating Scale (MADRS)74 scored at baseline and 2 weeks post treatment (week +5 from
randomisation), comparing patients randomised to metyrapone with those randomised to placebo.
Secondary objectives
Clinical objectives
l To determine the clinical effect size at 2 weeks post completion of treatment (5 weeks post
randomisation) of a 3-week course of metyrapone (vs. placebo) augmentation of antidepressants in a
representative sample of depressed patients who have failed to respond to at least two courses of
antidepressants, drawn from primary care and psychiatric outpatient clinics in the UK.
l To assess whether or not any observed response is sustained for up to 21 weeks post cessation
of metyrapone.
l To repeat the above analyses utilising the addition ‘atypical’ depression items (rating hypersomnia and
increased appetite). In this scoring of the MADRS, the highest score from the conventional sleep and
atypical sleep items, and conventional appetite and atypical appetite items, will be used to calculate the
total MADRS score.
l To assess the persistence of change in MADRS score, the Clinical Anxiety Scale (CAS), Beck Depression
Inventory (BDI) and State–Trait Anxiety Inventory (STAI) scores, using repeated measures analysis of
variance (ANOVA), adjusting for randomisation strata of centre and primary compared with secondary
care, and using all of the data points available.
l To assess whether or not metyrapone augmentation improves patients’ QoL as assessed by the
self-completed EuroQol European Quality of Life-5 Dimensions (EQ-5D) instrument (www.euroqol.org/).
l To assess the tolerability and safety of metyrapone augmentation in this study population.
Mechanistic objectives related to the full randomised controlled trial sample
l To assess whether or not metyrapone changes patients’ HPA axis function.
l To assess whether or not changes in HPA axis function with metyrapone persist after
stopping metyrapone.
l To assess whether or not the change in HPA axis function correlates with clinical response.
l To assess whether or not baseline HPA axis function predicts clinical response.
l To assess if type and severity of childhood trauma [as assessed by the Childhood Trauma Questionnaire
(CTQ) scores] predicts clinical response.
l To determine the nature and extent of neuropsychological abnormalities in patients with TRD
compared with healthy control subjects.
l To determine whether or not neuropsychological performance improves with metyrapone treatment.
Mechanistic objectives related to the Newcastle and Manchester subgroups
of the full randomised controlled trial sample
l To compare visual cortical LTP in patients with TRD and healthy control subjects.
l To examine if visual cortical LTP is altered by treatment with metyrapone.
l To compare emotional source memory performance, and its electrophysiological underpinnings,
in patients with TRD and healthy control subjects.
l To examine if emotional source memory performance, and its electrophysiological underpinnings,
is altered by treatment with metyrapone.
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l To determine whether or not EEG predictors of conventional antidepressant response, and in particular
specific predictors of response to serotonergic antidepressants, predict response to metyrapone augmentation.
l To compare the degree of activation of the amygdala in response to emotional faces and words in
patients with TRD and healthy control subjects.
l To compare neural activity during episodic and working memory tasks in patients with TRD and healthy
control subjects.
l To determine whether or not patients with TRD have altered hippocampal response to hydrocortisone
compared with healthy control subjects.
l To determine if the hippocampal response to hydrocortisone is modified in patients by
metyrapone treatment.
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Chapter 2 Methods
Trial design
Description of trial design
The ADD Study is a multicentre, two-arm (1 : 1 allocation), parallel-group, double-blind, patient-randomised,
placebo-controlled superiority trial of augmentation of serotonergic antidepressants with metyrapone in
patients with moderate to severe depression who have failed to respond to adequate trials of at least two
antidepressants in their current episode. These patients were recruited from primary and secondary
care settings.
All assessments were undertaken by trained research personnel under the supervision of the clinically
trained principal investigators (PIs: authors INF, RHMW, SW, IMA, AOH, HCRG, PMH, TH, AJL). There was
no planned interim analysis and no ‘stopping rules’ for the study as a whole. Individual patients were
withdrawn from the study medication if it appeared that to continue would be deleterious to their mental
health or safety. This was determined by the patient, the treating clinician and/or the research team, and
was supported by the use of the MADRS, particularly if there was an increase in the score for question
10 ‘suicidal thoughts’. Withdrawal from medication did not necessitate withdrawal from the study.
There was patient and public involvement in all stages of the study and this was invaluable. Two (FW, JW)
of the co-applicants and PIs were service users, one of whom was also a carer. They were very much
involved in the design of the study. In particular, they were involved in the design and content of all
information sheets and notices for general practitioner (GP) surgeries, etc. Both were involved in promoting
recruitment in their respective locales. At a later stage in the study the decision to promote the study to
the public through press releases was made and help in doing this well was obtained from the North East
Mental Health Research Network (NE MHRN) Hub Service User and Carer Forum. The subsequent articles
in the papers and the television appearance of the chief investigator acted as a catalyst, which the NE
MHRN Hub Service User and Carer Forum then used to promote the importance of the study further.
The response from the public was very marked and positive with frequent calls and referrals.
The study was registered on 21 December 2009 (ISRCTN45338259) under the public title ‘Antiglucocorticoid
augmentation of antiDepressants in Depression: the ADD Study’. Clinical trial authorisation was given by the
Medicines and Healthcare products Regulatory Agency (MHRA: EudraCT: 2009-015165-31). Ethical approval
was granted by the Sunderland Local Research Ethics Committee (REC reference number 10/H0904/9) on
22 April 2010.
Visits and assessments
These are outlined in Table 1 and summarised below.
Screening visit (week –2)
Written informed consent was obtained and study eligibility determined. Height, weight and safety
measurements were recorded. Baseline blood tests including urea and electrolytes (U&E), cortisol, thyroid
function test, liver function tests, full blood count and β-human chorionic gonadotropin (if indicated) were
taken. Family history (in first-degree relative) of mental illness was determined by clinical enquiry by a
trained psychiatrist. Background factors, personality, and childhood adversity and life events were assessed
between recruitment and randomisation, using the NewMood background questionnaire,75 given to
patients to complete and return at the next visit. This questionnaire includes the Big Five Inventory 44-item
personality questionnaire,76 a negative life events questionnaire adapted from the List of Threatening
Experiences,77 the Social Circumstances Questionnaire, which is an adaptation of the Social Support
Questionnaire78 as used in the NewMood study,75 the CTQ79 and the Ruminative Responses Scale.80
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TABLE 1 Schedule of assessments
Time point
Enrolment Randomisation Follow-up
Week –2 Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 8 Week 16 Week 24
Assessment of eligibility ✓
Informed consent ✓
Assessment of baseline characteristics –
NewMood questionnairea
✓
Experimental intervention
Assessment of depression severity – HDRS17 ✓ ✓
Assessment of clinical symptoms – MADRS,
CAS, BDI, STAI, YMRS
✓ ✓ ✓ ✓ ✓ ✓
Assessment of QoL – EQ-5D ✓ ✓ ✓ ✓ ✓ ✓
Assessment of side effects – TSES ✓ ✓ ✓ ✓
Assessment of side effects and AEs –
self-report
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Suicide risk assessment ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Pregnancy test if indicated ✓ ✓ ✓ ✓ ✓
Assessment of concomitant medication ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Measurement of HPA axis function (CAR plus
11 p.m. saliva sample)
✓ ✓ ✓
Physical observationsb ✓c ✓ ✓
Medical history ✓
Blood tests – U&E, cortisol ✓d ✓ ✓
Neuropsychological assessmente ✓ ✓
Neuroimaginge ✓ ✓
EEGe ✓ ✓
AE, adverse event; U&E, urea and electrolytes; YMRS, Young Mania Rating Scale.
a See Screening visit (below) for description of NewMood questionnaire details.
b Physical observations comprised sitting and standing pulse and blood pressure, and respiration rate.
c Screening physical observations also included height and weight.
d Screening blood tests also including thyroid function tests, liver function tests and full blood count.
e See neuropsychological assessment in Chapter 2 (Trial design).
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Depression severity was determined using the HDRS17, rated using the GRID Hamilton Depression Rating
Scale (GRID-HAMD) for improved reliability,81 and the MADRS.74
Randomisation visit (week 0)
Subjects were excluded if their HDRS17 score dropped to < 18 or if there was any change in their current
antidepressant medication (drug or dose) between weeks –2 and 0. Otherwise study medication was
supplied to commence the following day.
Follow-up
Data were collected at weeks +1, +2, +3 (end of active treatment period), +4, +5 (primary outcome time
point), +8, +16 and +24 from the date medication was started (± 2 days). The week +2 and +4 visits
could be completed by a telephone interview with the trained research assistant. Details of the
assessments at each time point are described in Chapter 3 (see Table 2). Depression severity was assessed
using the MADRS, administered by trained members of the research team at randomisation (week 0) and
weeks +3, +5, + 8, +16 and +24 relative to randomisation. The primary outcome measure was the
MADRS score, recorded at baseline and 5 weeks post randomisation. The MADRS has preferable
psychometric properties and higher sensitivity to change than other depression rating scales,82 and was
associated with the largest effect size in the Jahn study.33 Additional secondary outcome measures of
symptomatology [CAS,83 BDI,84 STAI85 and Young Mania Rating Scale (YMRS)86] were conducted at the
same time points as described for the MADRS. QoL was assessed using the self-completed EuroQol EQ-5D
instrument (www.euroqol.org/)87 and tolerability using the Toronto Side Effects Scale (TSES).88
Metyrapone treatment potentially engenders hypocortisolaemia with manifestations including a risk of
postural hypotension, hyperkalaemia and hyponatraemia. Therefore, safety assessments included serum
cortisol measures at week +1 and measurement of sitting and standing blood pressure and U&Es at
weeks +1 and +5.
Hypothalamic–pituitary–adrenal axis assessment
Cortisol levels to determine the CAR89 were obtained at the start of treatment (week 0) and then again at
weeks +3 and +5 for all patients. This entailed participants collecting 5ml of saliva, by passive drool,90 into
a plastic collecting tube on wakening and at 15-minute intervals for a further hour. A total of five samples
were collected on each occasion, either the day before or day after the planned study visit. Participants
were asked to collect a saliva sample by the same method for cortisol assay at 11 p.m. the night before
each of the three CAR assessments (weeks 0, +3 and +5). In addition to collection of saliva samples,
participants completed a brief questionnaire relating to the nature and quality of sleep the night before
the CAR assessment.
In addition to the saliva samples, serum samples were taken at weeks –2, +1 and +5 for analysis of cortisol
precursors and metabolites. Metyrapone administration has previously been shown to cause an increase in
levels of ACTH and 11-deoxycortisol, together with an increase in the cortisone–cortisol ratio.33,91 The
increase in 11-deoxycortisol between weeks –2 and +1 was used as a measure of adherence to medication,
as this has been shown to be highly sensitive to treatment with metyrapone.33,91
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Neuropsychological assessment
Spatial working memory
This test from the CAmbridge Neuropsychological Test Automated Battery (CANTAB) is a self-ordered
search task that places demands on spatial working memory and executive function. After the practice
trials (two to three boxes), subjects must search through an increasing number of boxes (four, six or eight)
for a hidden token. Once a token is found, it will not appear in the same box again. Subjects must
continue the search without returning to a box that has already contained a token. Accuracy is measured
as the number of between-search errors (BSEs – the number of times boxes that have already contained
tokens on previous trials are searched) and within-search errors (WSEs – the number of times boxes that
have already been examined on the current trial are searched).
Patients and control subjects [age- and sex-matched healthy volunteers (HVs) (see Healthy volunteers,
below)] were compared using baseline data by an analysis of covariance (ANCOVA) with Huynh–Feldt
correction: difficulty (‘level’ 4, 6 or 8) was a within-subject factor (for BSE and WSE), group (patient or
control) was a between-subject factor; and age and sex were covariates. Uncorrected degrees of freedom
(df) are presented in Chapter 3 for clarity. The effect of metyrapone treatment in patients was assessed
using multiple ANCOVA for each outcome with the post-treatment value as the dependent variable and
pretreatment value as the covariate.
Attentional Network Test
The Attentional Network Test (ANT) was developed by Fan et al.92 to fractionate and quantify the efficiency
of the functional attentional networks of alerting, orienting and executive control proposed by Posner
and Peterson.93 The ANT is a combination of cued reaction time (RT) and a flanker task, and has been
described in detail.92 Briefly, this is presented in a number of conditions, differing by the preceding cue and
the target flankers. The cue conditions are (1) no cue; (2) centre cue (a cue appears directly over the
central fixation point); (3) double cue (a cue appears simultaneously above and below the fixation); or
(4) spatial cue (a cue appears in either the upper or lower field, congruent with the location of the
subsequent target stimulus). The arrow stimuli are (1) neutral (flanked by directionless lines); (2) congruent
(flanked by arrows pointing the same direction as the target); or (3) incongruent (flanked by arrows
pointing the opposite direction to the target). Participants must respond as quickly as possible indicating
in which direction the arrow is pointing. The alerting effect is calculated by subtracting the mean RT of the
double-cue conditions from the mean RT of the no-cue conditions. These conditions provide information
that an event is about to occur, but not specifically where, therefore attention is diffused across the two
potential target locations. The orienting effect is calculated by subtracting the mean RT of the spatial
cue conditions from the mean RT of the centre cue. Both cues alert the participant that an event is about
to occur, although only the spatial cue provides precise spatial information, allowing the participant to
attend to the exact location. Finally, executive control of attention (conflict) is calculated by subtracting the
mean RT of all congruent flanking conditions, summed across cue types, from the mean RT of incongruent
flanking conditions.
Patients and control subjects were compared using baseline data by an ANCOVA with Huynh–Feldt
correction: group was a between-subject factor; age and sex were covariates. Uncorrected degrees of
freedom are presented for clarity. The effect of metyrapone treatment in patients was assessed using
multiple ANCOVA for each outcome with the post-treatment value as the dependent variable and
pretreatment value as the covariate.
Object-location memory
To assess memory for the locations of objects, the Object Relocation programme was used.94 The
programme presents stimulus displays on a PC fitted with a touchscreen monitor. A number of variations
of the task parameters are possible within the programme. Here the programme was run using the
immediate memory conditions from Kessels et al.95
METHODS
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First, subjects completed two control tasks that assessed object identity memory and visuospatial construction
and perception. In the object identity task, subjects viewed 10 different objects for 30 seconds; these objects
had to be remembered and subsequently recognised from a set of 20 objects, containing 10 of the ones
shown previously and 10 distractors. In the visuospatial construction task, subjects had to copy a frame
containing 10 different objects at different locations without a memory component. Each task condition
consisted of an example containing only four objects/positions, followed by two different test displays.
Following these control tasks, subjects completed three experimental task conditions:
(a) Position-only memory (POM) Subjects viewed an array containing 10 identical objects and were
required to remember their precise locations. After 30 seconds the array disappeared and the objects
appeared along the top of the screen. Subjects were then required to move the objects down into the
empty frame and recreate the exact positions of the array as accurately as possible.
(b) Object-location binding (OLB) Subjects viewed an array of 10 different objects and were required to
remember where they were located within the frame. After 30 seconds the array disappeared and the
objects appeared along the top of the screen. Subjects were then required to move the objects down
into the frame and recreate the array, although the precise positions that had been occupied were
indicated by premarked black dots.
(c) Combined memory condition (COM) This was identical to the OLB condition except for the relocation
stage, at which there were no premarked black dots, that is subjects were required to remember and
relocate the 10 different objects as precisely as possible to their exact previous locations.
Each task condition consisted of an example containing only four objects/positions, followed by two
different test displays. Performance measures were percentage incorrect items in the object identity control
condition and OLB conditions, and deviation error [millimetres (mm)] in the visuospatial construction and
perception control condition, and POM and COM tasks. In the case of the POM task, as all objects are
identical, it is impossible to specify to which location any given object is relocated and, consequently, the
best-fit error is used.95 All other tasks use the absolute error score.
Patients and control subjects were compared using baseline data by an ANCOVA with Huynh–Feldt
correction; group was a between-subject factor; age and sex were covariates. Uncorrected degrees of
freedom are presented for clarity. The effect of metyrapone treatment in patients was assessed using
multiple ANCOVA for each outcome, with the post-treatment value as the dependent variable and
pretreatment value as the covariate.
Digit span
To assess memory for verbal immediate/working memory, the forward and backward digit span measures
were completed. The test was administered according to standardised instructions.96 For the ‘experimental’
outcome measures, the total number of sequences correctly completed for forward, backward and total
was calculated (i.e. 1 point for each correct sequence; maximum forward and reverse= 14). For the clinical
span, the maximum sequence attained was recorded.
Patients and control subjects were compared using baseline data by an ANCOVA with Huynh–Feldt
correction; group was a between-subject factor; age and sex were covariates. Uncorrected degrees of
freedom are presented for clarity. The effect of metyrapone treatment in patients was assessed using
multiple ANCOVA for each outcome with the post-treatment value as the dependent variable and
pretreatment value as the covariate.
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Face emotion recognition task
Background
This task assesses the ability of a participant to identify each of the six basic facial emotions, and previous
research has shown an impaired ability to identify emotions in depression, an abnormality that resolves
with clinical improvement.97 Early improvement in recognition of happy faces has been reported to predict
response to antidepressant treatment.98
Each emotion (happiness, sadness, anger, fear, surprise, disgust) was presented for 1.0 second at three
intensities (30%, 50% and 70%) by four actors, together with 12 presentations of neutral expressions.
The inter-trial interval was 4.5 seconds, participants pressed a labelled key to indicate their choice
of emotion.
The data were analysed as accuracy (hit rate measured as the proportion of correct identifications of each
emotion to the total number of responses to that emotion) and misattributions (false alarm rate measured
as the proportion of misattributions of a specific emotion to the total number of responses to other
emotions). RTs are not reported as there was no instruction to react rapidly, and the need to choose
between seven response keys makes interpretation of the results unclear.
Patients and control subjects were compared using baseline data by an ANCOVA with Huynh–Feldt
correction: emotion type was a within-subject factor, group was a between-subject factor, and age and
sex were covariates, given evidence that they can influence face emotion recognition.97 Illustrative post hoc
analysis was by ANCOVA for each emotion separately. Uncorrected degrees of freedom are presented
for clarity.
The effect of metyrapone treatment in patients was assessed using multiple ANCOVA for each emotion
with the post-treatment value as the dependent variable and pretreatment value as the covariate.
Emotional memory task
This task measures immediate recall as a measure of encoding and recognition memory after 30 minutes
for emotional and neutral words. It tests both overall memory and whether or not there is an emotional
bias. Depressed patients have been reported to have both impaired memory and a negative memory bias.99
The task involved asking participants to learn a target list of 30 words (10 positive, 10 negative and 10 neutral),
with words presented one at a time for 5 seconds on a computer screen. The words were presented once and
then the participant was asked to recall as many words as possible straight after the presentation. Delayed
recognition was tested after 30 minutes. This involved the respondent identifying whether or not words
presented, one by one, on a computer screen (at a rate of one word every 1.2 seconds) were in the target list
(responding ‘yes’ or ‘no’). The recognition list included the 30 target words and 30 distractors. An alternative
version was available for repeat testing.
Group comparisons of recall and recognition were analysed using repeated measures ANCOVA, with
valence the within-subject factor (positive, negative, neutral) and group as the between-subject factor and
Huynh–Feldt correction applied. Zero-centred IQ was used as a covariate. Post hoc analysis of emotional
bias was tested by univariate analysis, with separate analysis of each valence as the dependent variable;
group as a fixed factor; and baseline values for total words recalled/recognised as the covariate.
Uncorrected degrees of freedom are presented for clarity.
Effect of treatment was analysed using univariate analysis, with the post-treatment value the dependent
variable, metyrapone or placebo as a fixed factor, and baseline value a covariate.
Immediate recall was measured as number of words of each valance remembered. It had been planned
to analyse intrusions but unfortunately these had not been sufficiently systematically recorded to give
valid results.
METHODS
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Delayed recognition was analysed as number of hits and numbers of false alarms for each emotion and
overall. RT results are not reported as there was no instruction to respond as rapidly as possible, making
interpretation unclear.
Affective GoNoGoTask
This task is measure of attentional emotional bias by measuring interference caused by words of conflicting
valence. Non-depressed participants have been reported to respond more quickly to positive than negative
words and the reverse has been reported for depressed patients.99
The computerised task consisted being asked to respond as quickly as possible with a key press to target
words presented on the screen, and to ignore distractor words. Six types of blocks were presented made
up of positive, negative and neutral targets, and of positive, negative and neutral distractors, for example
positive targets and negative distractors (GoPos+NoGoNeg), positive targets and neutral distractors
(GoPos+NoGoNeut), negative targets and positive distractors (GoNeg+NoGoPos), etc. For each type of
block, participants were instructed as to which type of target to respond. Each block contained nine
targets and nine distractors, with each word presented for 1.75 seconds. Each type of block was presented
twice, making 12 blocks in all. Some early participants received a version of the task with three blocks of
each type but it was decided that this made the task too long. These results are included in the analysis
correcting for the number of presentations by using hit rates (hits/targets presented) and false-alarm rates
(false alarms/distractors presented).
Given the large number of ways the data from the task could be analysed, and the number of blocks, we
collapse the blocks by either target or distractor to give three Go conditions (GoPos, GoNeg, GoNeut) and
three NoGo conditions (NoGoPos, NoGoNeg and NoGoNeut) and we present only the RT data. Participants
were excluded if the number of correct hits in any block fell outside three standard deviations (SDs) from
the mean (to exclude those who did not understand the instructions or were unable to identify the
correct valence).
Patients and control subjects were compared by an ANCOVA on pretreatment data with Huynh–Feldt
correction: valence was a within-subject factor; group was a between-subject factor; and zero-centred age
was a covariate. Post hoc analysis was by ANCOVA for each emotion separately and also covaried for each
individual’s mean RT to reveal whether or not valence affected response times. Uncorrected degrees of
freedom are presented for clarity.
The effect of metyrapone treatment in patients was assessed using multiple ANCOVA for each emotion
with the post-treatment value as the dependent variable and the pretreatment value as the covariate.
Functional magnetic resonance imaging
Newcastle
We investigated levels of blood-oxygen-level-dependent (BOLD) signal changes in response to negative
emotional stimuli in a subgroup of patients in the Newcastle centre using fMRI. Two emotional task
paradigms were utilised, which are known to recruit both limbic and prefrontal brain regions. The facial
emotion processing (FEP) task was based largely on work by Hariri et al.,100 and included two emotional
conditions [‘emotional matching’ (EM) and ‘emotional labelling’ (EL)] and one control condition [‘shape
matching’ (SM)]. The emotional enhancement of memory (EEM) task was based on work by Kensinger and
Corkin101 and included encoding conditions for negative arousing, negative non-arousing and emotionally
neutral words.
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The FEP task presented triplets of stimuli to participants, with two stimuli at the bottom left and right of
the screen, and one stimulus in the centre top. In all conditions participants had to indicate via button
press which of the two stimuli at the bottom matched the stimulus at the top. In the EM condition, all
three stimuli were greyscale photographs of faces (from the Ekman set),102 showing either anger or fear,
but from two different actors, with one of the bottom faces being repeated at the top. Thus theoretically
no explicit processing of the emotion in the faces was required. In the EL condition, the bottom images
showed one face displaying anger and one face displaying fear; the centre-top stimulus was an emotional
label (‘anger’ or ‘fear’). Thus participants had to explicitly identify which face showed the indicated
emotion. The SM condition showed simple elliptical and circular shapes, filled with random pixels of a
similar distribution of greyscale values as the faces. Similar to the EM condition, the top shape was exactly
identical to one of the bottom two shapes. Each triplet was presented for 3.5 seconds in blocks of five
trials. Within each condition, the order of trials was randomised. Blocks of trials were separated by periods
of baseline that were between 15.25 and 15.75 seconds long. Three blocks per condition were presented
in one of the two predefined orders of blocks.
In the EEM task, participants were presented with individual words displayed in the centre of the screen,
and had to decide whether or not the word was ‘concrete’ or ‘abstract’. Unbeknown to participants,
all words fell into one of three categories according to their emotional valence and arousal, based on
published word norms: negative arousing words, negative non-arousing words and neutral words.
Individual words were presented for 2400milliseconds, followed by a fixation cross of 600 milliseconds.
They were presented in short blocks of three or four words from the same category. Two blocks of trials
were always presented directly after each other. They were then followed by a short block of three trials of
a distractor task. In the distractor task, participants were presented with days of the week and had to
make a decision whether or not the day was in the first or second half of the week. The day directly in the
middle of the week, here defined as Thursday, was never presented. A baseline period of 9 seconds
followed each distractor block. In total, 28 words of each category were presented. There were two fixed
orders of trials that were counterbalanced across participants. Owing to the repeated nature of the task for
the patient group, all participants were informed that they would be asked to remember the presented
words after the scan. Data from this recognition test will not be presented here.
Scanning took place on an Achieva® 3.0T MR scanner (Philips Healthcare, Best, the Netherlands). The
functional tasks used standard echo planar imaging (EPI) sequences [FEP task: voxel size 2.5 × 2.5 × 4mm3,
35 slices, repetition time (TR)= 2500milliseconds, echo time (TE)= 30milliseconds; EEM task: 3 × 3 × 4mm3,
33 slices, TR= 2250milliseconds, TE= 30milliseconds]. To reduce motion-related distortions and artefacts,
slices were orientated sagittally to keep the most common type of motion (head tilts) within slices. REST
(REgional Saturation Technique) slabs were positioned above and below the head. In addition to these
functional sequences, a standard T1-weighted, 1-mm isotropic anatomical scan was performed. The
anatomical scans were utilised in the preprocessing of the functional data.
Functional image processing was undertaken using Statistical Parametric Mapping (SPM8) (Wellcome Trust
Centre for Neuroimaging, University College London, London, UK; www.fil.ion.ucl.ac.uk/spm) and
followed standard procedures, including slice timing correction, realignment and co-registration to the
anatomical scan. First-level models were computed in native space and included regressors for the different
stimulus types, the estimated realignment parameters and their first derivative. Contrast images from these
models were normalised to standard space using parameters estimated from the anatomical scan and
spatially smoothed with a 8-mm full width at half maximum Gaussian kernel. Second-level models were
created using the results from all included participants. Whole-brain analyses were performed to identify if
the different task conditions resulted in differential BOLD signal across both groups of participants in the
amygdala. If so, BOLD signals were extracted from the significant clusters. In addition, BOLD signals
were extracted from anatomically defined regions of interest of the amygdala using probabilistic
cytoarchitectonic maps.103 Extracted BOLD signals were analysed using repeated measures ANOVA, with
condition as within-subject factor, group as between-subject factor, and age, sex and premorbid IQ
as covariates.
METHODS
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Manchester
Subjects were scanned using a parallel, between-subjects design on a 1.5-tesla (1.5-T) scanner. The
scanning session, which took place between 12 noon and 3 p.m., consisted of a brief localisation
magnetic resonance imaging (MRI) scan, followed by two fMRI protocols in which participants undertook
the n-back task followed by the encoding emotional pictures memory task. After a 6-minute structural MRI
scan, subjects completed the retrieval emotional pictures memory task.
All computerised tasks were run on a PC in E-Prime 2.0 (Psychology Software Tools Inc., Sharpsburg, PA, USA)
and back-projected onto a screen visible to the participant via two mirrors attached to the head coil. The task
responses were acquired from the participant using a fibre-optic button box held in the right hand. All
participants received standardised training on how to perform the tasks prior to the scan.
The task used by Whalley et al.104 was adapted to create an in-scanner recognition memory task.
Additional images from the IAPS battery were used to lengthen the task.
For the encoding task, a total of 60 images were shown in five blocks of six positive and six neutral images
(each block lasting 48 seconds). These were followed by a block of rest, consisting of a fixation cross,
which also lasted 24 seconds each. There were five blocks of each condition shown, making the task
length 360 seconds in total. Participants were asked to indicate, using the button box, whether or not they
felt that the picture was ‘emotional’, and instructed to remember the images.
During the recognition segment of the task, a total of 96 images were shown in six blocks of eight positive
images and six blocks of eight neutral images (each block lasting 48 seconds). These were followed by a
block of rest, consisting of a fixation cross, which also lasted 24 seconds each. There were six blocks of
each condition shown, making the task length 432 seconds in total. All images shown in the encoding
section were re-shown. Participants were asked to indicate, using the button box, whether or not they
recognised the image from the encoding task.
A blocked version of the n-back task was adapted from the task of Koychev et al.105 It consisted of four
blocks of zero-back and four blocks of two-back, each lasting 32 seconds. These required three correct
responses from 13 stimuli per block using the button box. These blocks were interspersed with four blocks
of rest consisting of a fixation cross, lasting 20 seconds.
Scanning was carried out on an Intera® 1.5-T MRI scanner (Philips Healthcare, Best, the Netherlands) with
prospective motion correction. Data were acquired with T2*-weighted, gradient echo EPI. Full brain
coverage was used with TR= 2 seconds, TE= 40milliseconds, 3.5 mm in-plane resolution, 4.5-mm slice
thickness with 0.5-mm slice gap and 29 slices.
Data analysis
Behavioural and demographic data were analysed using Statistical Package for Social Science version 20.0
(SPSS Inc., Chicago, IL, USA). Behavioural data from both tasks were analysed using repeated measure
ANOVA with one within-subject factor condition (difficulty: e.g. emotional valency – positive, neutral
or zero-back, two-back) and one between-subject factor (participant group), as well as independent
t-tests. The outcome measures used for the tasks were speed of response, number omitted, number of
false positives and number correct. Results are presented as mean and SD, except when adjusted means
from ANCOVA analyses are reported with standard error of the mean (SEM). Error bars in figures are also
plotted as SEM for clarity, unless otherwise stated.
Data from fMRI were processed and analysed using SPM8. Scans were spatially preprocessed using
standard protocols. They were realigned, using the first scan as a reference, normalised into the Talairach
and Tournoux106 stereotactic space using Montreal Neurological Institute (MNI) templates then spatially
smoothed using a 8-mm Gaussian kernel. A mask was created, which was a sum of the regions of interest
(ROIs) for each task and used as single comparison in the analysis.
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For both of the emotional picture tasks (encoding and retrieval), positive and neutral conditions were
contrasted with rest. Second-level processing was performed using one-sample t-tests to explore the main
effect of task on positive pictures minus rest, neutral pictures minus rest, all pictures minus rest and vice versa,
and a two-sample t-test to explore the effect of depression on each level of the task (HVs minus patients and
vice versa). For the encoding task, our ROIs were the amygdala, hippocampus and parahippocampal gyrus,
dorsolateral prefrontal cortex (dlPFC) and inferior temporal area [Brodmann area 9 (BA9), BA20 and BA45].
For the retrieval task, the a priori regions of interest were amygdala, hippocampus, parahippocampal gyrus,
anterior cingulate cortex (BA32), insula, dlPFC and frontopolar areas (BA9 and BA10).
For the n-back task, both levels of n-back were contrasted with rest. Second-level processing was
performed using one-sample t-tests to explore (1) the main effect of task at the highest working memory
load (two-back minus zero-back) and (2) the effect of depression on each level of the task (HVs minus
patients and vice versa). Our ROIs were lateral premotor cortex (BA6), dorsal anterior cingulate cortex
(BA32), dlPFC (BA9, BA46) ventrolateral prefrontal cortex (BA44, BA45, BA47), medial posterior parietal
and inferior parietal lobule (BA7, BA40) and medial cerebellum, as per Symonds et al.107
Within these areas we report as significant areas family-wise error (FWE) corrected peak level p(FWE)< 0.05 for
the region of interest. Other areas surviving p(FWE)< 0.05 at a whole-brain level are also reported for interest.
Acute effects of hydrocortisone in treatment-resistant depression using
pharmacological functional magnetic resonance imaging
We aimed to examine the effect of an acute bolus of hydrocortisone on patients with TRD in comparison
with age- and sex-matched HVs. Using pharmacological functional magnetic resonance imaging (phMRI),107
we investigated whether or not BOLD signal is altered after acute administration of 100mg of intravenous
hydrocortisone in a between-subject, placebo-controlled parallel design study of 30 patients and
30 control subjects.
Electroencephalography
To examine the predictive ability of these identified EEG variables in response to metyrapone augmentation,
patients consenting to EEG recordings had recordings made prior to commencement of treatment with
metyrapone. Of particular interest was whether or not a high slope in the LDAEP analysis, predictive of
response to SSRIs, would predict response to metyrapone, suggestive of an enhancement of serotonergic
function. To examine both the effect of emotion on episodic memory retrieval and the putative ERP marker
of LTP, EEG was recorded prior to treatment with metyrapone in patients and a cohort of healthy control
subjects, with patients tested again at week +5.
Electroencephalography was recorded from 29 active silver/silver chloride electrodes attached to the scalp
using an EEG cap (EasyCaps, Germany) with electrodes placed according to the international 10–20 system.
Two further electrodes were placed on each mastoid process (right mastoid as a reference; left mastoid as
an active channel), two on the outer canthi of the eyes to record horizontal eye movements [horizontal
electrooculogram (HEOG) channel] and one on the nasion with linked electrodes under the midpoint of
each eye to record vertical eye movements [vertical electrooculogram (VEOG) channel]. All electrode
impedances were kept at < 5 kiloohms (kΩ). Recordings were made using a Neuroscan® SynAmps2®
amplifier (Compumedics Germany GmbH, Singen, Germany) with an analogue–digital conversion rate of
500 Hz, and high- and low-pass filters of 0.5 Hz and 30 Hz, respectively.
Resting electroencephalography
Resting EEG was recorded in four 5-minute blocks, with participants alternating between an eyes open
and eyes closed state (OCOC). Participants were instructed to sit still, avoiding any unnecessary
movements, and to look straight ahead during the ‘eyes open’ state.
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Loudness dependency of auditory evoked potentials recordings
The LDAEPs were recorded in relation to 200 individual 1000-Hz tones (50-milliseconds total duration,
10-milliseconds rise and fall times) presented binaurally through headphones at a random repetition rate
of 0.56–0.45 Hz. The tones were delivered at intensities of 54, 64, 74, 84 and 94 dB (40 of each) in a
randomised order.
Emotional Source Memory Task recordings
The Emotional Source Memory Task is divided into two elements: a study phase and a test phase. In the study
phase, participants were presented with an emotionally valenced background picture of an event or scene
drawn from the IAPS and were asked to rate its valence (7-point Likert scale, ranging from strongly negative
to strongly positive). Following this, the background picture was superimposed with a neutral object.
Participants were asked to make an association between the object and the event/scene in the background
picture. Following completion of the study phase and a 5-minute delay, the test phase entailed a surprise
memory test throughout which EEG was recorded. During the test phase, old and new neutral objects were
presented, and participants had to make a recognition judgement responding either ‘old’ or ‘new’ via a
keypad. If the participant recognised the object from the study phase, and responded as such, a follow-up
recollection response was required. For this, the participant was asked to recall the valence of the associated
background presented at study with the neutral object and respond via a keypad (positive, neutral, negative,
don’t know). Analysis focused on behavioural data and ERPs of correctly identified old objects that were also
associated with a correct identification of background valences (Hit–Hits), with relation to the emotional
valence rating of the associated background given during the study phase.
Long-term potentiation recordings
During each testing session visual evoked potentials (VEPs) were recorded. The visual stimuli and the
experimental procedure were based on those used by Teyler et al.69 The stimulus (a series of chequerboards)
was presented on a computer monitor (circular chequerboard stimuli subtending 8 degrees of visual angle, check
size 0.3 degrees of visual angle). Participants were instructed to fixate on a red square in the centre of the screen.
During baseline testing, the stimuli were presented at a frequency of 0.8 Hz (duration 33milliseconds), and there
were two baseline blocks of 100 flickers each. Baseline testing was followed by a block of photic tetanus when
the identical chequerboard stimulus is presented at 8.6 Hz for 1000 flickers. This was followed by 2 minutes’ rest
with eyes closed, followed by two post-tetanus test blocks (with stimulus presentation as per baseline testing) at
4-minute intervals. EEG was recorded during the two baseline and two post-tetanus test blocks.
Electroencephalogram analysis
All EEG analysis was conducted using Neuroscan 4.5 software. EEG recordings were arithmetically adjusted
to a linked mastoid reference. Blink correction was performed on the basis of VEOG recordings using the
Neuroscan’s ocular artefact reduction function. Residual artefacts were removed, whereby any epoch, for which
any channel (including HEOG but not VEOG) had a voltage deflection of > +75 µV or < –75 µV, was rejected.
It did not prove worthwhile analysing the EEG predictors of response, nor the ESMT ERPs for reasons
described below. However, the LTP EEG data were analysed. This is described in Chapter 3.
Continuous EEG recorded during the VEP test phases was epoched from –100milliseconds to
+ 500milliseconds around the presentation of the visual chequerboard stimulus. Epochs were artefact
corrected and rejected as described above. Retained epochs were averaged to generate VEPs. To
determine time windows within which N1, P1 and N1b amplitudes would be determined, peak detection
using Neuroscan algorithms was run on the grand-averaged VEP data (all time points, all subjects) for each
individual channel. The focus of analysis was on the Oz electrode, as this has been shown to demonstrate
the largest and most robust VEP.69 The average amplitude of N1, P1 and N1b was calculated as an area
under the curve for a 20-milliseconds window centred at 160milliseconds for N1, 248milliseconds for P2
and 204milliseconds for N1b, being halfway between N1 and P2. The magnitude of VEP potentiation was
calculated as the difference between averaged N1, P2 and N1b components pre-tetanic stimulation and
the first post-tetanic VEP measure.
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Important changes to methods
The initial study aim was to recruit 190 patients. However, as a result of initial slow recruitment rates and
after discussion with the funder, sponsor and the independent Data Monitoring and Ethics Committee
(DMEC), a revised target of 140 was agreed by accepting a reduction in power of the study from 90% to
80% on the primary outcome measure.
Participants
Patients
Eligibility criteria
l Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV)108-defined major
depressive episode, assessed using the Structured Clinical Interview for DSM (SCID) research version.109
l HDRS17110 score of ≥ 18 at weeks –2 and 0 (see below).
l Massachusetts General Hospital Treatment Resistant Depression (MGH-TRD) staging score of 2–10 as a
measure of treatment refractoriness.111 This cut-off is based on MGH-TRD scores seen in primary and
secondary care, but short of tertiary care, in the NHS.112
l Single-agent or combination antidepressant treatment that includes a serotonergic drug (SSRI, tertiary
amine tricyclic, venlafaxine, duloxetine or mirtazapine). At the point of randomisation, patients must
have been on their current antidepressant medication, at the current dose, for a minimum of 4 weeks.
l Aged between 18 and 65 years. An upper age limit was included to reduce rates of physical health
comorbidities that could complicate decisions around the safety of prescription of a drug (metyrapone)
that may lower cortisol levels.
Exclusion criteria
l Other DSM-IV axis 1 diagnosis, other than an anxiety disorder considered to be secondary to a primary
diagnosis of depression, confirmed using SCID.
l Physical comorbidity that would make metyrapone inappropriate, including untreated hypothyroidism,
disorders of steroid production, cardiac failure, angina, myocardial infarction in the last 3 years and
renal failure.
l Pregnancy or breastfeeding.
l Use of medication that would interfere with metyrapone.
l Dependence on alcohol or other drug(s) in the past 12 months, and/or current harmful use of such
substances (defined as meeting SCID criteria for harmful use or dependence).
l Current or recent participation in a research study that could interfere with results.
Healthy volunteers
Eligibility criteria
l No evidence of axis 1 disorder on the DSM-IV,108 assessed using the SCID research version.109
l Aged between 18 and 65 years.
Exclusion criteria
l Physical comorbidity as per above (see Patients).
l Pregnancy or breastfeeding.
l Use of medication as per above (see Patients).
l Dependence on alcohol or other drug(s) in the past 12 months, and/or current harmful use of such
substances (defined as meeting SCID criteria for harmful use or dependence).
l Current or recent participation in a research study that could interfere with results.
METHODS
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Settings and locations
Patient identification took place across two hubs of the UK National Institute for Health Research
MHRN – the North East, with centres in Newcastle and Durham/Teesside, and the North West, with
Manchester as the centre – and in the West Yorkshire Comprehensive Local Research Network (CLRN),
with centres in Leeds and Bradford. Potential patient participants were identified through routine clinic
appointments at study sites and Participant Identification Centres that included Primary Care and
Community Mental Health Teams. HVs were recruited by advertisements in the University of Manchester
and by e-mails sent to the Volunteer Database of the Institute of Neuroscience, Newcastle University.
Intervention
Participants continued their existing antidepressant regime. Randomisation was in a ratio of metyrapone to
matched placebo using permuted block randomisation and a web-based system, to ensure concealment
of allocation. To ensure blinding the metyrapone was overencapsulated and the placebo was visually
identical. Participants received study drug (metyrapone 500mg or placebo) twice daily, prescribed in
the morning and at noon, for 21 days. Adherence to medication was assessed using measures of
11-deoxycortisol as described above (see HPA axis assessment).
Apart from treatment with the experimental intervention, all other treatments remained under the control
of the patient’s normal treating psychiatrist and/or GP. However, the patients’ clinicians were encouraged
to avoid changes to any medications, particularly antidepressants, between enrolment (week –2) and the
primary outcome time point (week +5) unless there was a compelling clinical reason to alter treatment.
All current medication was recorded at all follow-up time points.
Outcomes
A full detailed Statistical Analysis Protocol was drawn up (and reviewed and agreed by the DMEC) prior
to completion of the study and breaking of the study blind. The Statistical Analysis Protocol is appended
as Appendix 1.
The analysis for the primary outcome was an intention-to-treat ANCOVA of the MADRS scores at +5 weeks,
with baseline MADRS included as a covariate, differences between strata (centres and whether or not the
patient originated in primary or secondary care) and the differences between groups (patients randomised
to metyrapone vs. patients randomised to placebo) were included as fixed effects. The persistence of change
in the MADRS score was assessed using repeated measures ANOVA utilising data from all time points.
Missing values were imputed as described in the Statistical Analysis Plan (SAP: see Appendix 1). Change and
persistence of the change in other clinical and QoL measures (secondary outcomes) were examined using
the same methods. Additional secondary outcomes included rates of response (defined as a ≥ 50%
reduction in MADRS score) and remission (defined as MADRS ≤ 10) with metyrapone compared with
placebo at week +5. Unless otherwise noted, bootstrap results are based on 1000 bootstrap samples.
With regard to the mechanistic objectives, the study examined whether or not treatment with metyrapone
led to a change in HPA axis function (assessed by examining the CAR and 11 p.m. cortisol measures) and
whether or not changes in HPA axis function, compared with baseline, were seen 2 weeks post treatment.
Both baseline HPA axis function and change in function with treatment were assessed to see if they
predicted clinical response to metyrapone defined by the change in MADRS between week 0 and week +5,
in an exploratory analysis.
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Sample size
The sample size was based on detecting a difference between groups in the change in MADRS scores
between baseline and 5 weeks post randomisation. The effect size for this measure in the Jahn study33 was
0.63. The study was powered around the more conservative moderate effect size of 0.5 which, assuming a
post-intervention SD of 12 points,33 corresponds to a 6-point difference on the MADRS. An achieved
sample size of 85 per group was required to detect effect size of 0.5 with 90% power, assuming α= 0.05.
Allowing for 10% attrition during the trial, the original aim was to randomise 95 per group (190 in total).
However, as described above, the recruitment target was modified to accept a power of 80%, requiring a
sample size of 63 per group. Again allowing for 10% attrition during the trial, we aimed to randomise
70 per group; 140 in total.
Randomisation and blinding
Patients were randomised in a 1 : 1 ratio to metyrapone or placebo using permuted block randomisation,
stratified by centre (North East, North West or Leeds/Bradford), level of care setting (primary or secondary
care) and, for the North East and North West centres, by whether or not the patient agreed to participate
in the mechanistic studies. The randomisation code to produce random permuted blocks was generated by
an independent statistician in the Newcastle Clinical Trials Unit. The length of each block was randomly set
at either 2 or 4 (with equal probability), with these limits being concealed from study personnel to ensure
concealment of allocation.
Coded (numbered) packs of study drug and matched placebo were produced according to the randomisation
schedule, by Catalent Clinical Trials Supply Company, Corby, UK. Metyrapone capsules were overencapsulated
(using Coni-Snap® capsules, Capsugel, Morristown, NJ, USA) and appeared identical to the placebo capsules.
These were distributed to the clinical trials pharmacist at Northumberland, Tyne and Wear NHS Foundation
Trust, located in Newcastle.
Randomisation was achieved through the use of a centralised web-based system set up by the Newcastle
Clinical Trials Unit. Within each site, patients were randomised when they returned for their second visit at
week 0. This was carried out by a trained member of the staff at that site. After logging on to the system,
he/she entered patient details including initials, date of birth and status, with respect to each of the
stratification variables. The system then supplied a study identification number to be used for that patient.
This was entered on to a prescription for study medication, which was then signed by an authorised
clinician at the site. A copy of the prescription was faxed and the original mailed to the pharmacy in
Newcastle. Patients received their medication through the post at their home address.
In case of serious untoward incidents, the code for a particular subject was available, without
compromising the blind for the other subjects, via the research pharmacist. Existing on-call arrangements
with pharmacy were utilised so that emergency code breaks could be accessed out of hours. The
randomisation list was available only to the study pharmacist at Northumberland, Tyne and Wear NHS
Foundation Trust, the independent statistician in the Newcastle Clinical Trials Unit who produced the list
and the database manager who programmed the system. In actuality, no requests were made during the
course of the study for unblinding information.
Blinding was maintained for all patients, the clinicians who cared for them, outcome assessors and data
analysis team until the protocol for the final 24-week visit had been followed. There were no requests
from DMEC to unblind patients, although they did examine the blinded group data to look for any
relationship between those taking metyrapone and suicidal thoughts/attempts.
METHODS
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Statistical methods
Statistical methods used to compare groups for primary and
secondary outcomes
The primary outcome was the MADRS score at 5 weeks post randomisation adjusted for the MADRS score
at baseline. The mean difference between treatment groups was estimated using a mixed model,
assuming a normal error structure. The dependent variable was the MADRS score at 5 weeks; the baseline
score was included as a covariate. Difference between centres was included as a random effect; origin of
care (primary or secondary) was included as a fixed effect. Unadjusted estimates of the difference between
groups are also presented (variation between centres and differences between origin of care were
removed from the model). The analysis was undertaken on an intention-to-treat basis (i.e. groups were
defined by randomised allocation rather than the actual treatment received).
Further secondary analysis of the primary outcome was prespecified. The changes in MADRS scores in the
two randomised groups 5 weeks post randomisation were compared using an independent sample t-test.
Two further binary outcomes were defined. Response was defined as a reduction in MADRS score that
was less than or equal to half of the score at baseline; remission was defined as a MADRS score that was
≤ 10. These variables were analysed using the mixed-model approach described above, but with the
assumption of a binomial error structure and logit link function.
Secondary outcomes (including the CAS, BDI and STAI) and QoL (EQ-5D health tariff and EuroQol health
scale) were analysed using the mixed-model approach described above.
A secondary clinical objective was to consider the persistence of the effect of metyrapone. The prespecified
analysis to assess persistence was to extend the mixed-model approach described above to include
repeated measures on individuals. Additional explanatory variables included in the model were change
over time (differences between scores observed at different visits) and an interaction between these
changes and treatment group.
A further clinical objective was to assess how well metyrapone was tolerated. Side effects were assessed
using the TSES and YMRS. The YMRS was analysed using the mixed-model approach described above.
For the TSES, the relative risk (RR) of individual symptoms in the two groups was calculated.
The number of non-serious adverse events (AEs) reported by patients in each of the randomised groups
was compared using a negative binomial regression model.
Methods for additional analyses, such as subgroup analyses and
adjusted analyses
In the SAP, further per-protocol analyses were specified, in which groups were defined on the basis of
compliance with medication, based on measurements of 11-deoxycortisol. (However, see Chapter 4,
Discussion, Limitations.) Additional survival analysis of time to response and time to remission, based on a
Cox proportional hazards model, was also specified.
Important changes to statistical methods as proposed
The primary analysis in the original protocol was an independent t-test of change in MADRS scores
(baseline to week +5). The main reason for specifying this as the primary analysis was that it corresponds
to the stated sample size calculation. The main disadvantage for specifying it as the primary analysis are
the following recommendations:
(a) ANCOVA is usually to be preferred to an analysis of change scores (see, for example, Van Breukelen,113
Senn114).
(b) The primary analysis should take into account the stratification factors used in the randomisation of
patients (Parzen et al.,115 Kahan and Morris116).
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Consequently, when formulating the SAP, the primary analysis was defined as ANCOVA, and the analysis
of change scores was defined as a secondary analysis of the primary outcome. The final version of the SAP
was approved prior to the breaking of the blind and is given in Appendix 1.
In retrospect, the proposed secondary analyses of persistence and times to response and remission should
have been specified as being conditional on metyrapone being proven to be clinically efficacious at the
primary end point. With no observed reduction in depression 5 weeks after randomisation, there was no
rationale for testing hypotheses based on differences between groups at further time points. For outcomes
for which there was no evidence of a difference between groups 5 weeks post randomisation, summary
statistics are presented for the subsequent visits.
The TSES was not analysed as a single score (as had originally been specified in the SAP), after a review of
the literature describing its development and use indicated that this was not appropriate.88
METHODS
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Chapter 3 Results
Participant flow
The numbers of participants who were referred, screened, randomised and followed up to primary end
point (5 weeks) and to the end of the study (24 weeks) are shown below in Figure 1. A total of 877 patients
were referred to the study team: 237 from primary care, 320 from secondary care and 310 as self-referrals
following media exposure of the study or seeing posters in GP surgeries. In 10 cases the source of the
referral was not clear. Of these 877 patients, 284 were screened for eligibility. Of the 593 who were not
877 patients identified/made
initial contact
593 not formally screened
• 123 declined to participate
• 294 non-response to invite
• 139 ineligible on telephone screening
• 37 other reasons
119 excluded
• 111 not meeting inclusion criteria
• 8 dropped out prior to randomisation
284 formally screened
for eligibility
83 allocated to metyrapone
69 analysed
14 lost to follow-up:
• 1 withdrew because of side effects
• 1 family bereavement
• 1 admitted and missed assessments
• 1 moved away
• 10 withdrew with no reason stated
46 analysed
23 lost to follow-up:
• 1 withdrew because of side effects
• 1 withdrew because of physical
   health corners
• 1 family bereavement
• 2 admitted for physical health
   problems
• 1 too psychiatrically unwell
• 17 withdrew with no reason stated
82 allocated to placebo
74 analysed
8 lost to follow-up:
• 6 withdrew with no reason stated
• 2 away on holiday
58 analysed
16 lost to follow-up:
• 1 withdrew because of lack of effect
• 1 withdrew because of side effects
• 1 too psychiatrically unwell
• 1 admitted because of physical
   health problems
• 12 withdrew with no reason stated
165 randomised
Allocation
Enrolment
Primary
outcome
(week + 5)
End of follow-up
(week + 24)
FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) diagram.
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screened, 123 declined when contacted, 294 did not respond to an invitation for screening or did not
attend and 139 were deemed ineligible on a brief telephone screening. The reasons for non-screening of
37 patients are not known. Of the 284 who were screened, 173 were deemed to be eligible. Of the 111
who did not meet inclusion criteria, 10 did not meet the criteria for a major depressive episode using the
SCID, 52 had HDRS17 item scores of < 18, 17 had axis 1 disorders other than anxiety, nine were on an
inappropriate antidepressant and three had MGH-TRD staging scores outside the range of 2–10,58 18 had
physical disorders that excluded them and five had other miscellaneous exclusion criteria (three patients
were excluded for more than one reason). Eight patients subsequently dropped out before randomisation
(i.e. between weeks –2 and 0), so 165 patients were randomised (82 to placebo and 83 to metyrapone).
For the purposes of randomisation and analysis, patients were divided into two groups: those recruited from
secondary care and those recruited from primary care (defined here as all those not clearly identified as
currently attending secondary care). Of the 165 randomised, 143 (86.7%) completed the primary outcome
at +5 weeks (74 on placebo and 69 on metyrapone) but 22 dropped out of the study (i.e. withdrew from
both treatment and follow-up data collection). A further 39 dropped out between weeks +5 and +24, so
that 104 (63% of those randomised) completed the study (58 on placebo and 46 on metyrapone).
Overall, 42% of patients were recruited from primary care (Table 2). This figure differed between sites.
In Newcastle and Durham, 69% of patients were recruited from primary care; for Leeds/Bradford this
figure was 40%, and in Manchester only 14% of patients were recruited from primary care.
The allocation of the patients into randomised groups by site and origin of care is shown in Table 3.
The losses and exclusions after randomisation for both groups are shown in Table 4. The only reason that
patients were excluded from the intention-to-treat analyses was that they declined to attend follow-up
TABLE 2 Origin of patient by site
Primary or secondary care?
Site
TotalLeeds/Bradford Manchester Newcastle/Durham
Primary Number 15 8 47 70
% within site 39.5 13.6 69.1 42.4
Secondary Number 23 51 21 95
% within site 60.5 86.4 30.9 57.6
Total Number 38 59 68 165
% within site 100.0 100.0 100.0 100.0
TABLE 3 Allocation of patients into groups by site and origin
Source of patient
Placebo Metyrapone
n % n %
Site
Leeds/Bradford 19 23.2 19 22.9
Manchester 29 35.4 30 36.1
Newcastle/Durham 34 41.5 34 48.2
Origin
Primary care 35 42.7 35 42.2
Secondary care 47 57.3 48 57.8
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visits despite prompts and their data were therefore not available. There were no exclusions for
other reasons.
Dropout was broadly similar in each of the two arms of the trial, although a slightly greater proportion of
those patients randomised to metyrapone failed to attend follow-up visits.
Recruitment
Dates defining recruitment and follow-up
The first patient was randomised at the beginning of March 2011 and the last patient in mid-December 2012.
The last 24-week follow-up was in late June 2013.
Recruitment was initially slow largely due to the complexity of the protocol which some clinicians and
patients found too daunting. This required the development of a recovery plan, agreed by the funder at
month 10, which included some changes to the protocol to reduce of the number of exclusions related to
medical comorbidities (criteria shown above are final ones). The presence of any axis 1 disorder in addition
to a major depressive episode was initially an exclusion criterion. This was relaxed to allow inclusion of
patients with an axis 1 diagnosis of an anxiety disorder. There was much greater emphasis by the MHRN
and others on promoting the study within clinical teams. The CLRN and Northumberland, Tyne and Wear
Trust supported the study by funding junior clinicians through the Research Capability Funding process and
these were an invaluable help, in particular with patients’ screenings. Several media events were also very
helpful in raising awareness of the study and enhancing recruitment. Adverts were also placed in some
local publications in Newcastle and Leeds, and this was a major reason for the higher proportion of
primary care patients in Newcastle than, for example, Manchester.
Why did the trial end or stop?
The trial was stopped at the end of the study, as agreed with the Efficacy and Mechanism Evaluation
(EME) Board after the last patient’s last visit. Owing to enhanced recruitment (n= 165 randomised), we
were able to exceed the revised target of 140, giving us 84% power to detect the effects hypothesised in
the sample size determinations. The trial period included a 7-month extension.
Baseline data
Baseline data of demographic and clinical characteristics are shown in Table 5. The placebo and the
metyrapone groups were well balanced on key demographic variables and clinical characteristics.
TABLE 4 Attendance at follow-up visits by group to which randomised
Visit
Group to which randomised
RR of attendingPlacebo (n= 82) Metyrapone (n= 83)
n % n % RR 95% confidence limits
Lower Upper
Week 3 77 93.9 72 86.7 0.92 0.83 1.02
Week 5 74 90.2 69 83.1 0.92 0.82 1.04
Week 8 66 80.5 62 74.7 0.93 0.79 1.09
Week 16 61 74.4 54 65.1 0.88 0.71 1.07
Week 24 58 70.7 46 55.4 0.78 0.61 0.99
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TABLE 5 Baseline demographic data and clinical characteristics
Characteristics
Group
Placebo (n= 82) Metyrapone (n= 83)
Gender n % n %
Male 30 36.6 36 43.4
Female 52 63.4 47 56.6
Race n % n %
White 77 93.9 80 96.4
Other 5 6.1 3 3.6
Age Mean SD Mean SD
Age (years) 45.2 10.4 47.6 9.9
Suicide risk n % n %
Zero 16 19.5 11 13.3
Low 32 39.0 38 45.8
Medium 13 15.9 10 12.0
High 21 25.6 24 28.9
‘Yes’ responses to suicide questions n % n %
Wished that they were dead 56 68.3 61 73.5
Self-harm 14 17.1 18 21.7
Suicidal thoughts 34 41.5 30 36.1
Suicide plan 7 8.5 2 2.4
Suicide attempt in last month 1 1.2 0 0.0
Suicide attempt ever 44 53.7 49 59.0
Yes to at least one question 66 80.5 71 85.5
Smoking status n % n %
Non-smoker 36 43.9 23 27.7
Ex-smoker 16 19.5 25 30.1
Current smoker 30 36.6 35 42.2
Alcohol consumption (n = 82 and 83, respectively) Mean SD Mean SD
Units per week 6.9 12.8 7.0 11.2
Medical history n % n %
Medical condition 47 57.3 48 57.8
Visited hospital 67 81.7 64 77.1
Waiting to attend hospital 28 34.1 29 34.9
Allergies 33 40.2 32 38.6
Chest pain/wheeziness 28 34.1 34 41.0
Skin condition 24 29.3 29 34.9
Faints/fits/seizures 20 24.4 23 27.7
Weight change 37 45.1 38 45.8
Liver/kidney disease 10 12.2 6 7.2
Heart disease 14 17.1 12 14.5
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
TABLE 5 Baseline demographic data and clinical characteristics (continued )
Characteristics
Group
Placebo (n= 82) Metyrapone (n= 83)
Vital signs Mean SD Mean SD
Height (cm) 169.6 10.4 169 10.4
Weight (kg) 90.0 22.2 89.4 19.8
BMI (kg/m2) 31.2 6.6 31.5 6.9
Respiratory rate (breaths per minute) 15.9 4.3 15.5 3.5
Systolic blood pressure, standing (mmHg) 132.9 15.8 133.7 19.7
Diastolic blood pressure, standing (mmHg) 86.1 11.7 86 12.2
Heart rate, standing (beats per minute) 79.1 14.4 79.4 15.2
Systolic blood pressure, sitting (mmHg) 133.7 15.9 132.2 18.4
Diastolic blood pressure, sitting (mmHg) 83.2 12.4 83.9 12.0
Heart rate, sitting (beats per minute) 71.4 11.9 79.4 15.2
Psychological health and QoL Mean SD Mean SD
STAI: state anxiety 41.0 5.8 42.8 6.5
STAI: trait anxiety 48.3 5.2 48.5 5.7
MGH 4.6 1.8 4.9 2.0
MADRS 28.1 5.4 27.7 6.7
CAS 10.0 4.6 9.5 4.5
BDI 34.8 10.3 35.6 10.9
HDRS17 at screening 23.0 3.9 23.3 3.9
HDRS17 at randomisation 22.3 3.2 22.2 3.5
EQ-5D 0.37 0.3 0.37 0.3
EQ-VAS 40.9 16.6 42.3 19.4
Big Five Inventory (n = 73 and 72, respectively) Mean SD Mean SD
Openness 3.14 0.85 3.11 0.85
Conscientiousness 3.17 0.73 3.08 0.79
Extroversion 2.23 0.79 2.32 0.85
Agreeableness 3.59 0.70 3.61 0.59
Neuroticism 4.31 0.54 4.28 0.56
Family history of psychiatric disorders (n = 82 and 82, respectively) n % n %
Any disorder 56 68.3 48 58.5
Depression 43 52.4 40 48.8
Suicide 12 14.6 8 9.8
Bipolar disorder 4 4.9 5 6.1
Anxiety 12 14.6 15 18.3
Obsessive–compulsive 5 6.1 6 7.3
Schizophrenia 6 7.3 7 8.5
Eating disorder 3 3.7 2 2.4
Drug or alcohol problem 9 11.0 10 12.2
Other 6 7.3 4 4.9
EQ-VAS, EuroQol visual analogue scale.
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In general, for data arising from interview-administered questionnaires, there were very few missing data
items (Table 6). There was a greater number of missing items in the data arising from self-completion
questionnaires, but, overall, the level of missing data was very low and only a small number of missing
values were imputed.
In general, for data arising from interview-administered questionnaires, there were very few missing
data items. There was a greater number of missing items in the data arising from self-completion
questionnaires, but, overall, the level of missing data was very low.
Numbers analysed
Analysis was on the basis of intention-to-treat by original assigned groups (placebo n= 82, metyrapone
n= 83). Details of the numbers analysed for each outcome measure, at each time point, for both groups,
can be found in Appendix 2.
TABLE 6A Mood, anxiety and QoL scores: level of missing data and data imputation at baseline
Measure n
No. of participants at baseline for whom:
Mean no. of
imputed itemsaScore is missing
Score has been calculated
All Without imputation With imputation
MADRS 165 0 165 165 0 –
CAS 165 0 165 165 0 –
State anxiety 165 3 162 154 8 1.13
Trait anxiety 165 3 162 153 9 1.00
BDI 165 3 162 160 2 6.00
YMRS 165 1 164 164 0 –
EQ-5D tariff 165 3 162 162 0 –
EQ-5D health 165 6 159 159 0 –
a The mean number of missing items for the subset of participants from whom a total score was calculated
using imputation.
TABLE 6B Mood, anxiety and QoL scores: level of missing data and data imputation at 5 weeks post randomisation
Measure n
No. of participants at primary end point for whom:
Mean no. of
imputed itemsaScore is missing
Score has been calculated
All Without imputation With imputation
MADRS 143 0 143 143 0 –
CAS 143 0 143 143 0 –
State anxiety 143 4 139 136 3 2.00
Trait anxiety 143 4 139 137 2 1.00
BDI 143 4 139 135 4 3.75
YMRS 143 0 143 143 0 –
EQ-5D tariff 143 4 139 139 0 –
EQ-5D health 143 9 134 134 0 –
a The mean number of missing items for the subset of participants from whom a total score was calculated
using imputation.
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Outcomes and estimation
Results for the primary and secondary clinical outcomes and secondary analysis of it, as outlined above and
described in detail in the prespecified SAP (see Appendix 1), are described below. There is one exception to
this: the prespecified analysis excluding patients who discontinued treatment during the 3-week treatment
period and another utilising the 11-deoxycortisol measure of apparent concordance with treatment are
not included, as these analyses have not been completed owing to lack of availability of the data
(see Analyses not yet complete, below).
Primary outcome measure: Montgomery–Åsberg Depression Research Scale
The primary outcome measure was depression as measured by the MADRS instrument. The key objective
of the trial was to ascertain whether or not the strategy of treating patients with metyrapone resulted in a
clinically significant reduction in depression at 2 weeks post treatment (5 weeks post randomisation) when
comparing treatment with placebo.
Baseline
The mean MADRS score at baseline was 26.0 (SD 5.8) for patients recruited from primary care and
significantly higher at 29.4 (SD 6.0) for patients recruited from secondary care; the mean difference at this
time point was 3.4 [95% confidence interval (CI) 1.5 to 5.3]. Mean scores were non-significantly higher for
patients recruited in Manchester than with the other two sites but this is primarily due to the higher
proportion of patients recruited from secondary care in that site. The distribution of baseline scores by site
and origin is shown in the box plots in Figure 2.
The horizontal line in the centre of each box corresponds with the median score; the lower and upper
edges of the box correspond to the lower and upper quartiles of the distribution, respectively. The
‘whiskers’ show the distribution of the remaining values.
The distribution of scores in the two trial arms is shown in Figure 3. Details of the box and whisker plot are
as described for Figure 2.
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FIGURE 2 Box plots of MADRS scores by site and origin of patient.
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Effect of treatment group on Montgomery–Åsberg Depression Research
Scale score
Summary statistics for the MADRS at all visits are given in Table 7, and the distributions of scores are
illustrated in Figure 4.
TABLE 7 Montgomery–Åsberg Depression Research Scale scores by visit and group to which randomised
Visit
Placebo Metyrapone Total
Mean n SD Mean n SD Mean n SD
Baseline 28.1 82 5.4 27.7 83 6.7 27.9 165 6.1
+3 weeks 20.8 77 9.9 22.6 72 10.9 21.7 149 10.4
+5 weeks 22.4 74 10.6 21.7 69 10.9 22.1 143 10.7
+8 weeks 22.6 66 10.8 21.2 62 10.4 21.9 128 10.6
+16 weeks 20.5 61 11.5 21.4 54 11.0 20.9 115 11.2
+24 weeks 20.0 58 11.6 21.0 46 11.1 20.4 104 11.3
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FIGURE 3 Box plots of MADRS scores by group to which randomised.
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FIGURE 4 Montgomery–Åsberg Depression Research Scale scores over time for patients treated with either
metyrapone or placebo. Data plotted as mean, with error bars representing the SEM.
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Examination of the summary statistics and Figure 4 suggests that there is a reduction in the mean scores at
all of the follow-up visits compared with baseline, but that there is little difference at any time point in the
groups randomised to metyrapone or placebo. The issue of whether or not this result may be effected by
differential dropout between the groups is discussed below (see Ancillary analyses) and later in this chapter
(see Figures 11 and 12).
Primary outcome analysis The prespecified primary analysis was an ANCOVA of week +5 MADRS scores,
with baseline scores included as a covariate, adjusted for differences between randomisation strata
(study site and primary or secondary care origin of the patients). The difference between groups was
estimated on an intention-to-treat basis, with patients being included in the group to which they
were randomised.
Fitting a simple regression model, including only baseline MADRS score and a binary indicator of group to
which randomised, yielded the following regression coefficients:
l baseline MADRS: 0.88 (95% CI 0.63 to 1.12)
l difference between groups (metyrapone–placebo): –0.43 (95% CI –3.48 to 2.63).
The MADRS score at 5 weeks was highly correlated with the score at baseline; the difference between
groups at 5 weeks did not differ significantly from zero.
Variation between sites was then included as a random effect, and the difference between patients
recruited from primary care and those recruited from secondary care was added as a fixed effect. There
was little change to the estimated effect of metyrapone; the estimated difference between groups, based
on the adjusted model, was –0.51 (95% CI –3.48 to 2.46).
Further analysis of Montgomery–Åsberg Depression Research Scale data
Change in MADRS scores between baseline and week +5: a prespecified secondary analysis was to
calculate the change in MADRS scores from baseline to week +5 for each patient and to compare group
means using an independent sample t-test. Summary statistics for baseline, week +5 and change scores
are given in Table 8.
There was a significant reduction in MADRS scores of approximately 6 points between baseline and
week +5. The difference between the changes in the metyrapone group and the change in the placebo
group was= –0.39 (95% CI –3.37 to 2.67) and did not differ significantly from zero (t141= 0.252;
p= 0.80). The estimated effect of metyrapone is very similar to that obtained from the ANCOVA.
TABLE 8 Mean MADRS scores at baseline and week +5 by group to which randomised
Groupa
Baseline Week 5 Reduction
Mean 95% CI Mean 95% CI Mean 95% CI
Placebo 28.2 26.9 to 29.4 22.4 20.1 to 24.8 5.8 3.7 to 7.9
Metyrapone 27.9 26.2 to 29.6 21.7 19.2 to 24.4 6.2 4.0 to 8.3
All 28.0 27.02 to 29.0 22.1 20.3 to 23.8 6.0 4.5 to 7.5
a Statistics are based on complete data on n= 74 (placebo group) and n= 69 (metyrapone group).
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Analysis using atypical Montgomery–Åsberg Depression Research Scale scores
These were calculated using the highest score from items 4a and 4b and items 5a and 5b on the MADRS.
The mean atypical MADRS score at baseline in the metyrapone group was 28.5 (SD 6.7) and 28.9 (SD 5.4)
in the placebo group. For both groups there was a significant reduction in atypical MADRS scores of
approximately ‘7’ between baseline and week +5. The difference between the changes in atypical MADRS
scores in the metyrapone group and the change in the placebo group was –0.42 (95% CI –3.36 to 2.63)
and did not differ significantly from zero (t141= 0.275; p= 0.79).
Persistence of change in Montgomery–Åsberg Depression Research
Scale scores
For each individual, the MADRS score was recorded on up to five occasions following randomisation. These
repeated measures were analysed using a mixed model in which we assume that for each patient the MADRS
scores varied randomly about an individual mean score (with SD σe), but that this mean varied randomly across
patients (with SD σu). A normal distribution was assumed for each of the random effects. Fitting an initial model
with only a constant term (corresponding to the assumption that the mean MADRS score is the same at all five
follow-up visits) in addition to the random effects, the estimated mean MADRS score across the five follow-up
visits was 21.6 (95% CI 20.1 to 23.0). There was significant variation of scores both within patients [σe= 6.57
(95% CI 6.17 to 6.99)] and between patients [σu= 8.58 (95% CI 7.54 to 9.78)].
As we are interested primarily in changes in depression, the second step was to include the baseline
MADRS score as a covariate. This model indicated a significant reduction in depression from baseline at
each of the five follow-up visits. Baseline depression explained some of the variation between individual
patients (the estimate of σu fell to 6.69) but there were still significant differences between patients.
Adding in differences between randomisation strata (sites and origin of patient – either primary or
secondary care) did not explain very much additional variability. With the baseline score as a covariate
there were no significant differences between these strata. The estimated difference in depression across
all five follow-up visits between patients on metyrapone and patients on placebo was 0.75 (95% CI
–1.59 to 3.10).
There was no evidence of any trend in depression over the follow-up visits. Adding a linear trend over visits
to the model, the estimated mean change in MADRS score between consecutive visits was –0.27 (95% CI
–0.65 to 0.10) and did not constitute a clinically important change in depression.
One of the objectives of the ADD Study was to ascertain whether or not the effect of metyrapone persists
over time. Given that there is no obvious impact of the drug at 2 weeks post treatment, this objective is
moot. However, fitting an interaction between the effect of metyrapone and time demonstrates that the
interaction is not significant; there is no evidence that changes in depression over time differ between
treatment groups.
Response rates
Response was defined as a reduction of ≥ 50% in MADRS score. The proportion of responders at each
time point is shown in Table 9.
At each visit the proportion of patients who reported a MADRS that was equal to or less than half their
baseline score was between 19% and 26%. At the primary end point of 5 weeks post randomisation,
21% of patients were deemed to be responders. Responder rates for each trial arm at 5 weeks are given
in Table 10.
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Response rates were almost identical in the two groups at this time point. The odds ratio (based on a
logistic regression model adjusted for site and origin of patient: metyrapone/placebo)= 0.95 (95% CI
0.41 to 2.20). The difference between groups was not clinically or statistically significant but the wide CI
(the odds could be less than half or more than double) suggests that the study was not adequately
powered to detect differences in this binary measure of outcome.
Remission rates
A patient was defined as being in remission if their MADRS score was ≤ 10. Remission rates broken down
by visit are shown in Table 11.
The proportions of patients in remission appear to be similar at each visit. The proportion of patients in
remission 5 weeks post randomisation by study group are shown in Table 12.
Remission rates at this time point were similar in the two groups. The odds ratio (based on a logistic
regression model adjusted for site and origin of patient: metyrapone/placebo= 0.97 (95% CI 0.40 to
2.55). Again, the width of the CI is large (the odds of ‘success’ in one group could be less than half or
more than double that in the other).
TABLE 10 Proportion of patients responding to therapy by group to which randomised
Therapy
Responder?
TotalNo Yes
Placebo n 58 16 74
%a 78.4 21.6 100.0
Metyrapone n 55 14 69
%a 79.7 20.3 100.0
Total n 113 30 143
%a 79.0 21.0 100.0
a Row percentages.
TABLE 9 Number and percentage of patients who have responded to treatment by visit
Responder?
Visit
+3 weeks +5 weeks +8 weeks +16 weeks +24 weeks
No n 111 113 104 88 77
%a 74.5 79.0 81.3 76.5 74.0
Yes n 38 30 24 27 27
%a 25.5 21.0 18.8 23.5 26.0
Total n 149 143 128 115 104
%a 100.0 100.0 100.0 100.0 100.0
a Column percentages.
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Suicidal thoughts
During the trial, the AE of increased suicidality was reported (as was to be expected in such a population).
The DMEC looked at this AE with the patients divided into two – still blinded – groups. DMEC
recommended no change to the conduct of the trial and that item 10 on the MADRS (‘Suicidal thoughts’)
was examined in the two groups during analysis, and this was incorporated into the SAP.
The prespecified analysis was an ANCOVA of week +5 suicidality score, with baseline score included as a
covariate, adjusted for differences between randomisation strata. The difference between groups was
estimated on an intention-to-treat basis, with patients being included in the group to which they
were randomised.
Fitting a simple regression model including only baseline MADRS score and a binary indicator of group to
which randomised yielded the following regression coefficients:
l baseline MADRS item 10 score: 0.73 (95% CI 0.59 to 0.87)
l difference between groups (metyrapone – placebo): –0.13 (95% CI –0.52 to 0.26).
Suicidality score at 5 weeks was highly correlated with the score at baseline; the effect of metyrapone did
not differ significantly from zero.
Variation between sites and the difference between patients recruited from primary care and patients
recruited from secondary care were then added as fixed effects. There was little change to the estimated
effect of metyrapone; the estimated difference between groups, based on the adjusted model, was –0.15
(95% CI –0.53 to 0.24).
TABLE 11 Proportion of patients with a MADRS score of ≤ 10 by visit
Patient in remission?
Visit
+3 weeks +5 weeks +8 weeks +16 weeks +24 weeks
No n 127 120 110 93 80
% 85.2 83.9 85.9 80.9 76.9
Yes n 22 23 18 22 24
% 14.8 16.1 14.1 19.1 23.1
Total n 149 143 128 115 104
% 100.0 100.0 100.0 100.0 100.0
TABLE 12 Proportion of patients in remission 5 weeks post randomisation by group to which randomised
Treatment
Patient in remission?
TotalNo Yes
Placebo n 62 12 74
% 83.8 16.2 100.0
Metyrapone n 58 11 69
% 84.1 15.9 100.0
Total n 120 23 143
% 83.9 16.1 100.0
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The estimated impact of metyrapone on suicidality score (as measured by item 10 on the MADRS) was a
change of –0.15 (95% CI –0.53 and 0.24).
Secondary outcome measures
Beck Depression Inventory
Baseline data
Similar to the MADRS data, baseline BDI scores were (non-significantly) higher for patients from
Manchester (mean 37.6, SD 9.6) than patients from Leeds/Bradford (mean 33.8, SD 10.3) and Newcastle/
Durham (mean 33.8, SD 12.1). This is consistent with the observation that baseline scores were higher for
patients recruited from secondary care (mean 37.5, SD 10.5) than for those recruited from primary care
(mean 32.1, SD 9.9), as a greater proportion of patients were recruited from secondary care in Manchester
than at the other two centres. The baseline difference between patients originating from primary and
secondary care was statistically significant (–5.4, 95% CI –8.5 to –2.3). Mean and SD of BDI scores for
each randomised group are reported at baseline in Table 5.
Effect of metyrapone on Beck Depression Inventory scores 5 weeks
post randomisation
As defined in the SAP, scores obtained 5 weeks post randomisation were analysed using ANCOVA, with
baseline scores included as a covariate. This suggested a difference of –2.65 (95% CI –6.53 to 1.23)
between the effects of metyrapone and placebo. Adjusting for random variation between centres and a
difference between patients originating from primary and secondary care gave an adjusted estimate of
–2.65 (95% CI –6.41 to 1.10), which was not significantly different from zero. The adjusted estimate
differs very little from the unadjusted one. Although not significant, the direction of effect is consistent
with that hypothesised. However, the estimated magnitude of the effect (–2.65) was small in comparison
with the average change between baseline and 5 weeks post randomisation of 6.14 (95% CI 4.19 to
8.09) in the two groups combined.
Persistence of effect
Given that the estimated impact of metyrapone at 5 weeks was not statistically significant, it was not felt
appropriate to undertake an analysis to assess the persistence of the effect over time. BDI scores over time
are plotted in Figure 5.
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FIGURE 5 Beck Depression Inventory scores over time for patients treated with either metyrapone or placebo.
Data plotted as mean, with error bars representing the SEM.
DOI: 10.3310/eme02040 EFFICACY AND MECHANISM EVALUATION 2015 VOL. 2 NO. 4
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ferrier et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
Clinical Anxiety Scale
Baseline data
The mean baseline CAS score for patients recruited at each centre were as follows: Manchester – mean
10.4, SD 4.0; Leeds/Bradford – mean 9.4, SD 6.2; and Newcastle/Durham – mean 9.5, SD 3.8. These
differences were not statistically significant. The anxiety scores for patients originating from primary care
(mean 9.5, SD 4.6) were similar to those originating from secondary care (mean 10.0, SD 4.5); the
difference in means was 0.5 (95% CI –1.0 to 2.0), which did not differ significantly from zero.
Effect of metyrapone on Clinical Anxiety Scale scores 5 weeks
post randomisation
Based on ANCOVA of CAS scores recorded 5 weeks post randomisation (with baseline scores included as
a covariate) the unadjusted estimate of the effect of metyrapone was 0.55 (95% CI –1.21 to 2.30).
Adjusting for differences between centres and patient origin of care the estimated effect of metyrapone
on CAS scores was 0.46 (95% CI –1.20 to 2.12). These estimates correspond to differences between
groups that are neither statistically nor clinically significant.
Persistence of effect
Lower anxiety levels were recorded at all follow-up visits compared with those observed at baseline.
However, there was very little difference between the groups at any time point. Given the lack of a
difference between metyrapone and placebo at week +5, no further analysis was conducted. CAS scores
over time are plotted in Figure 6.
State–Trait Anxiety Inventory
The STAI comprises two scales: state anxiety and trait anxiety. Because the study investigated the effect of
treatment with metyrapone over the short term, only state anxiety is described here. This scale evaluates
the current state of anxiety, asking how respondents feel ‘right now,’ using items that measure subjective
feelings of apprehension, tension, nervousness, worry, and activation/arousal of the autonomic
nervous system.
Baseline data
The mean baseline state anxiety score for patients recruited at each centre were as follows: Manchester –
mean 43.1, SD 6.9; Leeds/Bradford – mean 42.5, SD 6.6; and Newcastle Durham – mean 40.7, SD 5.1.
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FIGURE 6 Clinical Anxiety Scale scores over time for patients treated with either metyrapone or placebo.
Data plotted as mean with error bars representing the SEM.
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These differences were not statistically significant. The state anxiety scores for patients originating from
primary care (mean 41.4, SD 5.4) were similar to those originating from secondary care (mean 42.4,
SD 6.8); the difference in means was 1.0 (95% CI –0.8 to 3.0), which did not differ significantly from zero.
Effect of metyrapone on state anxiety scores 5 weeks post randomisation
Based on an ANCOVA, the estimated effect of metyrapone relative to placebo at week +5 was an increase
in state anxiety of 1.2 (95% CI –0.7 to 3.1). This is consistent with the larger fall in anxiety between
baseline and week +5 in the group randomised to metyrapone than in the other group that can be seen
in Figure 7. However, the difference between groups is not statistically significant (p= 0.21). Adjusting for
origin of patient care and differences between centres resulted in very little change in the estimated
impact; adjusted estimate was an increase in anxiety of 1.2 (95% CI –0.6 to 3.0).
Persistence of effect of metyrapone on State–Trait Anxiety Inventory scores
Given that there is no obvious effect on state anxiety 5 weeks post randomisation, persistence was not
formally assessed. However, it is clear from Figure 7 that there was very little change in anxiety levels in
either group of the period of follow-up.
EuroQol health tariff
Baseline data
The EQ-5D comprises five questions about different aspects of QoL, each with three response options.
Responses to these questions are converted into a single health tariff on a scale where ‘1’ corresponds to
perfect health and ‘0’ corresponds to being dead.87
Patients from Newcastle/Durham reported slightly higher QoL (mean 0.41, SD 0.30) than patients from
Leeds/Bradford (mean 0.34, SD 0.31) and Manchester (mean 0.34, SD 0.31). Patients originating from
primary care had a higher mean tariff (mean 0.40, SD 0.30) than patients originating from secondary care
(mean 0.35, SD 0.31); however, the difference of 0.06 (95% CI –0.02 to 0.16) does not differ significantly
from zero (p= 0.17).
Effect of metyrapone on EQ-5D health tariffs 5 weeks post randomisation
Quality-of-life scores appear to improve in both groups between baseline and the visit 5 weeks post
randomisation (Figure 8).
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FIGURE 7 State anxiety scores over time for patients treated with either metyrapone or placebo. Data plotted as
mean with error bars representing the SEM.
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Based on a simple ANCOVA model with baseline tariff value included as a covariate, the estimated effect
of metyrapone was a change in tariff value of 0.014 (95% CI –0.073 to 0.101). Adjusting for variation
between sites and origin of patient care, the estimated effect of metyrapone was 0.015 (95% CI –0.069
to 0.099). There was no evidence of a beneficial effect of treatment with metyrapone on EQ-5D QoL
tariff value.
EuroQol visual analogue scale
Baseline data
The EuroQol visual analogue scale (EQ-VAS) records the respondent’s self-rated health on a 20-cm vertical,
visual analogue scale with end points labelled ‘the best health you can imagine’ and ‘the worst health you
can imagine’. This information can be used as a quantitative measure of health, as judged by the individual
respondents. The response is recorded as a number between ‘0’ and ‘100’, with higher scores indicating
better health.
The EQ-VAS scores were higher for patients in Newcastle/Durham (mean 42.4, SD 19.4) and Leeds/Bradford
(mean 44.9, SD 17.0) than for patients recruited in Manchester (mean 38.8, SD 16.8). Consistent with this
pattern, patients recruited from primary care reported better health (mean 44.9, SD 19.7) than patients
recruited from secondary care (mean 39.2, SD 16.4), although the mean difference (5.70; 95% CI –0.07 to
11.3) was of only borderline significance (p= 0.053).
Effect of metyrapone on EuroQol visual analogue scale at 5 weeks
post randomisation
The EQ-VAS scores appear to improve in both groups between baseline and the visit 3 weeks post
randomisation (Figure 9).
The estimated effect of metyrapone at 5 weeks post randomisation (ANCOVA with baseline scores
included as a covariate) was 5.7 (95% CI –0.8 to 12.1). Adjusting for origin of patient and variation
between centres, the adjusted estimate is 5.6 (95% CI –0.7 to 12.0).
Persistence of effect
It is interesting to observe that the largest difference between groups was observed at week +5. It is likely that
this is a chance result, with the difference between groups being very much smaller at subsequent visits.
0
0.3
0.6
3 5 8 16
Week
E
Q
-5
D
 s
co
re
24
0.4
0.5
Placebo
Metyrapone
FIGURE 8 European Quality of Life-5 Dimensions tariffs over time for patients treated with either metyrapone or
placebo. Data plotted as mean with error bars representing the SEM.
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Young Mania Rating Scale
Baseline data
The YMRS is used to assess manic symptoms, with a score of ‘0’ being indicative of being symptom free.
Mean scores at baseline were similar in the three centres. In Leeds/Bradford the mean score was 2.1 (SD 1.8),
in Manchester the mean score was 2.4 (SD 1.4), and in Newcastle/Durham the mean score was 2.5 (SD 2.0).
The difference in mean scores between patients recruited from primary and secondary care was 0.1 (95% CI
–0.4 to 0.7), a non-significant difference.
Effect of metyrapone on Young Mania Rating Scale scores
Mean and SD YMRS scores for each randomised group are reported for all visits (Figure 10).
The estimated difference between patients randomised to metyrapone and placebo at 5 weeks post
randomisation (ANCOVA of week +5 scores with baseline scores included as a covariate) was –0.04
(95% CI –0.54 to 0.46). Adjusting for origin of patient and variation between centres resulted in almost no
change to the estimate; the adjusted estimate is –0.04 (95% CI –0.52 to 0.45). There is no evidence of
different levels of manic symptoms between patients randomised to metyrapone and placebo.
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FIGURE 9 EuroQol visual analogue scale scores over time for patients treated with either metyrapone or placebo.
Data plotted as mean with error bars representing the SEM.
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FIGURE 10 Young Mania Rating Scale scores over time for patients treated with either metyrapone or placebo.
Data plotted as mean with error bars representing the SEM.
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Ancillary analyses
Missing data
There may be some suggestion that patients randomised to metyrapone were less inclined to attend
follow-up visits than patients randomised to placebo. This is shown in Figure 11.
Fitting a Cox proportional hazards model, the estimated hazard ratio was 0.57 (95% CI 0.35 to 0.93);
patients randomised to metyrapone were less likely to be retained in the study than other patients. It is not
clear whether this is a chance finding (we were unlucky with the randomisation) or a genuine effect of
taking the active drug.
In order to investigate whether or not retention was related to baseline depression, the baseline MADRS
score was included in the Cox regression model. The hazard ratio corresponding to a unit increase in
MADRS score was 1.01 (95% CI 0.97 to 1.04). This suggest that time to drop out was not related to
baseline depression.
To further explore the reasons for non-attendance at follow-up visits, the relationship between change in
symptoms between baseline and week +3 (the period of treatment with metyrapone or placebo) and
attendance at the primary outcome time point at week +5 was examined. Figure 12 shows the change in
MADRS scores between baseline and 3 weeks for patients who did or did not attend at week +5.
The premise behind joint modelling is that whether or not a patient responds is influenced by outcome;
specifically patients with poorer outcomes are less likely to respond than other patients. The expectation
would be that the lines in the upper half of Figure 12 (corresponding to non-responders at week +5)
would have a greater downwards gradient than those in the lower plot (responders at week +5). There
is very little evidence of such a pattern either from inspection of the plot or examination of the mean
changes in depression from baseline to the visit at week +3, which are shown in Table 13.
Those who attended at week +5 had a slightly greater reduction in depression (mean change= 6.5) than
those who failed to attend (mean change= 4.8). The difference in these changes was 1.7 (95% CI –4.0
to 7.5). Although not statistically significant, the direction of effect is as hypothesised – there is a tendency
for patients who drop out to be those with worse outcomes. In practice, dropout rates were very similar in
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FIGURE 11 Cumulative survival (or retention) against visit number (visits at which MADRS was recorded are
numbered sequentially).
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the two groups and if anything were higher in patients randomised to metyrapone. Thus any adjustment
to the estimated impact of metyrapone based on joint modelling would be to further reduce the size of
the estimated reduction in depression. There is no evidence from the joint modelling to suggest a clinically
beneficial effect of metyrapone on depression.
Mechanistic outcomes
Hypothalamic–pituitary–adrenal axis function
Hypothalamic–pituitary–adrenal axis function was determined in order to gain an understanding of the
mechanism of action of the drug. Salivary cortisol was measured at 11 p.m. and then on five occasions,
15 minutes apart from wakening, on the following day, as per the standard protocol for the CAR. Patients
collected such samples at baseline, immediately after cessation of treatment and 2 weeks later. Healthy control
subjects collected samples at baseline. Areas under the curve [area under the curve ground (AUCg) and area
under the curve increase (AUCi)] were determined using trapezoidal method for the morning cortisols.117
The control subjects and patients did not differ in their cortisol parameters (Figure 13 and Table 14).
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FIGURE 12 Change in depression between baseline and 3 weeks post randomisation by whether or not the patient
attended the primary end point 5 weeks post randomisation. Lines correspond with individual patients.
TABLE 13 Reduction in depression from baseline to week +3
Status at week 5
Reduction in depression baseline to week +3
Mean SD
95% confidence limits of the difference
Lower Upper
Non-attenders 4.80 9.88 –2.26 11.86
Attenders 6.54 8.86 5.05 8.03
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Baseline AUCg did not impact on clinical response to treatment. This was analysed using repeated measures
ANCOVA with ‘visit’ as the within-subject factor (with MADRS score at week +3 and MADRS score at week +5
as the two levels), ‘treatment’ (metyrapone and placebo) as the between-subject factor, and baseline MADRS
score and baseline AUCg as the covariates (F1, 93= 1.275 df; p= 0.26).
Metyrapone did not significantly impact cortisol in the short or longer term. Change in HPA axis function
(measured using δAUCg, i.e. the difference between AUCg at baseline and AUCg at week +3) did not
impact on clinical response to treatment. This was analysed using repeated measures ANCOVA with ‘visit’
as the within-subject factor (with MADRS score at week +3 and MADRS score at week +5 as the two
levels), ‘treatment’ (metyrapone and placebo) as the between-subject factor and baseline MADRS score
and δAUCg as the covariates (F1, 81< 1; not significant).
Childhood trauma
The CTQ revealed that patients had experienced more childhood adversity than control subjects (Table 15).
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FIGURE 13 Salivary cortisol (µg/dl) at 11 p.m. and on awakening the following morning, and at 15-minute intervals
for 60 minutes thereafter in the two groups.
TABLE 14 Hypothalamic–pituitary–adrenal axis results in the two groups. No significant differences
Measures of cortisol Control subjects Patients Significancea
11 p.m. Mean= 0.042 µg/dl, n= 47 Mean= 0.064 µg/dl, n= 132 p= 0.084
AUCi Mean= 0.274, n= 45 Mean= 0.256, n= 114 p= 0.523
AUCg Mean= 1.34, n= 45 Mean= 1.21, n= 114 p= 0.848
a Independent samples Mann–Whitney U-test.
TABLE 15 Scores for individual items of CTQ in patients and control subjects
Subscale Patients Control subjects Significance
Emotional abuse 12.3 6.7 p< 0.0005
Emotional neglect 13.6 8 p< 0.0005
Sexual abuse 8.1 5.5 p= 0.004
Physical abuse 7.9 5.4 p< 0.0005
Physical neglect 8.6 5.8 p< 0.0005
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Emotional abuse, emotional neglect, physical abuse, physical neglect and sexual abuse did not predict
response to medication (analysed using repeated measures ANOVA with these subscores on the CTQ
entered as covariates: data not shown).
Neuropsychology
Spatial working memory
Groups at baseline
Valid data were available for 55 HVs and 65 depressed patients.
For BSE there was a significant main effect of group (F1,116= 8.609; p= 0.004), with patients making more
errors than control subjects (Table 16). There was also a significant group × level interaction (F2,232= 4.978;
p= 0.014). Comparison of patients and control subjects at each separate level of difficulty indicated
significantly poorer performance in patients at levels 6 (p= 0.001) and 8 (p= 0.004). There was a
non-significant trend towards poorer performance in patients at level 4 (p= 0.055). For WSE there was no
significant main effect of group (F1,116= 0.332; p= 0.566) and no significant group by level interaction
(F2,232= 0.015; p= 0.950).
Treatment (patients)
Valid data were available for 43 patients (20 metyrapone, 23 placebo) tested at baseline and at 5 weeks.
This analysis was conducted on totals for both the BSE and WSE. Results of the ANCOVA are presented in
Table 17. There were no significant main effects of treatment for either outcome measure.
TABLE 16 Between-search errors and WSE for each group
Outcome Control subjects: adjusted meana (SEM) Patients: adjusted meana (SEM)
BSE totalb 22.21 (2.63) 34.83 (2.54)
Four box 0.65 (0.22) 1.42 (0.33)
Six box 5.37 (0.93) 10.23 (1.04)
Eight box 16.19 (1.83) 23.18 (1.52)
WSE totala 1.42 (0.38) 1.74 (0.47)
Four box 0.04 (0.02) 0.12 (0.05)
Six box 0.23 (0.08) 0.42 (0.16)
Eight box 1.16 (0.34) 1.20 (0.35)
a Estimated marginal mean from ANCOVA model.
b Data from additional n= 2 control subjects available which were omitted from ANCOVA owing to missing
age/gender data.
TABLE 17 Spatial working memory performance at week +5 (covaried for baseline only) with ANCOVA main effect
of group
Outcome Placebo: adjusted meana (SEM) Metyrapone: adjusted meana (SEM) F1,40 p-value
BSE total 26.13 (2.58) 24.70 (2.76) 0.143 0.707
WSE total 0.85 (0.35) 1.67 (0.37) 2.546 0.118
a Estimated marginal mean from ANCOVA model.
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Attentional Network Test
Groups at baseline
Valid data were available for 54 HVs and 65 depressed patients. There was a significant trend in alerting,
no significant effect for orientating and a significant main effect of conflict (Table 18).
For the conflict effect, examination of the RTs that comprise this measure indicate that patients were
slower to respond overall but were slowed to a greater extent by incongruent flankers than were healthy
control subjects.
Treatment (patients)
Valid data were available for 38 patients (17 metyrapone, 21 placebo) tested at baseline and at 5 weeks.
This analysis was conducted on the alerting, orientating and conflict indices. Results of the ANCOVA are
presented in Table 19. There were no significant main effects of treatment on any ANT measure.
Object-location memory
Groups at baseline
Valid data were available for 56 HVs and 64 depressed patients. Patients were found to have significantly
poorer performance on all three primary outcome measures than control subjects (Table 20).
Treatment (patients only)
Valid data were available for 38 patients (16 metyrapone, 22 placebo) tested at baseline and at 5 weeks. This
analysis was conducted on the POM, OLB and COM. Results of the ANCOVA are presented in Table 21.
TABLE 19 Attentional Network Test performance at week +5 (covaried for baseline)
Outcome
Placebo: adjusted
meana (SEM)
Metyrapone: adjusted
meana (SEM) F1,35 p-value
Alerting 27.09 (7.37) 43.77 (8.20) 2.269 0.141
Orienting 28.37 (6.80) 37.66 (7.56) 0.834 0.367
Conflict 133.84 (12.12) 129.03 (13.47) 0.070 0.792
a Estimated marginal mean from ANCOVA model.
TABLE 18 Attentional Network Test performance for each group (covaried for age and sex)
Outcome
Control subjects: adjusted
meana (SEM)
Patients: adjusted
meana (SEM) F1,115 p-value
Alerting 28.43 (4.25) 16.90 (3.86) 3.882 0.051
Orienting 33.39 (4.09) 35.17 (3.71) 0.099 0.753
Conflict 107.90 (8.86) 155.87 (8.05) 15.459 < 0.001
a Estimated marginal mean from ANCOVA model.
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Accuracy
Digit span
Groups at baseline
Valid data were available for 56 HVs and 70 depressed patients. Patients performed more poorly than
control subjects on all outcome measures (Table 22).
TABLE 20 Object-location memory performance for each group (covaried for age and sex)
Outcome
Control subjects:
adjusted meana (SEM)
Patients: adjusted
meana (SEM) F1,116 p-value
Object memory (%) 2.64 (0.81) 5.11 (0.75) 4.802 0.030
Visuospatial reconstruction (mm) 107.50 (9.03) 95.68 (8.42) 0.879 0.351
POM (mm) 142.13 (6.80) 165.94 (6.34) 6.287 0.014
OLB (%) 20.47 (3.33) 32.17 (3.10) 6.354 0.013
COM (mm) 237.23 (17.92) 288.43 (16.71) 4.189 0.043
a Estimated marginal mean from ANCOVA model.
TABLE 22 Digit span performance for each group (covaried for age and sex)
Outcome
Control subjects:
adjusted meana (SEM)
Patients: adjusted
meana (SEM) F1,122 p-value
Experimental forwards 9.10 (0.33) 7.60 (0.30) 10.917 0.001
Backwards 7.73 (0.33) 6.56 (0.29) 6.860 0.010
Total 16.83 (0.60) 14.17 (0.53) 10.695 0.001
Span forwards 7.18 (0.20) 6.40 (0.18) 8.360 0.005
Backwards 5.43 (0.20) 4.79 (0.18) 5.588 0.020
a Estimated marginal mean from ANCOVA model.
TABLE 21 Object-location memory performance at week +5 (covaried for baseline)
Outcome
Placebo: adjusted
meana (SEM)
Metyrapone: adjusted
meana (SEM) F1,35 p-value
POM (mm) 152.89 (8.34) 162.09 (9.79) 0.510 0.480
OLB (%) 28.47 (4.09) 28.04 (4.80) 0.005 0.946
COM (mm) 284.90 (21.81) 311.08 (25.71) 0.583 0.450
a Estimated marginal mean from ANCOVA model.
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Treatment (patients only)
Valid data were available for 45 patients (22 metyrapone, 23 placebo) tested at baseline and at 5 weeks.
This analysis was conducted on all indices. Results of the ANCOVA are presented in Table 23. There were
no significant main effects of treatment on any measure.
Face Emotion Recognition Task
Groups at baseline
Valid data were available for only 43 HVs and 39 depressed patients as a result of technical problems with
the version of the task initially used.
Accuracy
For accuracy there was a significant effect of emotion type (F6,468= 5.777; p< 0.001) and group
(F1,78= 6.179; p= 0.015) but no ‘emotion × group’ interaction (F6,468= 1.245; p= 0.39).
Happiness and neutral face emotion were the best recognised, and anger and fear the worst. Patients
were less accurate overall, but on post hoc testing the difference was statistically significant only for
disgust with a trend for anger (Table 24).
TABLE 24 Accuracy (hit rate) by emotion and group (covaried for age and sex)
Emotion
Control subjects:
adjusted meana (SEM)
Patients: adjusted
meana (SEM) F1,78 p-value
All emotions 0.61 (0.02) 0.56 (0.02) 6.179 0.02
Anger 0.37 (0.03) 0.28 (0.03) 3.838 0.05
Disgust 0.58 (0.03) 0.46 (0.03) 7.599 0.01
Fear 0.35 (0.03) 0.36 (0.03) 0.024 0.88
Happiness 0.80 (0.02) 0.76 (0.03) 1.774 0.19
Sadness 0.61 (0.04) 0.57 (0.04) 0.513 0.48
Surprise 0.71 (0.03) 0.67 (0.03) 0.733 0.39
Neutral 0.86 (0.02) 0.81 (0.03) 1.756 0.19
a Estimated marginal mean from ANCOVA model.
TABLE 23 Digit span performance at week +5 (covaried for baseline)
Outcome
Placebo: adjusted
meana (SEM)
Metyrapone: adjusted
meana (SEM) F1,42 p-value
Experimental forwards 8.05 (0.29) 8.04 (0.30) 0.001 0.970
Backwards 6.60 (0.49) 7.19 (0.50) 0.724 0.400
Total 14.65 (0.67) 15.23 (0.69) 0.356 0.554
Span forwards 6.50 (0.20) 6.75 (0.21) 0.705 0.406
Backwards 4.83 (0.30) 5.00 (0.31) 0.164 0.688
a Estimated marginal mean from ANCOVA model.
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Misattribution
For misattribution there was a significant effect of emotion type (F6,468= 2.791; p= 0.03) and group
(F1,78= 5.436; p= 0.02) but no emotion × group interaction (F6,468= 0.729; p= 0.56).
Most misattributions were made for neutral, followed by surprise and sadness, and the fewest for
happiness. Patients misattributed emotions more often than control subjects, but on post hoc testing the
difference was only statistically significant for fear (Table 25).
Treatment (patients only)
Valid data were available for 22 patients (8 metyrapone, 14 placebo) tested at baseline and at 5 weeks.
Results of the ANCOVA are presented in Tables 26 and 27.
Accuracy
Patients receiving placebo had a lower hit rate at baseline than those who received metyrapone; at week
+5, patients receiving placebo increased their hit rate while those on metyrapone decreased it.
TABLE 26 Accuracy (hit rate) by emotion at week +5 (covaried for baseline)
Emotion
Placebo: adjusted
meana (SEM)
Metyrapone: adjusted
meana (SEM) F1,19 p-value
Anger 0.39 (0.04) 0.24 (0.05) 5.255 0.03
Disgust 0.54 (0.04) 0.53 (0.05) 0.031 0.86
Fear 0.35 (0.04) 0.38 (0.05) 0.102 0.75
Happiness 0.68 (0.06) 0.68 (0.04) 0.004 0.95
Sadness 0.59 (0.07) 0.57 (0.09) 0.210 0.89
Surprise 0.67 (0.04) 0.74 (0.06) 1.040 0.32
Neutral 0.77 (0.05) 0.82 (0.06) 0.263 0.61
a Estimated marginal mean from ANCOVA model.
TABLE 25 Misattribution (false alarm rate) by emotion and group
Emotion
Control subjects:
adjusted meana (SEM)
Patients: adjusted
meana (SEM) F1,78 p-value
All emotions 0.064 (0.003) 0.073 (0.003) 5.436 0.02
Anger 0.040 (0.005) 0.051 (0.006) 2.027 0.16
Disgust 0.040 (0.006) 0.040 (0.007) 0.003 0.96
Fear 0.030 (0.006) 0.054 (0.007) 7.185 0.01
Happiness 0.010 (0.003) 0.010 (0.003) 0.089 0.77
Sadness 0.066 (0.008) 0.081 (0.009) 1.688 0.20
Surprise 0.075 (0.006) 0.079 (0.007) 0.190 0.66
Neutral 0.192 (0.012) 0.193 (0.013) 0.008 0.93
a Estimated marginal mean from ANCOVA model.
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Misattribution
Emotional Memory Task
Groups at baseline
Valid data were available for 52 HVs and 65 depressed patients for recall, and 51 HVs and 63 depressed
patients for recognition.
Emotional word immediate recall
There was a significant effect of group (F1,114= 9.859; p= 0.002), with a trend to a significant effect of
valence (F2,228= 2.871; p= 0.062) and a significant group x valence interaction (F2,228= 3.133; p= 0.049).
Post hoc analysis of emotional bias is shown in Table 28. Patients remembered fewer words overall than
control subjects but a larger proportion of these were negative.
Emotional word delayed recognition: hits
There was no significant effect of group (F1,111= 1.835; p= 0.18), valence (F2,222= 1.030; p= 0.36) or a
significant group × valence interaction (F2,222= 1.389; p= 0.25). Post hoc analysis of emotional bias is
shown in Table 29. Although patients recognised fewer words overall than control subjects and a larger
proportion of these were negative, the differences were small and non-significant.
TABLE 27 Misattribution (false alarm rate) at week +5 (covaried for baseline)
Emotion Placebo: adjusted meana (SEM) Metyrapone: adjusted meana (SEM) F1,19 p-value
Anger 0.061 (0.011) 0.049 (0.015) 0.354 0.56
Disgust 0.047 (0.013) 0.077 (0.17) 1.905 0.18
Fear 0.051 (0.010) 0.050 (0.013) 0.003 0.96
Happiness 0.011 (0.003) 0.020 (0.004) 2.480 0.13
Sadness 0.079 (0.018) 0.070 (0.023) 0.099 0.76
Surprise 0.078 (0.009) 0.067 (0.012) 0.457 0.51
Neutral 0.180 (0.012) 0.184 (0.018) 0.053 0.82
a Estimated marginal mean from ANCOVA model.
TABLE 28 Immediate recall at baseline by group
Emotion Control subjects: adjusted meana (SEM) Patients: adjusted meana (SEM) F1,114 p-value
All wordsb 10.91 (0.42) 9.14 (0.38) 9.592 0.002
Positivec 3.20 (0.16) 2.92 (0.14) 1.622 0.21
Negativec 3.19 (0.14) 3.68 (0.13) 6.249 0.01
Neutralc 3.57 (0.19) 3.33 (0.17) 0.024 0.35
a Estimated marginal mean from ANCOVA model.
b Covaried for zero-centred IQ. Values taken from a univariate analysis on total words rather than repeated measures
ANCOVA in order to show total number of words rather than mean across valences.
c Covaried for total number of words recalled.
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Emotional word delayed recognition: false alarms
There was a strong trend towards a significant effect of group (F1,111= 3.931; p= 0.05), a significant effect
of valence (F2,222= 8.387; p< 0.001) but no significant group × valence interaction (F2,222= 1.235; p= 0.29).
Post hoc analysis of emotional bias is shown in Table 30. There were more false alarms for emotional than
neutral words, and patients had more false alarms overall. Although patients had relatively fewer positive
and more negative false alarms than control subjects, these were not significant.
Treatment (patients only)
Valid data were available for 41 patients (19 metyrapone, 22 placebo) tested at baseline and at 5 weeks.
Recall: No significant effect of treatment was found. Results of the ANCOVA are presented in Table 31.
Recognition: No significant effects of treatment were found. Results of the ANCOVAs are presented in
Tables 32 and 33.
TABLE 29 Delayed recognition: hits by group
Emotion Control subjects: adjusted meana (SEM) Patients: adjusted meana (SEM) F1,111 p-value
All wordsb 23.75 (0.64) 22.64 (0.56) 1.983 0.16
Positivec 7.75 (0.15) 7.62 (0.14) 0.389 0.53
Negativec 7.72 (0.16) 7.95 (0.14) 1.132 0.29
Neutralc 7.60 (0.15) 7.51 (0.14) 0.217 0.64
a Estimated marginal mean from ANCOVA model.
b Covaried for zero-centred IQ. Values taken from a univariate analysis on total words rather than repeated measures
ANCOVA in order to show total number of words rather than mean across valences.
c Covaried for total number of words recognised.
TABLE 30 Delayed recognition: false alarms by group
Emotion Control subjects: adjusted meana (SEM) Patients: adjusted meana (SEM) F1,111 p-value
All wordsb 4.16 (0.64) 5.49 (0.45) 3.931 0.05
Positivec 2.00 (0.14) 1.72 (0.13) 2.210 0.14
Negativec 1.68 (0.16) 1.89 (0.14) 1.006 0.32
Neutralc 1.21 (0.13) 1.28 (0.12) 0.158 0.69
a Estimated marginal mean from ANCOVA model.
b Covaried for zero-centred IQ. Values taken from a univariate analysis on total words rather than repeated measures
ANCOVA in order to show total number of words rather than mean across valences.
c Covaried for total number of false alarms.
TABLE 31 Immediate recall at week +5 by treatment (covaried for baseline)
Emotion Placebo: adjusted meana (SEM) Metyrapone: adjusted meana (SEM) F1,37 p-value
All words 10.18 (0.62) 9.44 (0.65) 0.671 0.42
Positive 3.10 (0.35) 2.52 (0.37) 1.287 0.26
Negative 3.64 (0.28) 3.35 (0.30) 0.505 0.48
Neutral 3.59 (0.42) 3.41 (0.45) 0.083 0.78
a Estimated marginal mean from ANCOVA model.
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Affective GoNoGoTask
Groups at baseline
Valid data were available for 47 HVs and 57 depressed patients.
Analysis by mean Go blocks
There was no effect of group (F1,101= 0.942; p= 0.33), a significant effect of valence (F2,202= 104.773;
p< 0.001), but no significant group × valence interaction (F2,202= 2.185; p= 0.12). RTs were longer for the
blocks with neutral targets than for those with emotional targets. Patients had longer RTs than control
subjects for positive targets. Post hoc analysis is shown in Table 34.
Paired-sample t-tests in each group separately showed that GoPos and GoNeg differed significantly in
patients (t56= 3.706; p< 0.001) but not control subjects (t46= 0.0569; p= 0.57).
Analysis by mean NoGo blocks
There was no effect of group (F1,102= 0.942; p= 0.33), a significant effect of valence (F2,202= 20.228;
p< 0.001) but no significant group × valence interaction (F2,202= 0.330; p= 0.72). RTs were shorter for the
blocks with neutral distractors than for those with emotional distractors. Patients had slightly longer RTs
than control subjects but this was not significant. Post hoc analysis is shown in Table 35.
Treatment (patients only)
Valid data were available for 38 patients (17 metyrapone, 21 placebo) tested at baseline and at 5 weeks.
No significant effect of treatment was found. Results of the post hoc ANCOVAs are presented in Table 36.
Functional magnetic resonance imaging
In the Newcastle centre patient sample
In total, 22 patients and 15 healthy control subjects participated in this aspect of the study at week 0.
Three patients and two control subjects were not included in the analysis due to excessive head motion.
TABLE 32 Delayed recognition: hits at week +5 by treatment (covaried for baseline)
Emotion Placebo: adjusted meana (SEM) Metyrapone: adjusted meana (SEM) F1,38 p-value
All words 21.96 (1.10) 22.63 (1.19) 0.171 0.68
Positive 6.95 (0.46) 7.32 (0.37) 0.304 0.59
Negative 7.97 (0.41) 7.93 (0.44) 0.007 0.94
Neutral 7.06 (0.47) 7.35 (0.50) 0.183 0.67
a Estimated marginal mean from ANCOVA model.
TABLE 33 Delayed recognition: false alarms at week +5 by treatment (covaried for baseline)
Emotion Placebo: adjusted meana (SEM) Metyrapone: adjusted meana (SEM) F1,38 p-value
All words 5.95 (0.89) 6.32 (0.95) 0.083 0.78
Positive 1.98 (0.39) 2.60 (0.42) 1.198 0.28
Negative 2.33 (0.32) 1.93 (0.34) 0.715 0.40
Neutral 1.62 (0.36) 1.81 (0.39) 0.121 0.73
a Estimated marginal mean from ANCOVA model.
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TABLE 34 Mean Go blocks by emotion: RTs (milliseconds) at baseline by group
Emotion
Control subjects: adjusted
meana (SEM)
Patients: adjusted
meana (SEM) F1,101 p-value
GoPosb 856 (15) 900 (14) 4.444 0.04
GoNegb 848 (17) 860 (15) 0.314 0.58
GoNeutb 998 (18) 997 (16) 0.001 0.98
GoPosc 865 (8) 892 (8) 5.458 0.02
GoNegc 860 (8) 854 (7) 0.320 0.57
GoNeutc 1008 (11) 988 (10) 1.992 0.16
a Estimated marginal mean from ANCOVA model.
b Covaried for zero-centred age.
c Covaried for mean RT.
TABLE 35 Mean NoGo blocks by emotion: RTs (milliseconds) at baseline by group
Emotion
Control subjects: adjusted
meana (SEM)
Patients: adjusted
meana (SEM) F1,101 p-value
NoGoPosb 915 (17) 930 (15) 0.445 0.51
NoGoNegb 923 (15) 944 (13) 1.052 0.31
NoGoNeutb 865 (16) 891 (15) 1.384 0.24
NoGoPosc 925 (8) 917 (7) 0.545 0.46
NoGoNegc 932 (7) 934 (7) 0.030 0.86
NoGoNeutc 875 (8) 882 (7) 0.377 0.54
a Estimated marginal mean from ANCOVA model.
b Covaried for zero-centred age.
c Covaried for overall RT.
TABLE 36 Mean Go and NoGo blocks by emotion: RTs (milliseconds) at week +5 by treatment (covaried
for baseline)
Emotion
Placebo: adjusted
meana (SEM)
Metyrapone: adjusted
meana (SEM) F1,35 p-value
GoPos 871 (16) 895 (18) 0.936 0.34
GoNeg 866 (18) 852 (20) 0.292 0.59
GoNeut 1,010 (17) 988 (20) 0.765 0.39
NoGoPos 941 (15) 910 (17) 1.843 0.18
NoGoNeg 916 (16) 944 (18) 1.285 0.27
NoGoNeut 893 (18) 880 (20) 0.211 0.65
a Estimated marginal mean from ANCOVA model.
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Facial emotion processing task
Whole-brain analysis showed a cluster of significantly higher (p< 0.05, FWE corrected) BOLD signal in the
right amygdala in both the EM condition and the EL condition than the SM condition (Figure 14). Table 37
shows the estimated marginal means of the BOLD signal in the three conditions in this cluster. Controlling
for age, sex and premorbid IQ [National Adult Reading Test (NART)], there was a significant difference
between patients and control subjects in the EM condition, but not in the EL or SM conditions, with
patients showing higher BOLD values than control subjects.
Estimated marginal means for the BOLD signal of the three conditions in anatomically defined amygdala
regions, separately for the left and right hemisphere, are shown in Table 38. There were no significant
differences between the two groups in any of the conditions in either region, although there was a
statistical trend for higher BOLD signal for patients in the left amygdala for the EM condition.
Emotional enhancement of memory task
A whole-brain analysis did not show clusters of differential BOLD signal between the three conditions
(negative arousing, negative non-arousing, neutral) in the amygdala across both groups (Table 39).
No significant differences in activation between patients and control subjects in any of the conditions
were found.
(a) (b)
FIGURE 14 Significant cluster of BOLD signal increases in the EM condition (a) and EL condition (b) over the control
condition SM across the entire sample (p< 0.05, FEW corrected, k= 10). Numbers in parentheses are MNI
coordinates (in mm) of the local signal peaks.
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TABLE 39 Estimated marginal means for the anatomically defined amygdala ROI
Neutral
Negative
Arousing Non-arousing
Left amygdala
Patients –0.075 (0.250) –0.201 (0.201) –0.019 (0.244)
Control subjects 0.037 (0.313) –0.015 (0.252) 0.020 (0.305)
Group effect F< 1 (n.s.) F< 1 (n.s.) F< 1 (n.s.)
Right amygdala
Patients –0.323 (0.131) –0.577 (0.155) –0.349 (0.151)
Control subjects –0.222 (0.164) –0.323 (0.194) –0.240 (0.189)
Group effect F< 1 (n.s.) F= 1.007; p= 0.324 F< 1 (n.s.)
n.s., not significant.
TABLE 37 Average BOLD signals (and SD) in the FEP task from a cluster showing significant differences between
the facial processing conditions (EM, EL) and the control condition in the right amygdala (MNI 18, –8, –16; k= 96)
EM EL SM
Patients 0.352 (0.371) 0.408 (0.446) –0.120 (0.295)
Control subjects 0.067 (0.371) 0.334 (0.449) –0.227 (0.298)
Group effect F= 5.076; p= 0.033 F< 1 (n.s.) F= 1.112; p= 0.301
n.s., not significant.
TABLE 38 Average BOLD signals (and SD) in the FEP task for anatomically defined regions of interest of the left
and right amygdala
EM EL SM
Left amygdala
Patients 0.280 (0.389) 0.450 (0.492) 0.244 (0.328)
Control subjects 0.018 (0.391) 0.373 (0.496) 0.108 (0.329)
Group effect F= 3.838; p= 0.061 F< 1 (n.s.) F= 1.455; p= 0.238
Right amygdala
Patients 0.317 (0.319) 0.307 (0.384) 0.114 (0.253)
Control subjects 0.141 (0.321) 0.357 (0.387) 0.072 (0.251)
Group effect F= 2.605; p= 0.118 F< 1 (n.s.) F< 1 (n.s.)
n.s., not significant.
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In the Manchester centre patient sample
Twenty-seven patients were eligible for this study, one of whom subsequently withdrew consent. Twenty-six
patients participated in the final study (13 females). Twenty patients were right handed, six ambidextrous and
1 left handed. Given the literature regarding laterality118 and hand preference combined with the relative
difficulty to recruit and retain patients with TRD, it was decided to take a pragmatic approach and recruit
patients with a preference for left-handedness and perform a post hoc sensitivity analysis. One scan from
the patient group was excluded from analysis owing to movement artefact, and another subject was
withdrawn from the study owing to the discovery of a structural abnormality; therefore, data are presented for
24 patients.
Thirty-two right-handed HVs were recruited from advertisements by the University of Manchester. Thirty
were eligible (15 females). All of the female subjects were on long-term hormonal contraception to control
for the effects of menstrual cycle on endogenous cortisol levels to allow reliable within-subject comparison119
but subjects were otherwise medication free, drank < 21 units of alcohol/week and were caffeine free on
the scan days.
One male HV was later excluded owing to a head-coil malfunction; therefore data are reported from
29 subjects.
The mean age of patients was 44.1 years (SD 7.7 years; range 26–57 years) compared with mean age
36.47 years (SD 5.94 years; range 31–55 years) for the HVs. The mean NART IQ score for the patient group
was 109.7 (SD 10.0) and for the HVs 113.3 (SD 10.4). There was no significant difference between the
patient and HV groups in either age or IQ (p= 0.22 and p= 0.15, respectively). The baseline GRID-HAMD
score for the patient group was 23.74 (SD 3.7) compared with 0.28 (SD 0.5) for the HVs. There was a
significant difference in handedness between the HV group and the patients, with one left-handed
individual and five ambidextrous individuals in the TRD group; however, the results were not substantially
altered by the removal of this individual in post hoc sensitivity analysis.
Behavioural results
Emotional pictures encoding task
There was no significant difference in the number of responses made between participant groups
(F1,51 = 0.02; p= 0.88) or RT (F1,51= 0.84; p= 0.36). There was a main effect for group for subjective
emotionality (F1,51= 5.14; p= 0.03), with patients classifying fewer positive images as ‘emotional’; however,
there was no significant participant group × valence effect (F1,51= 1.19; p= 0.28).
Emotional pictures retrieval task
There was no significant effect of the emotional valence (positive or neutral image) in the number of words
omitted in the retrieval tasks (F1,50= 2.40; p= 0.13) and no effect of group (TRD or HV) by emotional
valence on number omitted (F1,50= 2.03; p= 0.16). There was also no effect of emotion on RT (F1,50= 0.91;
p= 0.35) and no effect of group by emotion on RT (F1,50= 0.12; p= 0.73). There was also no effect of
emotion on number of words correctly recalled (F1,50= 0.01; p= 0.94) and no effect of emotion by group on
correct recognition (F1,50= 10.51; p= 0.25).
n-back task
There was no significant main effect of group on number correct (F1,53= 0.09; p= 0.76), omitted
(F1,53= 1.19; p= 0.28) or RT (F1,53= 1.12; p= 0.29). There was also no effect of level of difficulty or level by
group on any of these measures.
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Functional magnetic resonance imaging results
Emotional pictures encoding task
The main effect of task (all participants, all encoding images minus rest) showed increased BOLD signal in
bilateral parahippocampal, bilateral inferior frontal gyrus (BA47, BA9), left temporal gyrus (BA20) and right
hippocampus in keeping with findings of meta-analyses of encoding tasks literature.120,121
When the HVs were compared with the patients, patients with TRD showed a significant decreased BOLD
signal at whole-brain level in the posterior cingulate compared with the HVs during the encoding task
[HVs minus patients, all encoding images minus rest contrast, BA31; x= 9.5, y= –35, z= 35, Z= 3.47
p(FWE) (whole brain corrected)= 0.043. There were no significant findings in the pre-hypothesised ROIs].
(see Table 40 and Figure 15). There were no significant results in the opposite subtraction.
Emotional pictures retrieval task
The main effect of task (all participants, all retrieval tasks minus rest) showed increased BOLD signal in the
parahippocampus bilaterally, the left inferior temporal lobe (BA36), the left lingual gyrus (BA18) and left
BA9 and BA6. There was no significant change in BOLD signal in the hippocampus.
In the a priori ROI of the insula, the BOLD signal was increased in the patients compared with the control
subjects while completing the retrieval task, compared with the rest condition (patients minus control subjects,
retrieval images minus rest contrast) [posterior insula, BA40; x= –46.5, y= –21, z= 20, Z= 3.85 p(FWE)(ROI
analysis)= 0.046] (see Table 40 and Figure 16). In the anterior cingulate, another a priori ROI, the BOLD signal
was reduced in the patients compared with the control subjects while retrieving positive images, compared
with neutral images (control subjects minus patients, positive images minus neutral images contrast) [anterior
cingulate, BA33; x= –4.5, y= 17.5, z= 25, Z= 3.95 p(FWE)(ROI analysis)= 0.033] (see Table 40 and Figure 17).
TABLE 40 Results of the three fMRI tasks
Area BA Side
Coordinates (MNI) Cluster
p(FWE)x y z K Z
Emotional Pictures Encoding task
Encode–rest HV–Pts
Posterior cingulate 31 R 9.5 –35 35 77 3.47 0.043a
Emotional Pictures Retrieval task
Retrieve–rest HV–Pts
Insula 40 L –46.5 –21 20 56 3.85 0.046b
Positive–neutral HV–Pts
Anterior cingulate 33 L –4.5 17.5 25 18 3.95 0.033b
n-back task
2back–0back HV–Pts
dlPFC 9 L –25.5 7 50 68 4.53 < 0.001a
BA, Brodmann area; K, cluster size at p< 0.005; L, left; Pts, patients; R, right.
a Whole-brain corrected p(FWE)< 0.05.
b p(FWE)< 0.05 following a priori ROI analysis.
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FIGURE 16 Significant BOLD increase in the patients compared with the control subjects in the posterior insula
(–46.5, –21, 20), ROI p(FWE)= 0.046 during the retrieval task. Patients minus control subjects, all retrieval images
minus rest, error bars indicate SEM.
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FIGURE 17 Significant BOLD increase in the patients compared with the control subjects in the anterior cingulate
(–4.5, 17.5, 25) ROI p(FWE)= 0.033 during the retrieval task. Control subjects minus patients, positive minus neutral,
error bars indicate SEM.
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FIGURE 15 Significant BOLD decrease in the patients compared with the control subjects in the posterior cingulate
(9.5, –35, 35), p(FWE) whole brain= 0.043 during the encoding task. Control subjects minus patients, all encoding
images minus rest, error bars indicate SEM.
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n-back task
The main effect of the task (using all participant scans), the two-back compared with zero-back subtraction
showed increased BOLD signal bilaterally in the dlPFC, medial posterior parietal and lateral premotor cortices, in
keeping with the areas reported in a previous meta-analysis.122 In the control subjects minus patients two-back
minus zero-back contrast, the patients showed a decrease in BOLD signal compared with the control subjects
in the dlPFC [BA6; x= –25.5, y= 7, z= 25, Z= 50 p(FWE)(whole brain corrected)=< 0.001] (see Table 40 and
Figure 18). However, there was no difference seen in our ROI areas.
Acute effects of hydrocortisone in treatment-resistant depression using
pharmacological functional magnetic resonance imaging
The final sample consisted of 20 patients with TRD and 27 HVs. The a priori regions of interest were the
hippocampus, hypothalamus, amygdala and dorsolateral and ventrolateral prefrontal cortex (all areas rich
in corticosteroid receptors). We failed to demonstrate a difference between the TRD and HV groups,
and also a main effect of hydrocortisone, in contrast with our previous study.107 Reasons that may have
accounted for this result include lack of power and artefact.
Electroencephalography
At study initiation it had been intended to recruit 50 patients to the EEG mechanistic studies, giving
approximately 25 treated with metyrapone and 25 with placebo. Given the slow recruitment to the study
initially, two decisions were made – first, there was an acceptance of a lower sample size than the originally
planned 190, and, second, emphasis was given to recruitment to the main treatment element of the study,
including patients who did not wish to consent to recruitment to the mechanistic studies. A total of 34 patients
were recruited for the EEG studies. Twenty-five of these had MADRS data at the primary end point at week +5.
Of these, 14 were treated with placebo and 11 with metyrapone, with five responders and six non-responders.
These numbers did not provide sufficient power to warrant examination of the EEG variables suggested to
predict response to active treatment, and therefore this was not pursued further.
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FIGURE 18 Significant BOLD increase in the control subjects compared with patients in the dlPFC (–25.5, 7, 50)
whole-brain p(FWE)< 0.001 in the two-back minus zero-back contrast. Error bars indicate SEM.
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With regard to the ESMT, the issue of the small patient sample size was compounded by a methodological
issue. A large amount of horizontal eye movement was found in patients during the test phase. This led
to a high epoch reject rate. EEG analysis of the ESMT task was therefore not conducted owing to an
insufficient number of both patients and control subjects meeting EEG signal-to-noise ratio inclusion
criteria. For a satisfactory signal–noise ratio, at least 10 epochs would need to be present in each of three
task outcome measures (neutral, negative and positive correctly recalled items). Only three patients and
one control met this criterion.
With regard to the LTP analysis, this was conducted on 32 patients and 20 control subjects. The mean VEP
waveforms for patients and control subjects from the first pre-tetanus and first post-tetanus assessment are
shown in Figure 19. Data for the individual components of the VEP are shown in Figures 20–22.
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FIGURE 19 Mean VEP waveforms of patients (green lines) and control subjects (black lines) before (solid lines) and
after (dotted lines) visual tetanic stimulation.
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FIGURE 20 Shows N1 amplitude, together with the magnitude of enhancement from the mean of the two
pre-tetanus amplitudes to the first post-tetanus amplitude (error bars are SEM).
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There was no significant difference in magnitude of either the first or second pre-tetanus N1, P2 or N1b
components between the patients and the healthy control subjects (all p-values > 0.2). As can be seen,
there was an increase in amplitude of N1 and N1b post tetanus, especially in the healthy control subjects,
although little change in amplitude of P2. In the healthy control subjects there was a significant difference
in N1 and N1b amplitudes in the post-tetanus test 1 block compared with the mean of the pre-tetanus
blocks (t= 2.17, p= 0.035; t= 3.51; p= 0.001 respectively), but this was not seen for the P2 component,
or for any component in the patient group (p> 0.2 for all comparisons). Comparison of the magnitude of
the increase in N1 amplitude showed a significantly greater increase for the control subjects than the
patients (t= 2.01; p= 0.043). The difference in magnitude of increase in N1b between patients and
control subjects, however, did not reach significance (t= 1.52; p= 0.146).
It was not possible to examine the effect of metyrapone on the LTP EEG measure owing to insufficient
data being available.
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FIGURE 21 Shows P2 amplitude, respectively, together with the magnitude of enhancement from the mean of the
two pre-tetanus amplitudes to the first post-tetanus amplitude (error bars are SEM).
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FIGURE 22 Shows N1b amplitude, respectively, together with the magnitude of enhancement from the mean of
the two pre-tetanus amplitudes to the first post-tetanus amplitude (error bars are SEM).
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Analyses not yet complete
The data from, and analyses of, the following measures are not included in this report, as either the data are
not yet to hand or analyses are not yet complete: negative life events questionnaire [adapted from the List of
Threatening Experiences;77 the Social Circumstances Questionnaire, which is an adaptation of the Social Support
Questionnaire78 as used in the NewMood study;75 the Ruminative Responses Scale;80 the 11-deoxycortisol results
(data not yet to hand due to delays in optimising assay sensitivity, and therefore the secondary analyses bases on
this measure of apparent concordance with the drug)] and the genetic results (data not yet to hand). We have
not been able to carry out a per-protocol analysis on those patients who took medication for 3 weeks, as this
information was not available. A number of analyses that were to be based on responders were not carried out,
as there were insufficient numbers of responders for analysis and no metyrapone-versus-placebo difference in
the numbers of responders. A number of the cross-sectional analyses and the effect of differences in ratings of
depression between various scales remain to be fully evaluated. It is anticipated all the analyses will be complete
by the end of 2015.
Harms
Serious adverse events
A total of 14 serious adverse events (SAEs) were reported for 11 of the patients randomised to study
medication (five in the group randomised to metyrapone and six in the group randomised to placebo).
Events before and after randomisation are shown in Tables 41 and 42.
None of the above SAEs was deemed to be related to medication by the PI in the appropriate centre.
Most occurred well after the medication period and/or were related to pre-existing conditions.
TABLE 42 Events recorded after commencement of study medication
Event description Allocation
Breast cancer (diagnosis preceded randomisation), dehydration/leucopenia Placebo
Groin infection/abscess Placebo
Overdose (tramadol, pregabalin, amitriptyline and alcohol) Metyrapone
Migraine with medication over-use headaches, right Holmes–Adie pupil Metyrapone
Increased suicidal thoughts Placebo
Patient fell off bike – dislocated knee/broken leg Placebo
Overactive bladder Metyrapone
Mood deterioration following screening Metyrapone
Patient took unknown amount of ketamine Placebo
Increase in symptoms of depressed mood and re-emergence of suicidal ideation Placebo
TABLE 41 Events between screening and randomisation
Event Allocation
Committed suicide prior to randomisation Not randomised
Intracranial lesion discovered during scanning procedure Metyraponea
a This patient did attend visit 2 and was randomised to metyrapone. However, after the lesion came to light (scan taken at
screening visit), this patient was not given any study medication. The patient attended no follow-up visits.
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Adverse events
One AE was reported between screening and randomisation; the patient was not randomised and it is
excluded in the following analyses. Multiple entries with the same date at onset for a particular patient are
considered to be a single event. A total of 229 AEs were reported by patients recruited and randomised.
Of these, 83 (38%, 95% CI 32% to 45%) were thought to be possibly related to study medication and 18
(8%, 95% CI 4% to 12%) were thought to be definitely related to study medication. Twelve (5%, 95% CI
2% to 9%) of the events led to adjustment, interruption or discontinuation of study medication.
Of the 165 patients recruited and randomised, 105 (63.6%, 95% CI 55.8% to 71.0%) had at least one
AE. The mean number of events reported was 2.0 (3.2 if we consider only those 105 patients who
reported at least one). These data are shown in Table 43.
There were significant differences between centres in terms of the proportion of patients reporting AEs
and this is shown in Table 44.
There was very little difference in the likelihood of patients recruited in secondary care reporting an AE
compared with patients recruited in primary care (Table 45) but any difference may be masked by the
differences between centres.
The number of AEs was analysed using negative binomial regression. The incidence rate ratios (risk in
group randomised to metyrapone divided by risk in group randomised to placebo) were as follows:
unadjusted estimate= 1.34 (95% CI 0.90 to 1.98); estimate adjusted for centre and origin of
patient= 1.41 (95% CI 0.98 to 2.03). In each case the 95% CI spans one corresponding to equal risk of
the reporting of an AE in the two treatment groups. However, the upper limits are very close to two; we
cannot exclude the possibility that treating patients with metyrapone may increase the risk of AEs. If the
analysis is restricted to events classified as ‘possibly’ or ‘definitely’ related to study medication the
corresponding estimates are as follows: unadjusted estimate= 1.71 (95% CI 0.98 to 3.01); estimate
TABLE 43 Numbers of AEs in randomised groups
No. of AEs
Treatment
TotalPlacebo Metyrapone
0 36 24 60
1 14 16 30
2 13 13 26
3 6 11 17
4 4 6 10
5 3 4 7
6 1 2 3
7 1 2 3
8 1 2 3
9 0 2 2
10 1 0 1
11 2 0 2
13 0 1 1
Total 82 83 165
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adjusted for centre and origin of patient= 1.92 (95% CI 1.14 to 3.24). There were six instances of
hypocortisolaemia during the study (one on placebo and five on metyrapone). In all cases this was
asymptomatic. As part of a standard operating procedure, all patients with hypocortisolaemia had their
lying and standing blood pressure and urea and electrolytes checked but no abnormalities were detected
in these measures. Medication was continued and repeat cortisol measurements at later dates returned
to normal.
The DMEC requested that the risk of events indicating raised levels of suicidality be compared between the
two trial arms. The incidence rate ratio (metyrapone–placebo) based on a negative binomial regression
model adjusting for centre and origin of patient care was 0.47 (95% CI 0.17 to 1.32); there was no
evidence of an increased risk of events associated with suicidality in patients randomised to metyrapone.
Toronto Side Effects Scale
Across all 32 symptoms rated by this scale, there was no difference between the randomised groups in
terms of incidence. There were two symptoms where the difference was significant at the 5% level
(delayed ejaculation and weight loss both being greater in the placebo group), but this is only to be
expected given that there are 32 symptoms rated. No differences were seen in the incidence of central
nervous system side effects. The data for this are shown in Table 46. It is particularly noteworthy that the
rates of dizziness and postural hypotension are very similar in both randomised groups.
TABLE 45 Numbers reporting AEs in groups depending on origin of referral
Origin of patient
Any AE?
TotalNo Yes
Primary care Count 23 47 70
% 32.9 67.1 100.0
Secondary care Count 37 58 95
% 38.9 61.1 100.0
Total Count 60 105 165
% 36.4 63.6 100.0
TABLE 44 Numbers reporting AEs in each centre
Centre
Any AE?
TotalNo Yes
Leeds/Bradford Count 21 17 38
% 55.3 44.7 100.0
Manchester Count 26 33 59
% 44.1 55.9 100.0
Newcastle/Durham Count 13 55 68
% 19.1 80.9 100.0
Total Count 60 105 165
% 36.4 63.6 100.0
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
TABLE 46 Toronto Side Effects Scale: central nervous system side effects – incidence, frequency and severity
Side effect
Incidence Frequency Severity
Metyrapone Placebo Metyrapone/placebo Metyrapone Placebo Metyrapone Placebo
n % n % RR
95%
confidence
limits µ
95%
confidence
limits µ
95%
confidence
limits µ
95%
confidence
limits µ
95%
confidence
limits
Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper
Nervousness 53 77 53 72 1.1 0.9 1.3 2.9 2.5 3.3 2.5 2.2 2.8 2.6 2.3 2.9 2.4 2.1 2.7
Agitation 55 80 52 70 1.1 0.9 1.4 3.1 2.7 3.5 2.6 2.3 3.0 2.8 2.4 3.1 2.5 2.2 2.8
Tremor 28 41 21 28 1.4 0.9 2.3 1.9 1.5 2.2 1.6 1.4 1.9 1.7 1.4 2.0 1.5 1.2 1.7
Myoclonus 25 36 32 43 0.8 0.6 1.3 1.9 1.6 2.3 1.9 1.6 2.2 1.6 1.4 1.9 1.6 1.4 1.8
Weakness
or fatigue
56 80 61 82 1.0 0.8 1.2 3.6 3.2 4.0 3.6 3.3 4.0 3.1 2.8 3.5 3.5 3.1 3.8
Dizziness 24 53 25 34 1.0 0.7 1.6 1.7 1.4 2.0 1.7 1.4 1.9 1.7 1.4 2.0 1.7 1.4 1.9
Postural
hypotension
25 36 32 43 0.8 0.6 1.3 1.6 1.4 1.8 2.0 1.7 2.3 1.6 1.4 1.90 1.7 1.4 2.0
Drowsiness 48 70 55 74 0.9 0.8 1.2 2.9 2.5 3.3 2.8 2.5 3.2 2.6 2.2 3.0 2.5 2.2 2.8
Increased
sleep
15 22 18 24 0.9 0.5 1.6 1.5 1.2 1.8 1.6 1.3 1.9 1.3 1.1 1.6 1.4 1.2 1.7
Decreased
sleep
46 67 55 74 0.90 0.72 1.11 3.09 2.67 3.51 3.09 2.71 3.47 2.90 2.48 3.31 2.85 2.48 3.22
Sweating 39 56 43 58 0.97 0.73 1.29 2.20 1.87 2.54 2.27 1.94 2.60 2.13 1.81 2.45 2.11 1.80 2.42
Flushing 31 45 29 39 1.15 0.78 1.69 2.00 1.67 2.33 1.73 1.47 1.99 1.81 1.52 2.10 1.70 1.42 1.98
Oedema 17 25 17 23 1.07 0.60 1.93 1.72 1.38 2.07 1.57 1.29 1.84 1.48 1.22 1.73 1.50 1.25 1.75
Headache 47 68 57 77 0.88 0.72 1.08 2.35 2.03 2.66 2.68 2.36 2.99 2.26 1.95 2.57 2.55 2.25 2.86
Blurred vision 23 33 22 30 1.12 0.69 1.82 1.67 1.39 1.95 1.62 1.35 1.89 1.54 1.30 1.77 1.49 1.27 1.70
D
O
I:
1
0
.3
3
1
0
/e
m
e
0
2
0
4
0
E
F
F
IC
A
C
Y
A
N
D
M
E
C
H
A
N
IS
M
E
V
A
L
U
A
T
IO
N
2
0
1
5
V
O
L
.
2
N
O
.
4
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2015.
This
w
ork
w
as
produced
by
Ferrier
e
t
a
l.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
6
3
Chapter 4 Discussion
Limitations
In general there are a few limitations to the current study. Although the trial did not reach its original
target of 90% power, it achieved 84% power. In terms of the binary outcomes of response and remission,
the very wide CI suggests that the study is not adequately powered to detect differences in these measures
of outcome (and these were not the outcomes on which sample size was based). However, response rates
were almost identical in the two groups, suggesting that if there is any difference in efficacy between
metyrapone and placebo it is too small to be of clinical significance. This is also consistent with a lack of
effect of metyrapone on the primary outcome measure. There are no obvious biases in terms of those
patients who were randomised and the groups were very well balanced in terms of key demographic and
clinical variables (see Table 5). The numbers retained in the study to 24 weeks are reasonable, given the
complexity and severity of the underlying condition. The attrition rate in the follow-up phase was
somewhat higher in the metyrapone group than in the placebo group (see Figure 10) but there was no
evidence from joint modelling that this had any impact on the findings. Blinding was fully maintained
throughout the study (see Chapter 2, Randomisation and blinding). There was no limitation with
multiplicity of analyses, with the possible exception of the TSES, which involved the analysis of a large
number of variables. There was a suggestion of patients being recruited from one centre (Manchester)
having more severe depression that those recruited elsewhere. This probably relates to the significantly
more severe depression seen in patients recruited from secondary care compared with primary care
(as might be expected): in Manchester there was a relatively low rate of recruitment from primary care.
Interestingly, despite the differences in severity of depression in primary care compared with secondary
care patients, there was no difference in severity of anxiety in these two groups. Nevertheless, analysis has
included centre and source of patient as covariates.
A current limitation of this report is that we do not have good evidence of whether or not the patients
adhered to their medication. Medication was posted to patients and that system went well. Patients were
reminded to take medication and asked to return any unused capsules (which was a rare event). Thus
apparent concordance was good but it is known that, despite such measures, there can be problems in this
domain. Although the ADD Study did not include direct measures of metyrapone plasma concentrations in
patients, measurement of plasma 11-deoxycortisol after 1 week’s treatment serves as a sensitive assessment
of both compliance and pharmacodynamic effect of the treatment. Previous data show that metyrapone
administration is associated with highly significant increases in 11-deoxycortisol33,91 owing to its effect of
blocking 11β-hydroxylase. A prespecified explanatory analysis excluding patients who did not take or
discontinued treatment, assessed utilising the 11-deoxycortisol measure of apparent concordance with
treatment, will be performed and results published separately.
Previous studies have suggested that patients with baseline HPA axis dysregulation may preferentially
respond to metyrapone; this effect is not apparent in this data set.
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Generalisability
The ADD Study is the largest RCT of antiglucocorticoid treatment of major depression in the UK and one
of the largest worldwide. In general terms, a strength of the current study is that it is generalisable to the
large numbers of patients in the NHS and in the community who have TRD, as defined using the criteria
in this study. Compared with many previous studies, including a relatively large proof-of-concept study
of metyrapone augmentation of conventional antidepressants,33 the ADD Study recruited from a broad
population of patients, including those from both primary and secondary care. Inclusion criteria were
intentionally kept broad, and exclusion criteria to a minimum, in order to explore the efficacy of
metyrapone treatment in as ‘real world’ a setting as possible. This means that, for example, patients with
significant suicidal ideation, who are often excluded from RCTs in depression, were included in the ADD
Study. The help of the service users on the research team and that of the MHRN Service User Forum in
accessing such a broad group of patients cannot be underestimated. However, although the referral
system to this study was open to patients with this disorder from all types of settings (as discussed further
below), in practice 58% of randomised patients came from secondary care outpatient settings, which is
an over-representation, as most such cases are managed in the community. In addition, there was a large
number (n= 708) of dropouts between referral and randomisation. Some were not included because they
failed to meet criteria for inclusion, some as a result of meeting exclusion criteria, but others for unknown
reasons (e.g. did not attend) so we cannot be completely confident that our sample is fully representative
of the clinical condition in the community at large.
The patients included in the ADD Study were well characterised at baseline in relation to a number of
factors known to relate to TRD, and no marked baseline imbalances were noted, increasing confidence
that the observed outcomes were indeed attributable to intervention. The degree of treatment
refractoriness of patients was carefully assessed using the MGH-TRD staging scale,111 which included
taking a history of medication prescription and included perusal of hospital and GP records. There is a lack
of consensus as to which staging scale for refractory depression should be used in studies. We chose the
MGH-TRD scale owing to its ease of use, especially taking into account scoring for dose optimisation and
augmentation/combination treatment. We chose a minimum MGH-TRD score of 2 points for inclusion.
Use of a single antidepressant at an effective dose scores 1 point and hence the cut-off of 2 points
represents a failure to respond to at least two antidepressants, given usual UK practice in primary care of
not augmenting or combining medications for depression until after this stage.1 Beyond this point in the
treatment algorithm for individual patients there is great divergence in practice with patients being referred
to secondary care at different stages by individual clinicians. The maximum MGH-TRD score for inclusion
was set as 10 points. In practice, this means five or six trials of different antidepressants, allowing for
dose optimisation and augmentation/combination strategies used for some of these trials. Use of
electroconvulsive therapy scores 3 points in the MGH-TRD scale. As such, this, in itself, was not an
exclusion criterion in the ADD Study. However, as most patients receiving ECT will also have had at least
two antidepressants (often with dose optimisation and augmentation), in practice, few patients treated
with ECT have a score under the maximum cut-off of 10 points. The mean (SD) MGH-TRD score for the
randomised patients was 4.6 (1.9), indicating that most patients were well in the range of treatment
refractoriness but not in the later stages of treatment refractoriness.
In broad terms, the patients studied here could be described as having moderate depression. In terms of
generalisability, no patients could be described as having mild depression and very few as having severe
depression. This reflects the referral strategy from outpatient clinics, primary care and the community.
Although about 55% of patients randomised came from a secondary care setting, all of these patients
were outpatients. The remaining 45% of patients came from primary care or were self-referrals. It is
important to note that the recruitment to this study was therefore very different from that of the positive
proof-of-concept study of metyrapone augmentation of conventional antidepressants carried out by
Jahn et al.,33 which exclusively studied inpatients. The depression rating scale results further demonstrate
differences between the current study and that of Jahn et al.33 For example, the metyrapone group in
the Jahn study33 had a mean (SD) MADRS score at baseline of 31.5 (7.6) compared with 28.1 (5.5) in the
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current study, and the corresponding scores on the HDRS were 26.6 (6.5) and 23.3 (3.9), although it
should be noted the Jahn et al. study33 utilised the 21-item version of the HDRS, in contrast with the
17-item version used here. It is of interest that baseline BDI scores in the metyrapone group in the current
study were higher at 35.6 (10.9) than those seen in the Jahn et al. study33 (8.4). High BDI scores and a
high BDI/MADRS ratio have been associated with poor outcome in TRD.123 Our patients therefore may
have clinical characteristics known to be associated with worse outcome, which may link to the low
response and remission rates seen in the current study.
There was evidence that many patients had a family history of depression and high levels of anxiety, as
reflected in the CAS and STAI scores, as is commonly found in such patients in routine care in the NHS.
The dosing schedule for metyrapone selected for the ADD Study was 500mg twice a day, administered
in the morning and at noon. The total daily dose matches that given in previous studies.33 The rationale for
the timing of administration was physiological, to coincide with the portion of the day associated with the
highest cortisol concentrations. The study is novel in its length of follow-up and in its inclusion of a range
of mechanistic studies exploring how such treatments might work.
Interpretation
The overall conclusion from this study is that metyrapone augmentation of antidepressants is not efficacious for
moderately depressed patients in outpatient clinics and in the community who have failed to respond to at
least two antidepressants. There was no obvious benefit to its use either on the primary outcome or over the
period of follow-up and this negative result extended to other secondary outcomes, such as the CAS, the BDI
and measures of QoL. Metyrapone was generally well tolerated by this group as there were no SAEs
attributable to it and AEs occurring during its use were as common in the placebo group.
As discussed above, there is preliminary evidence for metyrapone being efficacious in TRD in a smaller
RCT carried out on more severely ill inpatients in Germany.33 It may be that the drug works only for more
severe depression but, unfortunately, our study was not powered for this type of subgroup analysis.
Alternatively, the positive result in the Jahn et al. study33 is a type I error. This TRD population was
characterised by increased exposure to childhood adversity (compared with the control subjects) and
normal HPA axis function. This finding accords with the existing literature in chronic populations;124,125
there is evidence that the former predicts non-response to treatment.126 None of baseline HPA axis
function, change in CAR in response to drug treatment or severity of childhood trauma predicted clinical
response to metyrapone.
The impact of metyrapone on the HPA axis is relevant to its potential mechanism of action. In the Jahn et al.
study,33 it exerted a minimal impact on circulating cortisol levels, this is presumably because cortisol
activation of mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) is a major homeostatic
regulator of HPA axis activity. Thus in the Jahn et al. study33 – using the same dose as this study – there was
a marked increase in other HPA axis hormones, notably ACTH and 11-deoxycortisol. The HPA axis response
to metyrapone will be more evident when the 11-deoxycortisol data are available. The issue of whether or
not HPA axis dysregulation at baseline would be expected to predict response to metyrapone is of interest
and relevance. Translational studies from our group show that antiglucocorticoid strategies – such as GR
antagonists – engender an increase in the prefrontal cortex serotonin response to SSRIs, even in rats with
normal HPA axis function,17 suggesting that HPA axis dysregulation is not a requirement for therapeutic
gain from HPA axis manipulation.
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There are very few data specifically on the neuropsychology of treatment-resistant depressed groups. Those
that have been conducted suggest that deficits are restricted to tests of processing speed.127 In this TRD
sample, we see broad deficits in verbal and visuospatial working memory compared with healthy control
subjects. Deficits in attention were not general and, instead, were restricted to the executive control of
attention. These findings are indicative of impairment in effortful processing in TRD. Cognitive deficits have
important clinical and functional consequences for depressed patients. They are associated with poor
functional outcomes, particularly employment, and with a greater risk of relapse and poorer clinical
outcomes.128 Patients also complain of the effects of limited cognitive function and find this dispiriting.
For these reasons, strategies to improve cognitive function in depression are an important target for
intervention. In patients with bipolar depression, the glucocorticoid receptor antagonist has been shown to
improve cognitive function, specifically spatial working memory.129 However, this strategy was ineffective
in schizophrenia.130 In the current study, metyrapone was not associated with improvement in cognitive
measures but, as has previously been demonstrated,125 there was no evidence of elevated corticosteroids in
this group of patients with TRD. It may be that antiglucocorticoid therapies improve cognition only when
dysregulation of the HPA axis leads to elevated corticosteroid levels, as is found in bipolar disorder131
but not TRD125 or schizophrenia.130 However, remediation strategies are showing more promise. Recent
work has demonstrated that cognitive remediation with supplemental ‘internet-based homework’ led to
significant improvements in aspects of cognition, especially attention/processing speed and verbal memory.
Improved cognition was also predictive of improvement in general functioning.132
Patients at baseline are less accurate in identifying emotions and more likely to wrongly attribute emotions.
The lack of an emotion by group interaction means that there is a lack of evidence of emotional bias, but
the greatest differences were seen in the negative emotions of anger, disgust and fear. These results are
broadly in line with the literature for depression and confirm for the first time that similar findings are
evident in TRD. The only differential effect of treatment allocation was seen for anger accuracy; however,
this is likely to be a chance finding and partly accounted for by baseline differences. One limitation is the
relatively small numbers due to loss of participants for technical reasons and dropout from follow-up.
Patients at baseline had poorer immediate recall than healthy control subjects, with evidence of a negative
emotional bias: negative words were recalled equally by control subjects but positive and negative words
less so. Control subjects did not show a positive bias in this study. No significant results for accuracy of
delayed recognition were seen, although the pattern was the same as for recall. However, there was a
strong trend for patients to wrongly identify words as having been seen before, driven most strongly by
negative words, suggesting there may be an alteration in emotional recognition discrimination or bias. No
significant effects of treatment were seen. The delayed recognition data need to be viewed as exploratory,
given the lack of a significant group or group by valence interaction. A limitation to the task is that
delayed recall was not measured.
Word valence affected rate of responding to targets, with neutral targets and emotional distractors having
the slowest rate and emotional targets and neutral distractors the fastest rates. This suggests that words
having an emotional valance capture attentional resources, indicating that the task appeared to work.
The main finding is that patients are slower to react to positive targets in the presence of neutral and
negative distractors, suggesting positive words capture less attentional resource and have less salience for
patients than they do for control subjects. There was no evidence that negative words captured more
attentional resource in patients and no positive bias was seen in control subjects (GoPos and GoNeg values
are very similar). No effects of treatment were seen. The lack of a significant group by valence interaction
makes the results for the GoPos condition exploratory. The task itself may have been limited by its
complexity and number of conditions presented.
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The results show similar hyperactivation in the amygdala in response to processing faces showing negative
emotions in patients with TRD, as previously reported in the literature.34 However, these hyperactivations
(compared with healthy individuals) were present only in the condition that did not require explicit
processing of the emotional content of the face. This may indicate that healthy individuals were better able
to ignore the displayed negative emotion when the task could be performed without explicitly referring to
the emotionality in the face, whereas patients may have had the tendency to process the emotion regardless
of its relevance for the task. When explicit processing of facial emotions was required, patients with TRD
and healthy control subjects showed similar levels of amygdala activation.
Contrary to previous work,101 there were no differential activations in the amygdala between the three
conditions of the EEM task across all participants. In general, brain activation differences between
the conditions were relatively small. Similarly, there were no differences in amygdala responses between
patients and control subjects. However, this might be related to the fact that we also did not see any
evidence for improved recognition memory for emotional over neutral words (results not shown here).
In addition, our implementation of the EEM task failed to elicit reliable amygdala activity. Various
methodological alterations in this task that were necessary for the current study and these negative
findings may be related to those alterations. Even though we tried to eliminate the amount of time that
participants had to explicitly rehearse the words, contrary to previous studies, they were still aware that
they would be tested on their memory performance during the encoding, which may have altered their
processing of the words. Additionally, as a result of time constraints, the number of words presented to
the participants was smaller than in other studies.
During the n-back task, the patients with TRD showed a reduced activation of the dorsolateral prefrontal
cortex compared with the control subjects. In the emotional memory task, the TRD group had less
activation of the posterior cingulate cortex while encoding both positive and neutral images, and reduced
anterior cingulate cortex activation while retrieving positive images compared with neutral images. While
retrieving images irrespective of valence, the TRD group demonstrated an increased activation of the
posterior insula compared with control subjects. The decreased activation of the prefrontal cortex during
the n-back task was demonstrated here in a treatment-resistant population. This study also suggests that
there is an alteration in the functioning of the cingulate and insular cortex in the encoding and retrieval of
positive emotional memories in this group of patients with TRD. Further study is needed to determine
whether or not there is alteration of negative emotional memory processing, and what relationship this has
to the degree of depression or a failure to respond to treatment.
The primary finding of the EEG substudies is that a putative marker of long-term potentiation, the enhancement
of VEPs following tetanic visual stimulation, is impaired in patients with TRD. Following tetanus, a significant
increase in the magnitude of the N1 and N1b components of VEPs were seen in control subjects, in line with
previous published data demonstrating this phenomenon.69,133–136 However, no significant enhancement was
seen in depressed patients in line with a previous report in non-treatment-refractory depressed patients,137
patients with bipolar disorder138 and patients with schizophrenia.139 This suggests that impaired visual
cortical plasticity is a phenomenon shared across a range of psychiatric disorders. Further research is
required to examine if this represents a wider impairment in cortical plasticity and its aetiology and
is of pathophysiological significance.
In summary, regarding the mechanistic outcomes, HPA axis measures were not different between the
groups and did not predict any clinical response to metyrapone. A number of abnormalities in the
neuropsychology and neural activity were found in the TRD population. Many of these were known from
previous work in depression but this study showed them to be present in TRD and quantified them.
No specific effects of metyrapone on these variables have been shown.
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Clinical implications and future research directions
The firm conclusion based on the primary outcome measure of the ADD Study is that in the population
of depressed patients studied, the addition of metyrapone to standard serotonergic antidepressants is
ineffective. A question remains as to why the ADD Study was negative, without any suggestion
whatsoever of an effect of metyrapone at any time point, when an effect of antiglucocorticoid treatment
is supported by preclinical data17 and with a previous German RCT of metyrapone augmentation being
positive.33 This may relate to the nature of the patients studied by Jahn et al.33 They studied inpatients,
which are usually, but not always, severely and acutely ill. We included many primary care patients and
outpatients with a high degree of treatment refractoriness and chronicity of depressive symptoms. A study
of HPA axis function in chronic depressed patients suggests that no abnormality is found,125 contrary to
findings in patients with more acute illnesses.18,19 Similarly, the ADD Study patients do not demonstrate
HPA axis abnormalities, at least as indexed by the CAR. Chronic depression has been shown previously
to be associated with normal HPA axis function,125 and it has been argued that normocortisolaemic
depression may predict non-response to biological treatments and hence may predict the development of
a chronic illness. Conversely, it has been suggested that the initial hypercortisolaemia of depression may
normalise with time in patients who continue to demonstrate symptoms; hence normal cortisol levels
may be a consequence or a cause of chronic TRD. This is an important issue for future research to clarify.
In addition, it would be of interest to explore the efficacy of metyrapone augmentation in acutely
depressed patients, particularly those with demonstrable hypercortisolaemia.
The research questions above notwithstanding, the clinical implication of the ADD Study is that
management of treatment refractory and chronically depressed patients should not include the use of
metyrapone as an augmentation strategy.
DISCUSSION
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Appendix 1 Statistical analysis plan
Background
Antidepressant drugs have established efficacy versus placebo in clinical trials but in naturalistic settings,
many patients have unsatisfactory outcomes and may be referred to be suffering from treatment-refractory
depression (TRD). However, a Cochrane review demonstrated the efficacy of antiglucocorticoid augmentation
of antidepressants in patients with TRD [1]. In the Cochrane meta-analysis of antiglucocorticoid treatments, the
largest effect size was seen with metyrapone [1], a cortisol synthesis inhibitor which crosses the blood–brain
barrier. In addition, a successful study has been conducted by Jahn and colleagues [2] in a centre in Germany,
with 63 depressed inpatients. Patients receiving metyrapone were significantly more likely to respond than
those receiving placebo, with an effect size of d= 0.63 without serious side effects. The study will extend
research in this area by exploring the translatability of the findings to a primary and secondary care, UK NHS
population and also extending the follow-up period for 6 months after metyrapone treatment has ceased, in
comparison with pre-existing antiglucocorticoid trials [1]. Additionally, an important element of the proposed
study is the further exploration of the mechanisms underlying the beneficial effects of metyrapone
augmentation on antidepressant response using neuropsychological outcome measures which may be markers
of its mechanism of action.
This document should be read in conjunction with the (to be) published ADD Study Protocol paper.
Study objectives
Primary clinical objective
l The primary objective is to determine whether metyrapone (500mg twice a day) for 21 days is
efficacious in augmenting conventional serotonergic antidepressants in TRD in a UK NHS primary and
secondary care setting. This is to be assessed by Montgomery–Åsberg Depression Rating Scale (MADRS)
scores measured at baseline and two weeks post treatment (week +5 from randomisation), comparing
patients treated with metyrapone to those treated with placebo.
Secondary clinical objectives
1. To determine the clinical effect size at two weeks post-completion of treatment of a three-week course
of metyrapone (vs placebo) augmentation of antidepressants in depressed patients who have failed to
respond to at least two courses of antidepressants, in primary care and psychiatric outpatient clinics in
the UK.
2. To assess whether the response is sustained for up to 21 weeks post cessation of metyrapone.
3. To assess whether metyrapone augmentation improves patients’ quality of life.
4. To assess the tolerability and safety of metyrapone augmentation in a large sample taken from a
representative population of psychiatric outpatients and primary care patients with TRD.
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Mechanistic objectives
In the full sample
1. To assess whether metyrapone changes patients’ HPA axis function.
2. To assess whether changes in HPA axis function are seen 2 weeks after metyrapone treatment.
3. To assess whether the change in HPA axis function correlates with clinical response.
4. To assess whether baseline HPA axis function predicts clinical response.
5. To assess if type and severity of childhood trauma [as assessed by the Childhood Trauma
Questionnaire (CTQ) scores] predicts clinical response.
6. To assess whether the change in, or baseline assessment of, HPA axis function has specific genetic
underpinning and whether this relates to, or explains better, the clinical response.
In subsamples
1. To determine the nature and extent of neuropsychological abnormalities in patients with TRD
compared with healthy control subjects.
2. To determine whether neuropsychological performance improves with metyrapone treatment.
3. To determine whether clinical improvements with metyrapone augmentation correlate with
improvements in neuropsychological function and particularly (a) changes in cortisol sensitive tasks,
e.g. spatial working memory and/or (b) 5-HT sensitive tasks, e.g. emotional processing.
4. To compare visual cortical long-term potentiation (LTP) in patients with TRD and healthy
control subjects.
5. To examine if visual cortical LTP is altered by treatment with metyrapone.
6. To compare emotional source memory performance, and its electrophysiological underpinnings,
in patients with TRD and healthy control subjects.
7. To examine if emotional source memory performance, and its electrophysiological underpinnings,
is altered by treatment with metyrapone.
8. To determine whether EEG predictors of conventional antidepressant response, and in
particular specific predictors of response to serotonergic antidepressants, predict response to
metyrapone augmentation.
9. To compare the degree of activation of the amygdala in response to emotional faces and words in
patients with TRD and healthy control subjects.
10. To determine whether abnormalities in the degree of activation of the amygdala in response to
emotional faces pretreatment is modified by metyrapone treatment.
11. To determine if changes in the degree of activation of the amygdala with metyrapone post-treatment
correlate with clinical outcome.
12. To compare neural activity during episodic and working memory tasks in patients with TRD and
healthy control subjects.
13. To determine whether abnormalities in neural activity during episodic and working memory tasks is
modified by metyrapone treatment.
14. To determine if changes in neural activity during episodic and working memory tasks correlate with
clinical outcome.
15. To determine whether patients with TRD have altered hippocampal response to hydrocortisone
compared with healthy control subjects.
16. To determine if the hippocampal response to hydrocortisone is modified in patients by
metyrapone treatment.
17. To determine the effect of genetic variations on cognitive and emotional processing and on predictors
of treatment outcome.
18. To examine the degree to which differences in ratings of depression between the scales used to assess
mood at baseline predict response to metyrapone, including a focus on the degree of disparity
between observer and self-ratings of mood.
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Study design
Patient randomised double-blind randomised controlled parallel trial with half the patients receiving
metyrapone and half the patients receiving a placebo.
Sample size
Two groups of 85 patients give 90% power to detect an effect size of 0.5 assuming a type 1 error rate of
5%. Allowing for 10% attrition during the trial, 95 per group would need to be randomised; 190 in total
aged 18–65 years. 55 healthy control subjects, aged 18–55, with no personal or family history of mental
illness are included.
The target number in the patient group was amended following a delay in starting recruitment and a slow
early rate of recruitment, following agreement from the Data Monitoring and Ethics Committee (DMEC),
the funder and the sponsor. A reduced power of 80% was agreed. Using the same assumptions as above,
and allowing for 10% attrition prior to the primary outcome measure, the aim was to randomise 70 per
group; 140 in total.
Study population
This is more fully defined in the ADD Study protocol publication. Patients included had to meet criteria
including i) having a DSM-IV confirmed diagnosis of a major depressive episode; ii) current symptoms
of moderate to severe severity as defined by Hamilton Depression Rating Scale-17 item (HDRS17) score of
≥ 18 at week –2 and 0; iii) have TRD as defined by a Massachusetts General Hospital Treatment Resistant
Depression (MGH-TRD) staging score of 2–10; iv) currently taking a serotonergic antidepressant.
CONSORT diagram
The flow of patients through the study will be described with the aid of a CONSORT diagram.
Characteristics of groups at baseline
The baseline characteristics of the study population will be summarised for each study group.
Compliance with medication and withdrawal from study medication
Adherence to medication will be assessed using measures of 11-deoxycortisol.
A 95% confidence interval for the relative odds of withdrawing from the two treatment arms will
be reported.
Completeness of data
The level of missing data will be reported for each of the study measures of outcome.
General analysis considerations
Unless otherwise stated, all analyses will use two-tailed tests where appropriate with significance level set
at 5%. Statistical packages used will include SPSS, STATA and R, as well as specialised packages for
MRI/EEG analysis, etc.
Primary outcome
The primary outcome will be assessed using an intention-to-treat analysis (patients allocated to the group
to which they were randomised regardless of whether they received the treatment).
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Primary analysis
l The estimated difference between the treatment groups at week 5 adjusting for randomisation strata
will be estimated using a mixed model. The dependent variable will be MADRS score at week 5.
The baseline score at week 0 will be included as a covariate. Differences between centres will be
incorporated as a random effect; differences between primary and secondary care origin of the patients
will be included as a fixed effect. (Statistical packages: SPSS, STATA, R.)
Secondary analyses
l The difference between MADRS at week 5 and MADRS immediately before treatment (week 0) in
two arms will be compared using an independent sample t-test utilising all patients in the study in an
intention-to-treat analysis.
l The impact of missing data due to patients declining to participate in data collection will be assessed
using joint modelling of ‘time to withdrawal from data collection’ and MADRS scores.
l In addition to analysing the data using the conventional MADRS score, the above primary and
secondary analyses will be repeated utilising the addition ‘atypical’ depression items (rating
hypersomnia and increased appetite). In this scoring of the MADRS, the highest score from the
conventional sleep and atypical sleep items, and conventional appetite and atypical appetite items,
will be used to calculate the total MADRS score.
l The intention-to-treat analyses above will be repeated in a ‘per-protocol analysis’ excluding patients
who discontinued treatment during the three week treatment period. A second ‘per-protocol’
definition will utilise the 11-deoxycortisol measure of apparent concordance with treatment.
Secondary clinical outcomes
1. In relation to clinical effect size:
i. Response (defined as 50% reduction in MADRS) and remission (defined as MADRS ≤ 10) rates at
week 5 will be analysed using logistic regression procedures analogous to the mixed models
described previously. Variation between centres will be incorporated as a random effect; differences
between primary and secondary care origin of patients and the difference between those randomised
to metyrapone and those randomised to placebo will be included as fixed effects. Results will be
presented in the form of a 95% confidence interval for the odds of response/remission.
ii. In relation to CAS, BDI and STAI measures:
– The CAS, BDI and STAI will be analysed by fitting a sequence of nested models. The baseline
model will include the score at week 5 as the dependent variable, the baseline score as a
covariate and the difference between study groups as a fixed effect. Variation between centres
will then be included as a random effect and the difference between primary and secondary care
origin as a fixed effect. Nested models will be compared using a likelihood ratio test. The impact
of compliance with treatment will be evaluated using the same approach (based on the
measures of compliance previously defined). Results will be given in the form of unadjusted and
adjusted 95% confidence intervals for the effect of treatment with metyrapone.
2. In relation to whether the response is sustained:
i. The persistence of change in MADRS, CAS, BDI and STAI scores will be assessed using repeated measures
ANOVA, adjusting for randomisation strata of centre and primary vs. secondary care, using all of the data
points available.
ii. The speed of response and speed of remission (both defined using MADRS as described above) with
metyrapone vs. placebo will be assessed using survival analysis; time to response and time to
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
remission will be analysed using a Cox proportional hazards regression model. Results will be given
in the form of a 95% confidence interval for the hazard ratio between the two groups.
3. In relation to whether metyrapone improves patient’s quality of life:
i. The EQ-5D data will be analysed by fitting a sequence of nested models. The baseline model will
include the score at week 5 as the dependent variable, the baseline score as a covariate and the
difference between study groups as a fixed effect. Variation between centres will then be included
as a random effect and the difference between primary and secondary care origin as a fixed effect.
Nested models will be compared using a likelihood ratio test. The impact of compliance with
treatment will be evaluated using the same approach (based on the measures of compliance
previously defined). Results will be given in the form of unadjusted and adjusted 95% confidence
intervals for the effect of treatment with metyrapone.
4. In relation to how well metyrapone is tolerated:
i. The Toronto Side Effects Scale scores will be analysed utilising data from all patients who had at least
one dose of study medication. A second ‘per-protocol’ definition will utilise the 11-deoxycortisol measure
of apparent concordance with treatment.
– The difference between TSES score at week 3 and TSES score immediately before treatment
(week 0) in two arms will also be compared using an independent sample t-test utilising all
patients in the study in an intention-to-treat analysis.
– The change in TSES score over time will be compared using a repeated measures ANOVA
including all available time points.
– Symptoms described by patients will be grouped into clinically relevant clusters and analysed.
This will include a specific focus on suicidal and any changes in this during or following treatment.
ii. The Young Mania Rating Scale (YMRS) will be analysed in a similar way to that described for the TSES.
Mechanistic outcomes
In the full patient sample
1. To assess whether metyrapone changes patients’ HPA axis function:
i. HPA function will be assessed by calculating the Area Under the Curve (AUC) for the CAR data,
measuring the peak change in cortisol on waking by comparing the initial waking sample with the
maximum, as well as examining the diurnal change in cortisol using the CAR and the 11 p.m. saliva
sample. The effect of metyrapone will be compared with placebo in relation to HPA axis function at
week 3 (end of metyrapone treatment) using ANOVA covarying for the baseline at week 0.
2. To assess whether changes in HPA axis function are seen 2 weeks after metyrapone treatment:
i. HPA axis function assessed as above comparing data at week 5 covarying for week 0.
3. To assess whether the change in HPA axis function correlates with clinical response:
i. The correlation between change in HPA axis function (CAR AUC and maximal peak, and diurnal
cortisol, both at week 3 and week 5 compared with week 0) with change in MADRS, CAS, BDI,
STAI, EQ-5D (week 5 compared with week 0) will be examined.
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4. To assess whether baseline HPA axis function predicts clinical response:
i. The correlation between HPA axis function (CAR AUC and maximal peak, and diurnal cortisol) with
change in MADRS, CAS, BDI, STAI, EQ-5D (week 5 compared with week 0) will be examined.
5. To assess if type and severity of childhood trauma [as assessed by the Childhood Trauma Questionnaire
(CTQ) scores] predicts clinical response:
i. The correlation between CTQ with change in MADRS, CAS, BDI, STAI, EQ-5D (week 5 compared
with week 0) will be examined.
6. To assess whether the change in, or baseline assessment of, HPA axis function has specific genetic
underpinning and whether this relates to, or explains better, the clinical response:
i. The relationship between clinical response (as described above) and HPA axis function compared
with a range of candidate polymorphisms will be examined.
In subsamples of patients
1. To determine the nature and extent of neuropsychological abnormalities in patients with TRD
compared with healthy control subjects:
i. This will be studied using the various outcome measures from the neuropsychological tasks
employed, comparing the patients with healthy control subjects. Analysis will include controlling
for age, gender and IQ (as assessed using NART).
2. To determine whether neuropsychological performance improves with metyrapone treatment:
i. This will be studied using the various outcome measures from the neuropsychological tasks
employed, comparing performance at week 5 to that at week 0, in patients treated with
metyrapone compared with those treated with placebo. This will be conducted both using an
intention-to-treat population and using a ‘per-protocol’ population.
3. To determine whether clinical improvements with metyrapone augmentation correlate with
improvements in neuropsychological function and particularly (a) changes in cortisol sensitive tasks,
e.g. spatial working memory and/or (b) 5-HT sensitive tasks, e.g. emotional processing:
i. The correlation between changes in neuropsychological function (as measured above) with changes
in clinical symptoms (MADRS, CAS, BDI, STAI) at week 5 compared with week 0 will be examined.
4. To compare visual cortical long-term potentiation (LTP) in patients with TRD and healthy
control subjects:
i. The degree and persistence of LTP induced in visual cortex by the tetanic presentation of a flashing
checkerboard in patients (at week 0) will be compared with that in healthy control subjects.
Analysis will include controlling for age, gender and IQ (as assessed using NART).
5. To examine if visual cortical LTP is altered by treatment with metyrapone:
i. The degree and persistence of LTP at week 5 compared with week 0 will be examined in patients
treated with metyrapone and placebo. This will be conducted both using an intention-to-treat
population and using a ‘per-protocol’ population.
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6. To compare emotional source memory performance, and its electrophysiological underpinnings, in
patients with TRD and healthy control subjects:
i. Behaviour responses, and related ERPs, recorded from patients at week 0 will be compared with
those from healthy control subjects. Analysis will include controlling for age, gender and IQ
(as assessed using NART).
7. To examine if emotional source memory performance, and its electrophysiological underpinnings, is
altered by treatment with metyrapone:
i. The Behaviour responses, and related ERPs, at week 5 compared with week 0 will be examined in
patients treated with metyrapone and placebo. This will be conducted both using an intention-to-treat
population and using a ‘per-protocol’ population.
8. To determine whether EEG predictors of conventional antidepressant response, and in particular specific
predictors of response to serotonergic antidepressants, predict response to metyrapone augmentation:
i. The correlation between a variety of EEG variables (including LDAEP slope, alpha power, alpha
hemispheric asymmetry, anterior cingulate located theta power, and combinations of these),
recorded at week 0 will be correlated with the change in clinical symptoms (MADRS, CAS, BDI,
STAI) at week 5 compared with week 0 will be examined.
9. To compare the degree of activation of the amygdala in response to emotional faces or emotional
words in patients with TRD and healthy control subjects:
i. The fMRI BOLD response to emotional stimuli, particularly in relation to activity in the amygdala,
recorded from patients at week 0 will be compared with those from healthy control subjects.
Analysis will include controlling for age, gender and IQ (as assessed using NART).
10. To determine whether abnormalities in the degree of activation of the amygdala pretreatment is
modified by metyrapone treatment:
i. The change in fMRI BOLD response to emotional stimuli, particularly in relation to activity in the
amygdala, at week 5 compared with week 0, in patients treated with metyrapone compared with
those treated with placebo. This will be conducted both using an intention-to-treat population and
using a ‘per-protocol’ population.
11. To determine if changes in the degree of activation of the amygdala with metyrapone post treatment
correlate with clinical outcome:
i. The correlation between change in amygdala activation at week 5 compared with week 0 with
change in MADRS, CAS, BDI, STAI, EQ-5D (week 5 compared with week 0) will be examined.
12. To compare neural activity during episodic and working memory tasks in patients with TRD and
healthy control subjects:
i. The fMRI BOLD response during episodic and working memory tasks recorded from patients at
week 0 will be compared with those from healthy control subjects. Analysis will include controlling
for IQ (as assessed using NART) and if required age and gender.
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13. To determine whether abnormalities in neural activity during episodic and working memory tasks is
modified by metyrapone treatment:
i. The change in fMRI BOLD response during episodic and working memory tasks at week 5
compared with week 0, in patients treated with metyrapone compared with those treated
with placebo.
14. To determine if changes in neural activity during episodic and working memory tasks correlate with
clinical outcome:
i. The correlation between change in BOLD response during episodic and working tasks at week 5
compared with week 0 with change in MADRS, CAS, BDI, STAI, EQ-5D (week 5 compared with
week 0) will be examined.
15. To determine whether patients with TRD have altered hippocampal response to hydrocortisone
compared with healthy control subjects.
i. The phMRI BOLD response related to the administration of hydrocortisone in patients at week 0
will be compared with those from healthy control subjects.
16. To determine if the hippocampal response to hydrocortisone is modified in patients by
metyrapone treatment:
i. The change in phMRI BOLD response related to the administration of hydrocortisone at week 5
compared with week 0, in patients treated with metyrapone
ii. The change in phMRI BOLD response related to the administration of hydrocortisone at week 5 in
patients treated with metyrapone compared with those treated with placebo.
17. To determine the effect of genetic variations on cognitive and emotional processing and on
predictors of treatment outcome using candidate genes with functional effects on HPA axis and
monoamine function.
18. To examine the degree to which differences in ratings of depression between the scales used to assess
mood at baseline predict response to metyrapone, including a focus on the degree of disparity
between observer and self-ratings of mood:
i. The difference in ratings of mood using the HDRS, MADRS and BDI at baseline will be correlated
with the change in mood (assessed using MADRS) at week 5 compared with week 0.
Additional cross-sectional analyses
These will include the following analyses to explore the relationship between various factors at baseline
(week 0) in the patient population (and where data are available in the healthy control subjects as well).
The list is not comprehensive and further analyses may be undertaken in the light of new developments or
for hypothesis testing or generating:
1. The relationship between HPA axis function (as defined above) and CTQ will be examined.
2. The relationship between HPA axis function (as defined above) and neuropsychological function,
particularly spatial working memory, will be examined.
3. The relationship between HPA axis function (as defined above) and LTP will be examined.
4. The relationship between HPA axis function (as defined above) and emotional source memory (both
behavior and related ERPs) will be examined.
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5. The relationship between HPA axis function (as defined above) and the amygdala response to
emotional faces.
6. The relationship between HPA axis function (as defined above) and the fMRI BOLD response in episodic
and working memory tasks.
7. The relationship between HPA axis function (as defined above) and the fMRI bold response
to hydrocortisone.
8. The relationship between LTP and neuropsychological function.
Subgroup analysis
The data will be analysed by dividing the sample into those with severe depression (defined as MADRS
≥ 30 at baseline week 0) or less-severe depression.
Missing data
Scores for the various scales used will be calculated in accordance with their author’s instructions. In the
absence of any rule for missing data imputation will be used provided at least half the items in any scale
have been completed (imputed missing value=mean value of non-missing items). Missing survival date will
be dealt with by using the date of censoring and the status of the patient at that point. The secondary
outcomes are being analysed using mixed models that make use of all data available. The analysis is
adjusted to take into account that some subjects have provided more information than others. If there is a
difference in survival rates we will have more ‘missing’ outcome data in one group than another. If this
situation occurs the data will be analysed using joint modelling as described above. Thus estimates of
functional health status and quality of life will be adjusted for differences in survival rates. There will be no
other data imputation.
Safety
The number of serious adverse events in each group will be reported along with a 95% confidence interval
for the relative odds (between the two treatment groups) of at least one event being reported.
The number of non-serious adverse events will be compared using a negative binomial regression model.
Results will be given in the form of a 95% confidence interval for the incidence rate ratio.
Implementation
A SAP Implementation Group will be formed to oversee the analysis of all ADD-related data. The analysis
of the clinical outcomes will be undertaken by the study team based in Newcastle. The mechanistic and
cross-sectional analyses will be undertaken by various individuals/centres with the agreement of the SAP
Implementation Group.
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Glossary of abbreviations
5-HT 5-hydroxytryptophan, serotonin
11-HSD 11β-hydroxysteroid dehydrogenase
ACTH Adrenocorticotrophic hormone
AE Adverse events
ANT Attentional Network Test
AUCg Area Under the Curve Ground
AUCi Area Under the Curve Increase
BDI Beck Depression Inventory
BFI-44 Big Five Inventory 44
BOLD Blood Oxygen Level Dependent
BSE Between-search errors
CANTAB Cambridge Neuropsychological Test Automated Battery
CAR Cortisol awakening response
CAS Clinical Anxiety Scale
CBT Cognitive behavioural therapy
CI Chief investigator
COM Combined memory condition
CRF Case report form
CTA Clinical trial authorisation
CTQ Childhood Trauma Questionnaire
CTIMP Clinical trial of an investigational medicinal product
DHEA Dehydroepiandrosterone
DMEC Data Monitoring and Ethics Committee
DSM-IV Diagnostic and Statistical Manual-Fourth Edition
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ECMT Emotional Categorization and Memory Test
EEG Electroencephalogram
EEM Emotional enhancement of memory
EL Emotional labelling
EM Emotional matching
EME Efficacy Mechanism and Evaluation
ERP Event-related potential
ESMT Emotional Source Memory Task
EQ-5D EuroQol Quality of Life scale
FEER Facial Emotional Expression Recognition
FEP Facial emotion processing
fMRI Functional magnetic resonance imaging
FWE Family Wise Error
GCP Good Clinical Practice
GR Glucocorticoid receptors
GRID-HAMD GRID Hamilton Depression Rating Scale
HDRS17 Hamilton Depression Rating Scale-17 item
HPA Hypothalamic–pituitary–adrenal
HV Healthy volunteers
HTA Health technology assessment
IAPS International Affective Picture Set
IMP Investigational medicinal product
LDAEP Loudness dependency of auditory evoked potentials
LTE List of Life Threatening Experiences
LTP Long-term potentiation
MADRS Montgomery-Åsberg Depression Research Scale
MCV Mean cell volume
MGH Massachusetts General Hospital
MHRA Medicines and Healthcare Regulatory Agency
MHRN Mental Health Research Network
MR Mineralocorticoid receptors
MRC Medical Research Council
MTA Material Transfer Agreement
NRES National Research Ethics Service
NICE National Institute of Clinical Excellence
NIHR National Institutes of Health Research
OLB Object-location binding
OLM Object-location memory
PCRN Primary Care Research Network
phMRI Pharmacological functional magnetic resonance imaging
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PI Principal investigator
PIC Participant Identification Centres
POM Position-only memory
QoL Quality of life
R&D Research and development
RAVLT Rey Auditory Verbal Learning Test
REC Research Ethics Committee
ROI Region of interest
RRS Ruminative Responses Scale
RT Reaction time
SAE Serious adverse event
SARs Serious adverse reactions
SD Standard deviation
SEM Standard error of the mean
SM Shape matching
SmPC Summary of major product characteristics
SOP Standard operating procedure
SCID Structured Clinical Interview for DSM
SCQ Social Circumstances Questionnaire
SPM8 Statistical Parametric Mapping
SSI Site-specific information
SSRI Selective serotonin reuptake inhibitor
STAI State–Trait Anxiety Inventory
SUSAR Suspected unexpected serious adverse reaction
SWM Spatial working memory
TSC Trial Steering Committee
TSES Toronto Side Effects Scale
VEP Visual Evoked Potential
WSE Within-search errors
YMRS Young Mania Rating Scale
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Appendix 2 Numbers analysed and descriptive
statistics
TABLE 47 Mean MADRS scores at follow-up visits in each randomised group
Visit
Placebo Metyrapone
Mean n SD Mean n SD
Baseline 28.1 82 5.4 27.7 83 6.7
Week 3 20.8 77 9.9 22.6 72 10.9
Week 5 22.4 74 10.6 21.7 69 10.9
Week 8 22.6 66 10.8 21.2 62 10.4
Week 16 20.5 61 11.5 21.4 54 11.0
Week 24 20.0 58 11.6 21.0 46 11.1
TABLE 48 Mean BDI scores at follow-up visits in each randomised group
Visit
Placebo Metyrapone
Mean n SD Mean n SD
Baseline 34.8 81 10.3 35.6 81 10.9
Week 3 28.7 75 14.0 30.5 69 15.1
Week 5 29.6 72 14.5 27.9 67 15.3
Week 8 30.9 63 14.4 28.7 61 14.9
Week 16 28.0 61 15.7 30.5 52 14.2
Week 24 28.9 57 16.9 28.2 47 14.2
TABLE 49 Mean CAS scores at follow-up visits in each randomised group
Visit
Placebo Metyrapone
Mean n SD Mean n SD
Baseline 10.00 82 4.57 9.53 83 4.51
Week 3 7.40 77 5.21 8.46 72 6.16
Week 5 8.23 74 5.78 8.52 69 5.98
Week 8 8.53 66 5.59 8.71 62 6.02
Week 16 7.70 61 4.87 8.46 54 4.96
Week 24 7.43 58 5.29 7.87 46 5.72
DOI: 10.3310/eme02040 EFFICACY AND MECHANISM EVALUATION 2015 VOL. 2 NO. 4
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ferrier et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
95
TABLE 50 Mean state anxiety scores at follow-up visits in each randomised group
Visit
Placebo Metyrapone
Mean n SD Mean n SD
Baseline 41.09 81 5.83 42.83 81 6.49
Week 3 39.87 75 5.45 42.87 69 7.10
Week 5 40.26 72 6.02 42.13 67 6.88
Week 8 40.70 64 6.95 41.32 59 7.22
Week 16 41.17 58 7.32 42.25 52 6.14
Week 24 41.25 56 6.23 42.43 47 6.13
TABLE 51 Mean EQ-5D tariffs at each visit in each randomised group
Visit
Placebo Metyrapone
Mean n SD Mean n SD
Baseline 0.370 81 0.314 0.368 81 0.301
Week 3 0.464 75 0.334 0.440 69 0.332
Week 5 0.468 72 0.354 0.502 67 0.347
Week 8 0.447 64 0.357 0.471 60 0.337
Week 16 0.445 60 0.359 0.491 52 0.334
Week 24 0.443 58 0.370 0.487 47 0.348
TABLE 52 Mean EQ-VAS scores at each visit for each of the randomised groups
Visit
Placebo Metyrapone
Mean n SD Mean n SD
Baseline 42.3 79 19.4 40.9 80 16.6
Week 3 47.3 74 20.8 48.4 65 20.8
Week 5 47.5 71 22.1 50.6 63 21.9
Week 8 49.4 64 22.0 49.4 59 20.0
Week 16 47.0 61 23.9 48.2 51 20.0
Week 24 47.4 58 25.0 48.3 47 19.7
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TABLE 53 Mean YMRS score at each visit for each of the randomised groups
Visit
Placebo Metyrapone
Mean n SD Mean n SD
Baseline 2.35 82 1.83 2.34 82 1.71
Week 3 1.92 77 2.19 2.03 72 1.67
Week 5 1.74 74 1.87 1.70 69 1.62
Week 8 1.74 66 1.88 1.55 62 1.73
Week 16 1.69 61 2.10 1.85 54 1.90
Week 24 1.80 59 2.10 1.54 46 1.75
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